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'\..man will occassionally stumble over the truth, 
but usually manages to pick himself up, walk over 
or around it, and carry on.
Winston S. Churchill (1874-1965)
Abstract
The human G protein-coupled receptor (GPCR) SIP4 (formerly named Edg6 ) 
was identified as an orphan receptor and assigned to the Edg family on the basis 
of sequence similarity with other Edg receptors. SIP4 was recently shown to 
couple to GoCi and G a^/n  G proteins in response to stimulation by the 
lysophospholipid, sphingosine-1-phosphate (SIP). This thesis describes 
functional characterisation of the SIP4 receptor using a modified [^^SJGTPyS 
binding assay.
CHO-Kl cells were stably transfected to express SIP4, or a fusion protein 
between SIP4 and a pertussis toxin-resistant form of GOii. SIP4 exhibited 
significant constitutive activity and treatment with SIP or phytoSlP further 
stimulated the receptor in a dose-dependent manner. Pertussis toxin treatment 
demonstrated that both SIP4 constitutive activity and the effects of SIP were 
transduced via endogenous GoCi G proteins, whilst the SlP4-G(Xii fusion signalled 
via the tethered, pertussis toxin-insensitive G protein. Residue was shown to 
be important in governing SIP4 ligand selectivity; mutation of the naturally 
occurring glutamic acid to glutamine attenuated the ability of the receptor to 
respond to SIP and conferred sensitivity to the related compound, 
lysophosphatidic acid.
Since most cell types express endogenous SIP and LPA family receptors, the 
profile of Edg family receptor expression in CHO-Kl cells was investigated. 
Transcripts for SlPi,2,4 and LPAi receptors were detected using RT-PCR with 
species-specific oligonucleotides.
Further investigations into SIP4 constitutive activity, which were undertaken 
using an inducible expression system, demonstrated direct correlation between 
SIP4 expression and constitutive activity. This suggested that SIP4 constitutive 
activity represents an inherent property of this receptor. In common with other 
naturally constitutively active GPCRs, SIP4 lacks a generally conserved cysteine 
residue within the first extracellular loop. It is proposed that this may account 
for SIP4 constitutive activity and may be relevant to the in vivo function of this 
receptor.
II
Acknowledgements
Firstly I would like to thank my supervisors for their insight, support, guidance and 
humour during this project: Professor Graeme Milligan at the University of Glasgow 
and Dr’s Gill Hutchinson and Martin Perry at Celltech R&D. Dr Ray Owens also 
supervised the initial phase of this work. I must extend my thanks to Dr Martin 
Perry for initially suggesting that I do my PhD at Celltech, and to Dr Melanie Lee 
for agreeing with him.
As is the nature of such a project, there are many people whose willingness to share 
their considerable expertise must be acknowledged. Mr Craig Carr at the University 
of Glasgow introduced me to GPCR functional assays and was a general fountain of 
knowledge. Thanks to Dr Pat Slocombe at Celltech for assistance with all things 
DNA, being prepared to debate the literature and never being at all grumpy. Dr 
Derek Brown helped with the fluorescence microscopy and Mr James Snowdon 
provided assistance with bioinformatics. Dr Jim Turner made the space-filling 
models and Mr Stuart Bailey co-ordinated synthesis of the FTY720 and AAL 
analogues (and is probably still trying to work out what he did to deserve this.) Dr 
Lloyd King and Miss Aijinder Rayet performed LC-MS analysis of in vitro 
phosphorylation reactions. My colleagues in labs L242 and L236 discussed ideas, 
helped sort out technical problems and generally put up with me, for which I’m 
grateful.
I’d like to thank my friends, who showed an interest in what I was doing and 
wondered why I answered through gritted teeth when they asked if I’d finished yet. 
Anna, Sarah and Krystyna did a fantastic job of humouring me, talking shop and 
then reminding me that there was life beyond the lab -  cheers guys. I understand the 
most effective means of thanking you all is by buying the beers. Fm also very 
grateful to my Mum for proof-reading my thesis.
I must express my gratitude to all of my family for being having faith in me, it 
means a lot. Finally, a huge thank you to Nigel for always being there and never 
taking it personally when I was a little preoccupied with work. I couldn’t have done 
it without you, and I promise I won’t do another one!
Ill
Abbreviations
5-HTia 5 -hydroxytryptamine 1A receptor
5-HT2B 5-hydroxytryptamine 2B receptor
Â angstrom
A (aa) alanine
A(nt) adenine
aa amino acid
AAL 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol
ŒiaAR aiA adrenergic receptor
Œ2AAR (%2A adrenergic receptor
ANOVA analysis of variance
ATP adenosine 5’-triphosphate
BCA bicinchoninic acid
Bcl-2 B cell lymphoma 2
PiAR pi adrenergic receptor
P2AR P2 adrenergic receptor
P-Arr p-arrestin
BGH bovine growth hormone
BH3 Bcl-2 homology 3 domain
bp base pairs
Bq Becquerel
BSA bovine serum albumin
C Celsius
C(aa) cysteine
C(nt) cytosine
CAM constitutively active mutant
cAMP adenosine 3’,5’-cyclic monophosphate
CB cannabinoid
CCRl CC chemokine receptor 1
cDNA complementary DNA
CHO Chinese hamster ovary
Ci Curie
CMV cytomegalovirus
CNS central nervous system
CRLR calcitonin receptor-like receptor
CsA cyclosporin A
CTR-2 calcitonin receptor 2
CXCRl CXC chemokine receptor 1
D (aa) aspartic acid
B 2 io n g dopamine D2 long isoform receptor
Da dalton
DAPI 4’ , 6  ’-diamidino-2-phenylindole
DBD DNA binding domain
DCM dichloromethane
dhSlP dihydrosphingosine- 1 -phosphate
DMEM Dulbecco’s modified Eagle’s medium
DMS dimethylsphingosine
DMSO dimethylsulphoxide
IV
DNA deoxyribonucleic acid
DNase I deoxyribonuclease I
dNTP deoxyribonucleoside triphosphate
dpm disintegrations per minute
DTT dithiothreitol
E (aa) glutamic acid
E. Coli Escherichia Coli
e.g. exempli gratia (for example)
E/GRE ecdysone/glucocorticoid receptor elements
EBV Epstein-Barr virus
EC50 half maximal concentration
ECMV encephalomyocarditis virus
EcR ecdysone receptor
Edg endothelial differentiation gene
EGF epithelial growth factor
EEC EBV-induced molecule 1 ligand chemokine
ELISA enzyme linked immunosorbent assay
eNOS endothelial nitric oxide synthase
Erk extracellular signal related kinase
F (aa) phenylalanine
FACS fluorescence activated cell sorter
FCS foetal calf serum
FITC fluorescein 5(6)-isothiocyanate
FMLP formyl-methionine-leucine-phenylalanine
FTY720 2-amino-2-[2-(4-octylphenyl)ethyl]-propane-l,3-diol
g gram
g gravity
G(nt) guanine
G protein guanine nucleotide binding protein
G2A G2 accumulation G protein-coupled receptor
GAPDH glyceraldehyde-3 -phosphate dehydrogenase
GDP guanosine 5’-diphosphate
GFP green fluorescent protein
GPCR G protein-coupled receptor
GRK G protein-coupled receptor kinase
GTP guanosine 5’-triphosphate
GTPyS guanosine 5’-[y-thio]triphosphate
HA haemagglutinin
HER human embryonic kidney
HEPES 4-(2-hydroxyethyl)piperazine-l -ethanesulphonic acid
HPLC high performance liquid chromatography
HRP horseradish peroxidase
HUVEC human umbilical vein endothelial cell
I(aa) isoleucine
i.e. id (that is)
Ig immunoglobulin
IPTG isopropyl p-D-thiogalactopyranoside
1RES internal ribosome entry site
lUPHAR International Union of Pharmacology
IVS intervening sequence
V
k
K(nt)
L
LB medium
LC-MS
LPA
LPC
LPPl
LTB4
m
M
MAP
MC
m G lula
MMLV
mol
MOPS
Mr
mRNA
MuA
n
N (aa)
N(nt)
NCBI
NF-kB
NGF
NK
nt
OGRl
P
psi
P2Y 1
PAF
PBMC
PBS
PC12
PCR
PDGF
pH
phSlP
PKA
PKC
PLC
pit
PonA
PTx
PVDF
Q (aa)
kilo
guanine or thymine 
litre
Luria-Bertani medium
liquid chromatography-mass spectrometry
lysophosphatidic acid
lysophosphatidylcholine
lipid phosphate phosphohydrolase 1
leukotriene B4
milli
molar
mitogen activated protein 
melanocortin
metabotropic glutamine l a  receptor 
Moloney Murine Leukaemia Virus 
mole
3 -morpholinopropanesulphonic acid 
molecular mass 
messenger RNA 
muristerone A
(2P,3p,5p,lla,14a,20R,22R-heptahydroxycholest-7-en-6-one)
nano
asparagine
adenine, cytosine, guanine or thymine
National Centre for Biotechnology Information
nuclear factor kB
nerve growth factor
natural killer
nucleotide
ovarian cancer G protein-coupled receptor 1 
pico
pounds per square inch 
P2 purinoceptor type Y 1 
platelet activating factor 
peripheral blood mononuclear cell 
phosphate buffered saline 
pheochromocytoma 1 2  
polymerase chain reaction 
platelet-derived growth factor
negative logarithm of the concentration of hydrogen ions
phytosphingosine- 1 -phosphate
protein kinase A
protein kinase C
phospholipase C
paucity of lymph node T cells
ponasterone A
(2p,3p, 14a,20R,22R-pentahydroxy-5 p-cholest-7-en-6-one) 
pertussis toxin 
polyvinylidene difluoride 
glutamine
VI
R (aa) arginine
R(nt) adenine or guanine
RAMP receptor activity modifying protein
RGS regulators of G protein signalling
RH rat hepatoma
rpm revolutions per minute
RPMI Rosweli Park Memorial Institute
RSV rous sarcoma virus
RXR retinoid X receptor
S (aa) serine
S(nt) guanine or cytosine
SIP sphingosine- 1 -phosphate
SDS sodium dodecyl sulphate
SEM standard error of mean
siRNA short interfering RNA
SK sphingosine kinase
SLC secondary lymphoid tissue chemokine
SLC-1 somatostatin-like receptor 1
SPG sphingosylphosphorylcholine
SPP sphingosine- 1 -phosphate phosphatase
SSTi somatostatin type 1 receptor
SSTz somatostatin type 2  receptor
T tera
T (aa) threonine
T(nt) thymine
TDAG8 T-cell death-associated gene 8
TM transmembrane domain
TNF-a tumour necrosis factor a
TRAF2 TNF receptor-associated factor 2
uv ultraviolet
V2 vasopressin 2  receptor
vzg-1 ventricular zone gene 1
Y(aa) tyrosine
Y(nt) cytosine or thymine
micro
VII
Contents
Abstract..........................................................................................................................I
Acknowledgements.................................................................................................... Ill
Abbreviations............................................................................................................. IV
Contents...................................................................................................................VIII
List of Figures......................................................................................................... XIII
List of Tables..........................................................................................................XVII
Chapter 1 -  Introduction
1.1 General introduction........................................................................................... 1
1.2 G protein-coupled receptors...............................................................................1
1.2.1 Introduction............................................................................................... 1
1.2.2 Structural features of GPCRs...................................................................2
1.2.3 Classification of GPCRs.......................................................................... 4
1.2.4 Activation of GPCRs................................................................................. 7
1.2.4.1 Basic receptor theory...........................................................................7
1.2.4.2 Conformational changes associated with GPCR...................... 8
activation
1.2.4.3 Constitutive activity of GPCRs....................................................... 9
1.2.5 Heterotrimeric G proteins.......................................................................12
1.2.6 Termination of signalling at GPCRs......................................................16
1.3 The Edg family of GPCRs............................................................................... 18
1.3.1 Introduction to Edg receptors................................................................. 18
1.3.2 Classification of Edg receptors.............................................................. 21
1.3.3 The SIP receptor family..........................................................................22
1.3.4 The LPA receptor family........................................................................29
1.3.5 SIP4 (Edg6 ) ..............................................................................................33
1.3.6 Other lipid GPCRs.................................................................................. 40
1.4 Sphingolipid signalling.................................................................................... 42
1.4.1 Sphingosine and ceramide.......................................................................42
1.4.2 Sphingosine-1 -phosphate........................................................................43
1.4.3 Phytosphingosine-1 -phosphate.............................................................. 52
1.5 FTY720 and SIP receptors.............................................................................. 54
VIII
1.6  Project Aims...................................................................................................... 58
Chapter 2 -  Materials and Methods
2.1 General chemicals and materials......................................................................61
2.1.1 Media for bacterial growth......................................................................63
2.1.2 Buffer formulations................................................................................. 63
2.1.3 Sources of cDNA.................................................................................... 6 6
2.1.4 Bacterial strains....................................................................................... 6 6
2.1.5 Antibodies.............................................................................................. 6 6
2.1.6  Oligonucleotides..................................................................................... 67
2.1.7 Mammalian cell lines.............................................................................. 72
2.2 DNA methods...................................................................................................72
2.2.1 PCR amplification of DNA fragments...................................................72
2.2.2 Analysis of DNA fragments by gel electrophoresis..............................74
2.2.3 Spin column purification of PCR products........................................... 75
2.2.4 Purification of DNA fragments from agarose gels...............................75
2.2.5 Analysis of DNA fragments by restriction enzyme digest................... 76
2.2.6 Alkaline phosphatase treatment of digested vector...............................76
2.2.7 Phenol-chloroform extraction of DNA..................................................77
2.2.8 Ligation of DNA fragments....................................................................77
2.2.9 Transformation of DNA into competent E. Coli cells..........................78
2.2.10 TOPO cloning of PCR products............................................................. 78
2.2.11 Isolation of plasmid DNA using QIAGEN Miniprep...........................79
columns
2.2.12 Isolation of plasmid DNA using QIAGEN Maxiprep k it.....................80
2.2.13 Optical density measurement of DNA................................................... 80
2.2.14 DNA sequencing......................................................................................81
2.2.15 Isolation of genomic DNA from mammalian cells............................... 82
2.2.16 Isolation of total RNA from mammalian cells...................................... 82
2.2.17 Synthesis of first strand cDNA by RT-PCR..........................................83
2.3 Cell culture and cell biology methods..............................................................84
2.3.1 General cell culture..................................................................................84
2.3.2 Transient transfection of HEK-293 cells................................................85
IX
2.3.3 Generation of stable cell lines................................................................8 6
2.3.4 Induction of HA-S1P4 expression in ecdysone-inducible....................87
CHO-EcR cell line
2.3.5 Detection of cell-surface proteins (FACS analysis)............................. 8 8
2.4.6 Fluorescence microscopy....................................................................... 89
2.4 Protein methods................................................................................................89
2.4.1 Preparation of cell membranes...............................................................89
2.4.2 Determination of protein concentration................................................ 90
2.4.3 Immunological detection of protein (Western blotting)....................... 90
2.5 Receptor activity assays.................................................................................. 91
2.5.1 Handling of receptor agonists................................................................91
2.5.2 [^^S]GTPyS binding assay.......................................................................93
2.5.3 Data analysis........................................................................................... 94
Chapter 3 - Cloning of Human SIP4 and Production of 
Expression Constructs
3.1 Introduction...................................................................................................... 96
3.2 Results...............................................................................................................98
3.2.1 Cloning of HA-tagged SIP4 ....................................................................98
3.2.2 Generation of HA-tagged SlP4-GOii(C^^^I) fusion construct 102
3.2.3 Generation of HA-tagged SIP4 construct for inducible.................... 105
expression
3.2.4 Generation of HA-tagged S1 P4(E^^^Q) mutant fused....................... 107
with pertussis toxin-insensitive GoCii(C^ ^^ I)
3.2.5 Determination of expression of endogenous SIP an d ........................110
LPA receptors in CHO-Kl cells by RT-PCR
3.3 Discussion.......................................................................................................125
Chapter 4 -  Expression and functional responses of SIP4
4.1 Introduction..................................................................................................... 131
4.2 Results............................................................................................................. 135
4.2.1 Transient expression of a 2AAR-Gaü(C^^^I) fusion in HEK-293..... 135
cells
X
4.2.2 Comparison of immunoprécipitation efficiency of different.............135
anti-G protein antisera in [^^SJGTPyS binding assay
4.2.3 Stable expression of HA-SIP4  in CHO-Kl cells................................137
4.2.4 Optimisation of HA-SIP4  response in [^^SJGTPyS............................139
binding assay
4.2.5 Constitutive activity of HA-SIP4  in [^^SJGTPyS binding.................. 142
assay
4.2.6 Pertussis toxin-sensitivity of HA-S 1P4  dose-response to S IP ...........142
in [^^SJGTPyS binding assay
4.2.7 Stable expression of HA-SlP4-Gaii(C^^^I) fusion in CH O -K l 144
cells
4.2.8 Optimisation of HA-SlP4-GOii(C^^^l) response in [^^S]GTPyS....... 146
binding assay
4.2.9 Constitutive activity of HA-SlP4-Gaii(C^^^l) in [^^SJGTPyS  148
binding assay
4.2.10 Pertussis toxin-sensitivity of HA-S 1 P4-Gai 1 (C^  ^^ 1) dose-................. 149
response to SIP in [^^SJGTPyS binding assay
4.3 Discussion........................................................................................................ 151
Chapter 5 -  Use of an Inducible Expression System to Examine 
the Constitutive Activity of SIP4
5.1 Introduction...................................................................................................... 156
5.2 Results...............................................................................................................161
5.2.1 Generation of HA-SIP4 inducible expression stable cell line............ 161
5.2.2 Characterisation of the effect of the ecdysone-receptor......................161
hormone analogues, ponasterone A and muristerone A,
on cell-surface expression of HA-S 1P4
5.2.3 The effect of cell-surface receptor expression level o n ..................... 171
HA-SIP4 basal activity in [^^SJGTPyS binding assay
5.2.4 The effect of cell-surface receptor expression level on SIP-............. 175
stimulated HA-SIP4 activity in [^^S]GTPyS binding assay
XI
5.2.5 Correlation analysis of HA-SIP4 constitutive and S IP -.................   177
stimulated [^^SjGTPyS binding activity with the level of 
HA-SIP4 cell-surface expression
5.3 Discussion.................................................................................................  179
Chapter 6  -  Investigation into SIP4 Ligand Preference
6.1 Introduction...................................................................................................... 191
6.2 Results.............................................................................................................. 196
6.2.1 Activation of HA-SIP4 by phSlP in [^^SJGTPyS binding.................196
assay
6.2.2 Inactivity of FTY720 and AAL compounds as HA-SIP4 .................. 197
receptor agonists in [^^SJGTPyS binding assay
6.2.3 In vitro phosphorylation of FTY720 and AAL compounds...............197
via incubation with rabbit blood
6.2.4 Stable expression of HA-S 1 P4(E'^ ^Q)-GOi i I) in CHO-Kl 201
cells
6.2.5 Investigation of HA-SlP4(E^^^Q)-GOii(C^^^l) ligand preference..... 202
in [^^SJGTPyS binding assay
6.2.6 The effect of LPA hydrocarbon chain length on activation...............205
of HA-SlP4(E^^^Q)-G0Cii(C^ ^^ l) in [^^SJGTPyS binding assay
6.2.7 Dose-dependent stimulation of HA-S lP4(E^^^Q)-GoCii(C^^ l^)...........207
by 14:0 LPA in [^^SjGTPyS binding assay
6.3 Discussion.......................................................................................................210
Chapter 7 -  Final Discussion
7.1 Introduction.....................................................................................................219
7.2 The in vivo role of SIP4 .................................................................................. 223
7.2.1 SIP4 constitutive activity..................................................................   224
7.2.2 Regulation of SIP4 .................................................................................225
7.2.3 Sphingosine-1 -phosphate signalling.................................................... 227
7.3 Summary......................................................................................................... 229
R eferences....................................................................................................... 230
XII
List of Figures
1.1 Schematic representation of a GPCR residing in the plasma........................ 2
membrane
1.2 Phylogenetic tree of selected family A GPCRs............................................. 5
1.3 Schematic representation of the extended ternary complex model.............10
1.4 GPCRs exist in an ensemble of microstates..................................................11
1.5 Structures of Edg family ligands................................................................... 20
1.6 Phylogenetic tree of Edg family receptors................................................... 22
1.7 Signal transduction by SIP family receptors............................................... 23
1.8 Expression of SIP4 detected in tissue sections............................................ 37
1.9 Synthesis and degradation of S IP ................................................................. 44
1.10 The ceramide-S 1P rheostat............................................................................47
1.11 Structure of p h S lP ..........................................................................................53
1.12 Structure of FTY720...................................................................................... 55
1.13 Structure of FTY720-P................................................................................... 57
1.14 Structure of (R)-AAL-P................................................................................. 58
3.1 Schematic diagram of the pIRESpuro mammalian expression................... 96
vector
3.2 Schematic diagram of the pIND ecdysone-inducible mammalian.............. 97
expression vector
3.3 Construction of SIP4/PÏRES.......................................................................... 99
3.4 Construction of HA-S 1P4/PÏRES.................................................................101
3.5 Construction of HA-SlP4(No Stop)/pIRES................................................ 103
3.6 Construction of Gail(C^^^I)/pIRES..............................................................104
3 . 7  Construction of HA-SlP4-GOii(C^^‘l)/pIRES............................................. 106
3.8 Construction of HA-S IP4/PIND................................................................... 107
3.9 Construction of HA-SlP4(E‘^ ^Q)-Goiii(C^’‘l)/pIRES.................................109
3.10 PCR amplification of partial SIP and LPA receptor sequences................112
from Chinese hamster genomic DNA
3.11 Alignment of human, mouse and rat SIP and LPA receptor.....................113
protein sequences with translated partial hamster sequences
obtained from PCR reactions using Chinese hamster genomic 
DNA
XIII
3.12 Expression of SIP and LPA receptor mRNA in CHO-Kl cells..............124
by RT-PCR
4.1 Schematic diagram showing guanine nucleotide exchange cycle 132
on Gapy G proteins
4.2 Expression of a 2AAR-Gaii(C^^^I) in HEK-293 cells................................. 136
4.3 Comparison of different anti-G protein antisera in [^^SJGTPyS.............. 137
binding assay
4.4 Expression of HA-SIP4 in CHO-Kl cells................................................... 138
4.5 Determination of optimal GDP concentration using HA-SIP4 in............. 139
[^^SJGTPyS binding assay
4.6 Optimisation of response of HA-S IP4 in [^^SJGTPyS binding..................141
assay
4.7 Constitutive activity of HA-S 1P4 after expression in CHO-Kl.................143
cells
4.8 Concentration dependent stimulation of HA-S 1 P4-mediated....................144
L^S]GTP-yS binding by SIP
4.9 Expression of HA-SlP4-Gotii(C^^'l) in CHO-Kl cells.............................. 145
4.10 Determination of optimal GDP concentration using HA-SIP4 - ............... 146
Gan(C^"l) in [“ SlGTPyS binding assay
4.11 Optimisation of response of HA-SlP4-Gotii(C^^'l) in [^^SJGTPyS........... 147
binding assay
4.12 Constitutive activity of HA-SlP4-Gotii(C^^^l) expressed in CH O-Kl.... 148 
cells
4.13 Concentration dependent stimulation of HA-SlP4-GOii(C^^^l)-............... 150
mediated [^^S]GTPyS binding by SIP
5.1 Schematic diagram describing the ecdysone-inducible............................. 159
mammalian expression system
5.2 Structures of the ecdysone receptor hormone analogues,..........................160
ponasterone A and muristerone A
5.3 Dot plot analysis of parental CHO-EcR cells.............................................162
5.4 Concentration dependent induction of cell-surface receptor.....................163
expression by ponasterone A treatment of ecdysone-inducible
HA-S 1 P4-transfected CHO-EcR cells
XIV
5.5 Concentration dependent induction of cell-surface receptor.....................165
expression by muristerone A treatment of ecdysone-inducible 
HA-SlP4-transfected CHO-EcR cells
5.6 Induction of cell-surface receptor expression by ponasterone A  167
treatment of ecdysone-inducible HA-S 1 P4-transfected CHO-
EcR cells detected by fluorescence microscopy
5.7 Time dependent induction of cell-surface receptor expression by 169
ponasterone A and muristerone A treament of ecdysone-inducible
HA-S 1 P4-transfected cells
5.8 Analysis of receptor expression in ecdysone-inducible HA-S IP4  171
transfected CHO-EcR cells using Western blotting
5.9 Constitutive activity of HA-S 1P4 expressed in ecdysone-......................... 174
inducible CHO-EcR cells
5.10 Constitutive activity of HA-S 1P4 is not influenced by th e ....................... 175
presence of ponasterone A
5.11 SIP-stimulated activity of HA-SIP4 expressed in ecdysone-................... 176
inducible CHO-EcR cells
5.12 Correlation of HA-S 1P4 constitutive- and S1 P-stimulated activity 178
from membranes prepared from ecdysone-inducible CHO-EcR
cells with percentage of cells deemed to express HA-SIP4
5.13 Model to represent the effect of ponasterone A concentration o n ............185
cell-surface HA-SIP4 expression in ecdysone-inducible CHO-
EcR cells
6.1 Structures of three naturally occurring forms of LPA ............................... 194
6.2 Models of LPA analogues and SIP............................................................. 195
6.3 Concentration dependent stimulation of HA-S 1 P4-mediated................... 196
[^ ’S]GTPvS binding by phSlP
6.4 FTY720 and AAL compounds are unable to stimulate H A -.................... 198
SlP4-mediated [^^SJGTPyS binding
6.5 Conversion of FTY720 and AAL compounds to phosphate......................199
metabolites via in vitro incubation with rabbit blood
6 . 6  Snake plot of SIP4 .........................................................................................201
6.7 Expression of HA-SlP4(E'“ Q)-GOii(C^’‘l) in CHO-Kl cells................. 203
XV
6 . 8  Ligand preference of HA-SlP4(E'^^Q)-Gaii(C^®‘l) in [^^S]GTPyS 204
binding assay
6.9 The effect of acyl chain length on stimulation of HA- S1 P4(E^^^Q)-.......206
GOii(C^’ ‘l)
6.10 Concentration dependent stimulation of HA-S1P4(E'^^Q)-.......................209
GOii(C^^'l)-mediated [^^SjGTPyS binding by 14:0 LPA
XVI
List of Tables
1.1 Summary of G protein a  subunit actions......................................................13
1.2 Summary of G protein activation by Edg family members........................ 20
1.3 Summary of Edg family receptor classification consistent with.................21
lUPHAR guidelines
1.4 Sequence identity between SIP4 and other SIP and LPA...........................34
receptors
1.5 Summary of tissues and cells reported to express SIP4 ...............................36
2.1 Oligonucleotides and PCR programs used to amplify SIP and.................. 74
LPA receptor gene fragments from Chinese hamster genomic
DNA or first strand cDNA
3.1 Oligonucleotides used to clone fragments of SIP and LPA......................I l l
receptor genes from Chinese hamster genomic DNA
3.2 Summary of similarities between cloned partial Chinese hamster 121
SIP and LPA receptor sequences and those from mouse, rat and
human
3.3 Oligonucleotides used for RT-PCR analysis of CHO-Kl mRNA............ 122
to identify endogenously expressed SIP and LPA receptor genes
3.4 Summary of SIP and LPA expression data in ovarian tissues and........... 129
CHO-Kl cells
5.1 Summary of ecdysone analogue potency for induction of......................... 166
HA-S 1P4 expression in HA-S 1 P4-transfected ecdysone-
inducible CHO-EcR cells
5.2 Summary of statistical analyses performed on data describing.................177
the relationship between the percentage of cells expressing
HA-SIP4 and [^^SjGTPyS binding attributable to the presence 
of this receptor
- XVII -
Chapter 1 -  Introduction
1.1 General introduction
The activity of virtually every cell in the body is regulated by extracellular 
stimuli, which provide signals that are transmitted via a complex array of plasma 
membrane-associated receptors and intracellular proteins. A large proportion of 
these cell-surface receptors, including the SIP4  receptor which is the topic of this 
thesis, belong to the G protein-coupled receptor (GPCR) superfamily. In this 
chapter, the GPCR family will be introduced before the SIP 4  receptor is 
considered within the context of the Edg receptor family, of which it is a 
member. The nature of the ligands which act at SIP4  and their routes of 
production in vivo will be reviewed and the aims of this thesis will be outlined.
1.2 G protein-coupled receptors
1.2.1 Introduction
G protein-coupled receptors are integral membrane proteins which are found in a 
wide variety of organisms, including yeast [Marsh and Herskowitz, 1988] and 
the slime mould Dictyostelium discoideum [Ueda et ah, 2001], the plant 
Arabidopsis thaliana [Josefsson and Rask, 1997] and higher mammals such as 
man. The GPCR superfamily represents one of the largest protein families in the 
human genome. The first human GPCR was cloned in 1986 [Dixon et a l, 1986] 
and since this event, research in the field has continued and the range of 
techniques which can be employed in the analysis of the functions and properties 
of receptors has expanded. GPCRs are the subject of much industrial research 
since they are involved in many normal physiological and pathophysiological
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processes and it has been estimated that 50 % of marketed drugs exert their 
actions via interactions with GPCRs [Howard et al, 2001].
1.2.2 Structural features of GPCRs
GPCRs share common structural elements which may be illustrated by analysis 
of their amino acid sequences. Each GPCR sequence contains seven distinct 
regions of hydrophobic residues, which are believed to form a-helices and span 
the cellular membrane. These helices are connected by intracellular and 
extracellular loops comprised of hydrophilic amino acids. The amino-terminal 
region of a GPCR is located outside of the cell, whilst the carboxy-terminal tail 
resides intracellularly. Figure 1.1 shows a schematic representation of a GPCR 
located within the plasma membrane.
N H
Extracellular
Intracellular
COOK
Figure 1. 1
Schematic representation of a GPCR residing in the plasma membrane.
This diagram illustrates the seven membrane-spanning a-helices of a GPCR. 
These are linked via intra- and extracellular loop regions. The amino-terminal 
tail of the receptor is located extracellularly whilst the carboxy-terminal tail is 
situated intracellularly.
The highest degree of sequence homology between GPCRs is observed within 
the transmembrane (TM) regions and each TM domain is comprised of between 
approximately 20-27 amino acids. The sequences of the loops and tails of
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different GPCRs tend to be far more divergent. The size of the amino-terminal 
region varies and can contain between ten and 500 residues, whilst the loop 
sections can consist of as few as five amino acids to greater than 2 0 0  residues 
and the carboxy-terminal tail between 12 and 400 residues. In spite of their 
common structural elements, GPCRs are activated by myriad structurally diverse 
molecules including photons, odourants, neurotransmitters, nucleotides, lipids 
and amines, to polypeptides and proteins.
Direct study of the three-dimensional structures of GPCRs has not been as 
straightforward as it has been for cytosolic proteins such as non-receptor tyrosine 
kinase enzymes, due to the transmembrane spanning nature of GPCRs. Much of 
what was known about GPCR structure was inferred from studies of 
bacteriorhodopsin (reviewed by Khorana, 1988; Gether, 2000), a light activated 
proton pump expressed in the salt-loving archaebacterium Halobacterium 
halobium. This protein possesses seven a-helices, which span the membrane 
and, like vertebrate rhodopsin, uses the molecule retinal as a chromophore. In 
contrast, however, to mammalian GPCRs, bacteriorhodopsin is not coupled to G 
proteins and shares little sequence similarity with known GPCRs.
In 2000, the structure of rhodopsin, the first GPCR to be crystallised, was 
recorded at a resolution of 2.8 A [Palczewski et ah, 2000]. The crystal structure 
of this inactive receptor was a highly organised heptahelical transmembrane 
bundle, with the seven a-helices arranged in an anticlockwise manner when 
viewed from the extracellular perspective. This structure has provided an 
improved template for the analysis of GPCR structure-function studies and 
computational modelling of receptors for use in drug discovery activities.
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1.2.3 Classification of GPCRs
Over recent years, estimates of the number of GPCRs in the human genome have 
ranged from several hundred to greater than 1000. It is possible to categorise 
GPCRs into “endoGPCRs”, which are activated by endogenous molecules, and 
“chemosensory GPCRs”, which respond to exogenous stimuli such as odours 
and pheromones. A recent survey calculated there to be 367 endoGPCRs in the 
human genome, of which the majority have known ligands [Vassilatis et a l, 
2003]. The remaining GPCRs have no known ligand and are therefore classified 
as orphan receptors. There has been much interest in the identification of ligands 
for these orphan receptors, since many may represent novel therapeutic targets 
(reviewed by Stadel et a l, 1997; Murphy et a l, 1998; Wilson et a l, 1998; 
Howard et a l , 2001 ).
GPCRs may be classified into four distinct categories using phylogenetic 
analysis. Family A (rhodopsin-like) contains the majority (284) of endoGPCRs, 
which are activated by peptides (e.g. chemokine, bradykinin and orexin 
receptors) and small molecules such as neurotransmitters (e.g. dopamine, 
serotonin and acetylcholine receptors) and lipids (e.g. SIP, LPA and cannabinoid 
receptors) or were classed as orphan receptors (98). Family B 
(secretin/glucagon) comprises 50 GPCRs, of which 16 are activated by peptides; 
the remainder were orphans. Family C (metabotropic glutamate) receptors 
number 17, including 6  orphans, whilst family D receptors numbered 10 with no 
orphans [Vassilatis et a l, 2003].
Of the four families, family A, to which the SIP receptor family belongs, is the
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largest and best characterised. A phylogenetic tree of some family A receptors is 
shown in Figure 1.2.
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Figure 1. 2
Phylogenetic tree of selected family A GPCRs.
A number of highly conserved motifs are found within family A GPCRs, even 
though the overall homology between family members is quite low. This 
receptor family contains several proline residues present in TM domains IV, V, 
VI and VII, which probably introduce kinks into the helices. The conserved
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D/ERY motif is located at the intracellular end of TM III and appears to be 
important in receptor activation. The arginine residue of this amino acid 
sequence is the only residue to be absolutely conserved throughout family A. 
Many family A receptors possess two cysteine residues: one present within the 
second extracellular loop and the other located at the top of TM III. The 
disulphide bridge which forms between these two residues serves to subdivide 
this extracellular loop into two smaller loops and may function to constrain the 
transmembrane bundle.
The extracellular amino-terminal tail of family A receptors varies in length and 
frequently contains a number of N-linked glycosylation motifs (N-X-T/S). The 
role of this post-translational modification remains unclear but may influence 
transportation of protein to the cell membrane after its synthesis in the 
endoplasmic reticulum as well as stabilising the protein on the cell-surface 
[Fiedler and Simons, 1995]. The length of the carboxy-terminal intracellular tail 
is also highly variable but it is typically rich in serine and threonine residues, 
which are sites for phosphorylation by intracellular kinases. The intracellular tail 
of family A GPCRs also contains one or more cysteine residues: these are sites 
of palmitoylation which causes tethering of the C-terminal tail to the cytoplasmic 
face of the plasma membrane to create a fourth intracellular loop [Wess, 1998].
The site of ligand binding for family A receptors is dependent on the nature of 
the ligand. Small ligands such as biogenic amines, purines, eicosanoids and 
lipids are believed to bind within the transmembrane crevice whilst peptide and 
protein ligands appear to interact with the extracellular loop and tail regions of 
the receptor.
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1.2.4 Activation of GPCRs
1.2.4.1 Basic receptor theory
Ligands of GPCRs possess two fundamental properties: affinity and efficacy. 
The term affinity describes how well that ligand binds to the receptor, whilst the 
property of efficacy depicts the extent of the change in activation status of the 
receptor induced by that ligand. It is possible to determine the affinity of a 
ligand for a receptor using a technique such as radioligand binding, which allows 
calculation of the apparent dissociation constant (Kd) of that ligand for that 
receptor. If that ligand induces a functional response after binding, it is 
considered to display positive efficacy and is therefore defined as an agonist. In 
the current study, the term efficacy is used in the context of relative efficacy, and 
provides a description of the maximal response induced by that agonist, 
expressed as a percentage of that achieved by a full agonist (in this case SIP for 
the SIP4 receptor). An agonist that exhibits an relative efficacy of less than 100 
% is termed a partial agonist. Functional assays such as [^^SjGTPyS binding, 
adenylyl cyclase activation and receptor internalisation provide a means to 
measure the consequences of a ligand binding to a receptor and are used to 
determine the potency of a ligand. Agonist potency is described by the E C 5 0  
value, which represents the concentration of agonist required to elicit 50 % of the 
maximal response in that system. If a ligand merely binds a receptor and in so 
doing, prevents activation of that receptor by an agonist, it has zero efficacy and 
is therefore classed as an antagonist. In recent years, many molecules that were 
thought to be antagonists have been reclassified as inverse agonists. This reflects 
the ability of a receptor system to display activity in the absence of agonist 
stimulation (the phenomenon of constitutive activity, discussed in this chapter.
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section 2.4.3). An inverse agonist possesses negative efficacy and is able to 
reduce receptor constitutive activity (reviewed by Milligan et a l, 1995; de Ligt 
a/., 2000).
1.2.4.2 Conformational changes associated with GPCR activation
Despite the diversity amongst ligands which activate members of the GPCR 
superfamily, the underlying fundamental mechanism of activation of these 
proteins appears to have been conserved throughout evolution. This allows a 
receptor activated by a small molecule to stimulate the same intracellular 
signalling pathways via the same class of G proteins, as a receptor activated by a 
protein. Regardless of the location of the ligand binding pocket, GPCR 
activation is achieved via conformational change.
GPCRs appear to preferentially exist in an inactive conformation, which is likely 
to be the result of evolutionary pressure and is mediated by constraining 
intramolecular interactions. This concept resulted from a landmark study of the 
aib-adrenergic receptor [Kjelsberg et a l, 1992] in which mutation of A^ ^^  to any 
other amino acid conferred a constitutively active phenotype to this receptor. It 
was subsequently shown that a constitutively active mutant of the p2-adrenergic 
receptor was structurally unstable. Hence it seemed probable that receptor 
activation as a consequence of agonist binding or the introduction of a 
constitutively activating mutation reflected the release of inactivating constraints.
The highly conserved D/ERY motif present within TM III of family A receptors 
may be involved in initiating the conformational change which occurs as a 
consequence of GPCR activation. Protonation of the aspartic or glutamic acid 
residue within this motif promotes rotation of TM VI [Gether, 2000]. Movement
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of this transmembrane domain, along with TM III and possibly TM VII seems to 
be critical for the transition of a GPCR to the activated state (reviewed by Wess, 
1998; Gether, 2000).
1.2.4.3 Constitutive activity of GPCRs
Traditional receptor theory proposed the existence of a single quiescent receptor 
state in which binding of an agonist promoted a conformational change in the 
receptor to yield the activated, or functional state. Recent evidence suggests that 
GPCRs have the potential to be active in the absence of agonist stimulation; this 
phenomenon is known as constitutive activity (reviewed by Leurs et a l, 1998; de 
Ligt et a l, 2000; Gether, 2000).
The discovery of agonists which possessed negative efficacy (defined in this 
chapter, section 2.4.1) implied the existence of a pre-existing equilibrium 
between two receptor states, in which one receptor state was associated with G 
proteins (and hence may be thought of as being active) and the second state was 
as a free (or inactive) receptor. Based on this assumption, the mode of action of 
the inverse agonist was to inhibit the spontaneous interaction of the receptor with 
G protein.
In a landmark study of receptor constitutive activity, replacement of residues 
266-272 of the P2-AR with the homologous region of the aib-AR resulted in 
agonist-independent receptor signalling [Samama et a l, 1993]. The authors 
determined that the established ternary complex model of receptor activation was 
unable to mathematically describe the experimental results obtained with the 
constitutively active P2-AR. The ternary complex model was therefore extended 
so that it could account for constitutive activity. This model (shown in Figure
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1.3) assumes that the receptor exists in an equilibrium between two states, the 
uncoupled inactive receptor (R) and the active state (R*). Only the active R* 
form is capable of binding G protein and so the state AR*G represents the sole 
ternary complex which may be formed. The extent of spontaneous isomérisation 
between R and R* is described by the isomérisation constant (J). An increase in 
the term J therefore accounts for enhanced basal activity observed with 
constitutively active receptors.
A + R + G
A + R* + G
M
PK
A R +G
pj
AR* + G
a  + r *g  -,
aM
AR*G
Figure 1.3
Schematic representation of the extended ternary complex model.
This theoretical model describes the interactions of receptor which is considered 
to exist in equilibrium between the resting state (R) and the active state (R*), 
with agonist (A) and G protein (G). Equilibria are described by the various 
constants shown.
Reproduced from [Samama et a l, 1993].
Contrary to the traditional concepts, where receptors were thought to be “on” or 
“o ff’, it seems likely that GPCRs are mobile proteins which are subject to 
constant local unfolding and refolding reactions. Each of these reactions has the 
capacity to subtly change the receptor conformation and hence a GPCR may be 
considered to exist in an ensemble of conformational states [Kenakin, 2002].
-10 -
C h a p t e r  1
This range of conformations may be represented by a Gaussian distribution. In 
the absence of agonist, this population may be considered to exist in the 
“inactive” state. After agonist stimulation, the population shifts and is in the “G 
protein bound state” which allows activation of G protein and hence propagation 
of the signal. These two states may intersect (Figure 1.4) and the population of 
receptors within this intersection may spontaneously activate G protein without 
the need for agonist activation and hence represent the property of GPCR 
constitutive activity [Kenakin, 2002].
inactive'
state
G protein 
bound state
constitutive
activity
Figure 1. 4
GPCRs exist in an ensemble of microstates.
The inactive (non-signalling) and G protein bound (signalling) states are shown 
as two normal distributions. The shaded intersection between the two ensembles 
represents the conformations common to the two states. Receptors nominally in 
the inactive state that fall within this intersection can spontaneously activate G 
protein and hence represent GPCR constitutive activity.
Even though only a small proportion of the population of states of a given 
receptor may be in the constitutively active conformation, it is often possible to 
detect agonist-independent signalling simply by over-expressing that receptor. It 
has been suggested that many GPCRs possess a degree of basal activity and that 
receptor density is directly related to constitutive activity. Many studies of this 
nature have been reported (for example see Casarosa et a l, [2001]). The
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physiological relevance of constitutively active receptors is unclear, but it may 
be related to the concept of tonic regulation of physiological systems by 
receptors. Tonic regulation had previously been explained by the presence of an 
endogenous agonist and its continued interaction with that receptor system; 
however, the realisation that receptors possess constitutive activity sheds new 
light on this idea. It is tempting to speculate that physiological tone mediated by 
GPCRs may be mediated by receptor basal activity as an addition to, or instead 
of, the action of endogenous agonists.
1.2.5 Heterotrimeric G proteins
Guanine nucleotide binding proteins (G proteins) couple membrane bound 
GPCRs to their cellular effector systems. GPCR-mediated signal transduction is 
considered to progress via activation of G proteins. Recently however, it was 
reported that a mutant of the angiotensin 11 type 1 (ATla) receptor which lacked 
the ability to couple to G proteins was able to activate the ERK pathway [Seta et 
a l, 2002]; so it is possible that a GPCR can still transmit information to cells 
even if interaction with their cognate G protein is prevented.
Heterotrimeric G proteins have been said to be “involved in everything from sex 
in yeast to cognition in humans” [Marx, 1994]. The G protein heterotrimer 
comprises a, P and y subunits, which are the products of distinct genes. When 
stimulated, G proteins undergo a cycle of activation and deactivation in which 
the a  subunit and Py heterodimer are able to interact with their reaction partners 
(such as the GPCR itself, guanine nucleotides and effector molecules). During 
this cycle, the inactive, GDP bound G protein heterotrimer interacts with an 
activated receptor. This causes dissociation of bound GDP from the G a subunit.
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which is replaced by GTP present within the cellular cytosol. Binding of GTP 
promotes a conformational change within the G a subunit, causing dissociation of 
this subunit from the Py heterodimer and allowing interaction of the GTP-bound 
G a and Py subunits with effector molecules. Intrinsic GTPase activity of the G a 
subunit cleaves the terminal phosphate group from the bound GTP, converting it 
to GDP and permitting reassociation of the G a G protein with the py 
heterodimer, which causes deactivation of the G protein subunits.
At least 20 G protein a  subunits, encoded by 17 different genes, have been 
identified. These may be divided into the four families: Gas, Gai/o, Gaq/n, 
G ai2/i3, which couple to different effector systems (summarised in Table 1.1).
Family Effector systems regulated______________________________
Gas Stimulates adenylyl cyclase isoforms
Gai/o/t Further divided into Gai/o/z and Gapg sub groups
Gai/o/z subunits inhibit some adenylyl cyclase isoforms 
Gat/g subunits: Gat stimulates retinal phosphodiesterase;
Gag presumably stimulates a gustatory effector 
Gaq Activates p-isoenzymes of phospholipase C and non-receptor
Btk family tyrosine kinase enzymes 
G ai2/i3 Regulates low molecular weight Rho family G proteins_______
Table 1.1 
Summary of G protein a  subunit actions.
Activation of adenylyl cyclase and formation of cAMP is the most well 
established paradigm for second messenger generation in response to GPCR 
activation and is mediated by the Gag class of G protein. Activation of a Gaj/o 
subunit inhibits cAMP formation via inhibition of adenylyl cyclase. There are 
three distinct Goti species: Gau, Gai2 and Gaig. Subunits of the Gaq/n class 
couple to various isoforms of phospholipase C (PEG) and include Gaq, G an,
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G ai4 and G ai5/i6. The Ga^/is family appear to be involved in activation of the 
low molecular weight G protein, Rho (reviewed by Sah et a l, [2000]).
Activation of G a and Gpy subunits can affect the activity of a whole host of 
effector molecules and/or ion channels. Thus, the pattern of effects which result 
from receptor activation are complex. Additionally, cells may express multiple 
receptors that respond to the same ligand by activating opposing signalling 
pathways. It has also been suggested that the actions of different agonists at the 
same receptor can activate different G proteins (the phenomenon of agonist 
trafficking, [Kenakin, 2002; Hermans, 2003]).
Clearly, the ability of a given GPCR to propagate a signalling response via 
activation of a particular G protein requires interaction between receptor and G 
protein. Investigations into the regions of the receptor involved in mediating 
such interactions have been obtained through the analysis of hybrid receptors 
constructed between functionally distinct GPCRs. Amino acids present within 
the second and third intracellular loops appear to be essential to confer selectivity 
of G protein recognition [Wess, 1998; Hamm, 2001]. Similarly, efforts have 
been made to understand the areas of the G a subunit which form contacts with 
the active GPCR. The five carboxy-terminal amino acids of G a subunits are key 
in controlling the specificity of receptor-G protein coupling [Wess, 1998]. 
Chimeric G a G proteins in which these five amino acids are replaced with those 
from a different class of G protein have been used to stimulate pathways that 
would not normally be activated by that particular receptor [Milligan and Rees, 
1999; Kowal et a l, 2002]. For example, expression of a Gaq/i chimera (which is 
a Gaq backbone containing the final five amino acids from Gai) permits
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stimulation of PLCP by the dopamine D2 or adenosine A1 receptors, which 
normally couple exclusively to 0%  G proteins [Wess, 1998].
Many G a subunits have been shown to be expressed almost ubiquitously in 
mammalian cells, with exceptions such as Gao, which is expressed in brain, and 
G ai6, expression of which is restricted to B and T cells [Offermanns and Simon, 
1995; Grant et a l, 1997]. The murine G protein, G ai5 and its human orthologue, 
G ai6, are promiscuous G proteins which are thought to be able to couple to most 
GPCRs [Stables et a l, 1997] and hence are often employed when attempts are 
made to assign ligands to orphan receptors. The likelihood of the orphan 
receptor coupling to the promiscuous G protein is high and any activation of the 
receptor may be conveniently measured using calcium flux assays.
Various exogenous agents can interfere with the interaction between G proteins 
and GPCRs, or can modulate the activity of the G protein itself. Such reagents 
may be useful in the elucidation of the nature of G proteins activated by a 
particular receptor. The bacterium Bordetella pertussis, the causative agent of 
whooping cough, produces a number of toxins of which one, pertussis toxin (also 
named islet activating protein), inactivates G proteins of the Gai class via ADP- 
ribosylation. This covalent modification serves to prevent interaction of an 
agonist- (or constitutively-) activated receptor with GDP-bound G protein. 
However, pertussis toxin treatment does not affect the intrinsic ability of the G a 
subunit to exchange guanine nucleotides or to hydrolyse GTP (reviewed by 
Milligan [1988]). The location of Gai G protein subunit ADP-ribosylation by 
pertussis toxin is a conserved cysteine residue present near the carboxy-terminus
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of the protein. Mutation of this residue to any other amino acid has been shown 
to confer resistance to the actions of this toxin [Bahia et a l, 1998].
Another exotoxin, in this case isolated from culture supernatants of Vibrio 
cholerce, modulates Gag G protein activity. Like pertussis toxin, cholera toxin 
also possess ADP-ribosyltransferase activity which catalyses the transfer of 
ADP-ribose to an arginine residue present in the GOg subunit. This modification 
stabilises the GTP-bound form of the a  subunit of Gg, and as the intrinsic 
GTPase activity of the subunit is inhibited, the Gotg subunit is in a permanently 
activated state.
1.2.6 Termination of signalling at GPCRs
Activation of a GPCR leads to its interaction with G protein, which becomes 
stimulated as a result of this interaction. In its active conformation, a GPCR may 
stimulate many G protein molecules resulting in amplification of the initial 
stimulus. Negative regulation of responses to agonists is clearly necessary to 
allow control of such systems.
The lifetime of the signalling event is dictated by the longevity of the Ga-GTP 
species, which is dependent on the intrinsic GTPase activity of the G a subunit. 
This activity promotes hydrolysis of GTP back to GDP and allows reassociation 
of the G a subunit with the py heterodimer to form the inactive, GDP-bound 
heterotrimeric G protein. However, this is not normally sufficient to account for 
the rapid termination of signalling which is observed in most systems. Recently, 
the actions of a family of RGS (regulators of G protein signalling) proteins have 
been shown to further attenuate signalling mediated via Gai or Gaq G proteins.
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Interaction between RGS proteins and the GTP-bound G a subunit causes a 
significant increase (100-1000 fold) in the GTPase activity of the target G a 
subunit and therefore silences the G protein-signalling pathway (reviewed by 
Hepler, 1999; Zhong and Neubig, 2001).
Signalling is also commonly regulated at the level of the GPCR itself via the 
phenomenon of receptor desensitisation. There are two types of desensitisation: 
homologous and heterologous, each of which will be briefly considered.
Homologous desensitisation describes the specific attenuation of signalling 
arising from an activated receptor. The active receptor conformation is a target 
for phosphorylation by members of the G protein-coupled receptor kinase (GRK) 
family (reviewed by Buenemann and Hosey, 1999; Penn et a l, 2000; Ferguson, 
2001). These kinases phosphorylate serine and threonine residues present in the 
third intracellular loop and carboxy-terminal tail of the active receptor, which 
permits binding of P-arrestin proteins [Ferguson, 2001]. P-arrestin appears to 
function as an adapter protein to link the receptor with components of the 
clathrin internalisation machinery. Subsequent to GPCR phosphorylation and 
binding of P-arrestin, receptors may be sequestered from the plasma membrane. 
Once internalised, the GPCR may be resensitised, dephosphorylated and 
recycled back to the plasma membrane or targeted to lysosomes for degradation. 
The fate of the internalised GPCR appears to depend on the arrangement of 
serine residues in the carboxy-terminal tail of the receptor. Receptors which 
possess a serine cluster within this region are internalised and recycle slowly 
(e.g. vasopressin V2 receptor) whereas receptors which lack such a cluster are 
rapidly dephosphorylated and recycled back to the cell-surface (e.g. p]AR)
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[Oakley et a l, 1999]. In addition to their primary role in GPCR densitisation, 
there is some evidence that P-arrestins can also act as scaffold proteins and may 
facilitate GPCR-mediated activation of the mitogen activated protein (MAP) 
kinase pathway [McDonald et a l, 2000]. It has also been suggested that agonist- 
dependent phosphorylation of GPCRs on serine/threonine residues may be 
mediated by casein kinase l a i n  addition to the actions of GRKs (reviewed by 
Tobin [2002]).
The process of heterologous desensitisation is independent of stimulation of that 
receptor by an agonist and is achieved via receptor phosphorylation by the 
serine/threonine kinases, protein kinase A (PKA) and protein kinase C (PKC), 
which leads to loss of receptor function.
1.3 The Edg family of GPCRs
1.3.1 Introduction to Edg receptors
In 1990, an abundant transcript induced in phorbol ester-treated differentiating 
endothelial cells was cloned and found to encode a 381 amino acid orphan 
GPCR [Hla and Maciag, 1990]. The gene product was named Endothelial 
differentiation gene i  (Edgl) and was the first member of this new receptor 
subfamily. Even before the ligand for this receptor had been identified, it was 
suggested that Edgl may be involved in angiogenesis since it was an immediate-
early gene induced in cultured human umbilical vein endothelial cells (HUVEC).
An elegant study used the yeast two-hybrid system to demonstrate the ability of 
the third intracellular loop of Edgl to associate with Gai G proteins hence 
suggesting the pathway that may be stimulated by this orphan receptor. [Lee et 
a l, 1996]. The subsequent observation that Edgl-transfected HEK-293 cells
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formed a network of cell-cell aggregates when grown in FCS-containing 
medium, whilst untransfected cells maintained normal morphology under the 
same conditions led to the identification of sphingosine- 1 -phosphate (SIP) as the 
putative endogenous agonist for this receptor [Lee et a l, 1998]. The related 
Edg2 receptor, which had been cloned from a neuronal cell cDNA library, had 
already been identified as a receptor for lysophosphatidic acid (LPA) [Hecht et 
a l, 1996]. These findings suggested that the remaining orphans within this 
receptor family would be activated by these ligands and that the Edg receptors 
represented a new receptor family, which were activated by the 
lysophospholipids SIP and LPA. Further Edg family members were cloned and 
studies of these GPCRs conducted by many groups have confirmed their identity 
as high affinity receptors for SIP or LPA (reviewed by Fukushima et a l, 2001; 
Kluk and Hla, 2002; Takuwa et a l, 2002). A total of eight family members have 
been identified and phylogenetic analysis of GPCRs from the human genome 
predicted that there are no further Edg receptors [Vassilatis et a l, 2003].
The ligands for the Edg receptor family are structurally similar. SIP and LPA 
(shown in Figure 1.5) both contain a polar head group with a long chain fatty 
acid tail. The Edg receptors are most closely related to the cannabinoid (CB) 
receptor family (shown in the phylogenetic tree in Figure 1.2), and share 
approximately 25 % sequence identity with CB receptors. The endogenous 
ligands of the cannabinoid receptors, anandamide and 2 -arachindonoylglycerol, 
have structures which are similar to SIP and LPA since they also comprise a 
polar head group and long aliphatic tail. In common with the CB receptors, Edg 
family GPCRs lack the commonly conserved cysteine residue present within the 
first extracellular loop of most family A receptors (previously discussed in this
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chapter, section 2.3). These common features might suggest that Edg and CB 
receptors evolved from a common ancestral gene.
B
Figure 1. 5
Structures of Edg family ligands.
A Sphingosine-1-phosphate (SIP)
B Lysophosphatidic acid (LPA)
(shown here is 18:1 LPA)
The signalling characteristics of the Edg receptor family have been extensively 
studied and the G proteins to which each receptor couples has been determined. 
Each Edg receptor couples to GoCi G proteins and with the exception of Edgl, 
they couple to additional G protein families (summarised in Table 1.2).
Receptor Ligand G protein coupling
Edgl SIP Gi
Edg2 LPA G i, Gq, G i2/13
Edg3 SIP G i, Gq, G i2/13
Edg4 LPA G i, Gq, G i2/13
Edg5 SIP G i, Gq, G i2/13
Edg6 SIP G i, G i2/13
Edg7 LPA G i, Gq
Edg8 SIP G i, G i2/13
Table 1. 2
Summary of G protein activation by Edg family receptors.
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1.3.2 Classification of Edg receptors
The colloquial name “Edg”, which has been used to describe this family of 
receptors was originally used to describe the immediate early response gene 
product cloned from HUVEC, Edgl [Hla and Maciag, 1990]. Other orphan 
receptors were cloned and given various trivial names (e.g. vzg-1 for Edg2) and 
it became clear that the term Edg bore no relevance to the other seven receptors. 
The Edg family members were renamed in 2002, in accordance with lUPHAR 
guidelines, whereby a receptor is named using an abbreviation for the natural 
agonist with the highest potency, followed by a subscript Arabic numeral [Chun 
et a l, 2002]. The order of the numbering of the reclassified Edg receptors was 
also chosen to reflect the chronology of publication of the novel receptor 
sequences. Table 1.3 shows the new names of the Edg receptors.
lUPHAR name Edg name Previous names Ligand
SlPi Edgl
SIP2 Edg5 H218, AGR16
SIP3 Edg3 SIP
SIP4 Edg6
SIP5 Edg8 nrg-1
LPAi Edg2 vzg-1 , reel.3
LPA2 Edg4 LPA
LPAs Edg?
Table 1.3
Summary of Edg family receptor classification consistent with lUPHAR 
guidelines.
Phylogenetic analysis of the Edg receptor family reveals that the receptors form 
two clusters, which correspond to the ligands by which they are activated (Figure 
1.6).
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-LPA, (Edg2) 
-LPAj (Edg4) 
— LPA3 (Edg?)
'SIP, (Edgl) 
-S IP 3  (Edg3) 
-SIP3 (EdgS)
-S lP g  (EdgS) 
—  SIP4 (Edg6)
Figure 1. 6
Phylogenetic tree of Edg family receptors.
Comparison of sequences of Edg family GPCRs reveal the receptors form two 
clusters, which correspond with ligand preference. The Edg family was renamed 
to reflect ligand preference exhibited by the receptors (in accordance with 
lUPHAR guidelines) and the new nomenclature is used here.
1.3.3 The SIP receptor family
The SIP receptor family has been the subject of several comprehensive reviews 
(for example see, Pyne and Pyne, 2000a; Takuwa et a l, 2001; Takuwa et a l, 
2002; Kluk and Hla, 2002; Siehler and Manning, 2002). SIP receptors are found 
in many organisms, including the puffer fish Takifugu rubripes [Yamaguchi et 
a l, 1999] and the sea squirt Ciona intestinalis, which indicates the highly 
conserved nature of GPCR-mediated SIP signalling. Characterisation of the 
members of the SIP receptor has revealed that these highly specific SIP 
receptors mediate different responses to SIP and that cells may express multiple 
SIP receptors which activate opposing pathways (summarised in Figure 1.7). 
Dissection of the pharmacology of the individual SIP receptors has been 
hampered by the expression of endogenous SIP receptors on most cell types and 
the lack of receptor selective agonists or antagonists. Progress is being made in 
this area however, and a recent publication described the identification of an 
SlPi/3 selective agonist [Im et a l, 2 0 0 1 a].
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Figure 1. 7
Signal transduction by SIP family receptors.
SIP, present in serum binds to members of the SIP receptor family to activate 
the various G proteins shown. Different SIP receptors couple to different G 
protein subfamilies (e.g. SI Pi activates Gj whilst SIP2 is linked to G,, Gq and 
G12/13). G protein activation leads to stimulation or inhibition of various 
downstream intracellular pathways, some of which are shown here.
Reproduced and updated from Spiegel and Milstien [2003].
Since it is the prototypical SIP receptor, SI Pi has been the most extensively 
studied member of this receptor family. The SI Pi receptor, which was 
previously named Edgl and has been introduced in this chapter, section 3.1, is a 
381 amino acid protein, the mRNA of which is widely expressed. The human 
SI Pi gene is located on chromosome lp21. As described previously in this 
chapter, overexpression studies defined SlPi as a high affinity SIP receptor (fQ 
= 8.1 nM) [Lee et a l, 1998]. The related molecule, dihydrosphingosine-1 - 
phsophate, which lacks the double bond present within the SIP backbone, was 
also able to bind and activate this receptor. High concentrations of the related 
molecule sphingosylphosphorylcholine (SPC) were able to displace SIP, in 
common with its effects as a low affinity ligand for other SIP receptors. Rapid 
internalisation of the receptor occurs after stimulation with SIP which is
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followed by recycling of the receptor back to the plasma membrane [Liu et a l, 
1999]. Additionally, Kohno et ah, [2002] showed that internalisation of this 
receptor was dependent on receptor glycosylation since mutant SI Pi which could 
not be glycosylated was poorly internalised in response to SIP. Agonist- 
dependent phosphorylation of SI Pi has been found to be mediated by GRK-2 
and the extreme carboxy-terminus of the receptor was shown to be the target for 
the actions of this kinase. Phosphorylation of residues within this region was 
required for receptor internalisation [Watterson et a l, 2002].
Many different cellular responses to SIP have been shown to depend on SI Pi. 
SI Pi couples to Goti G proteins and stimulation of the receptor with SIP 
promotes activation of ERK, inhibition of adenylyl cyclase and Rac-dependent 
chemotaxis. Reports describing the ability of SI Pi to stimulate mobilisation of 
calcium are conflicting and may suggest that this response is cell type dependent 
[Siehler and Manning, 2002]. Activation of SI Pi positively regulates 
proliferative/survival and migratory signalling pathways in many cell types. 
Endothelial cells migrate towards SIP in a manner which requires 
phosphorylation of SI Pi by Akt [Lee et a l, 2001], although it is unlikely that 
other SIP receptors would be Akt substrates as the residue of SI Pi which is 
phosphorylated is not conserved throughout this receptor family. Binding of SIP 
to SI Pi expressed on endothelial cells has been shown to stimulate endothelial 
nitric oxide synthase (eNOS), resulting in production of the potent vasodilator, 
nitric oxide (NO) [Igarashi and Michel, 2001].
Disruption of the SI Pi gene in mice caused embryonic lethality between El 2.5 
and E14.5. This was due to the lack of vascular smooth muscle cell recruitment
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to the developing vasculature and demonstrated a clear role for SI Pi in vascular 
maturation [Liu et a l, 2000]. Specific deletion of the SI Pi gene in endothelial 
cells of mice using the conditional Cre/LoxP system produced a highly similar 
phenotype to that of the SI Pi knockout. It was suggested the phenotype of the 
SI Pi V mice was due to the loss of function of this receptor in endothelial cells, 
rather than vascular smooth muscle cells, since deletion of SI Pi in vascular 
smooth muscle cells did not affect vascular maturation [Allende et a l, 2003].
Interestingly, the phenotype of the SI Pi '/' mice was similar to that caused by 
deletion of platelet-derived growth factor (PDGF-p) or its receptor (PDGFR-p) 
in mice. This suggested that vascular maturation may involve cross-talk between 
SlPi and the PDGF-P receptor. This concept was supported by the observations 
of Hobson et a l, [2001] who showed that PDGF-stimulated cell motility in 
HEK-293 cells was dependent on SlPi expression. The authors proposed a 
sequential model in which PDGF activates sphingosine kinase promoting release 
of SIP, which acts as an autocrine mediator to stimulate SI Pi thereby activating 
the small G protein Rac which is required for cell motility. Studies by Alderton 
et ah, [2001] reported that PDGFR-p forms a tethered complex with SlPi in 
HEK-293 cells and is involved in cell proliferation. Within this complex, 
efficient stimulation of the ERK pathway by SIP and PDGF was reported to 
occur through a mechanism that involves PDGR-P tyrosine phosphorylation of 
GoCi, which is released upon SI Pi stimulation.
SIP2 (Edg5) was independently cloned from rat by two groups and named 
AGR16 or H218 [Fukushima et a l, 2001]. The human gene, located on 
chromosome 19pl3.2, encodes a 352 amino acid protein and SIP was shown to
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be a high affinity agonist (Kd = 27 nM) of this receptor [Van Brooklyn et a l,
1999]. The SIP2 transcript is abundantly expressed in heart and lung, is detected 
at lower levels in brain and is expressed more strongly in embryonic brain. 
Transfection of cells with SIP2 induces cell rounding and neurite retraction in 
response to SIP [Van Brooklyn et a l, 1999]. SIP2 couples to multiple (GoCi, 
Gaq, G ai2/i3) G proteins and can also activate Rho and induce stress fibre 
formation. In contrast to SI Pi, which stimulates Rac and promotes cell 
movement, SIP2 is chemorepellant, inhibiting Rac and blocking migration to 
SIP [Takuwa, 2002].
Targeted deletion of the SIP2 gene was reported to lead to neuronal dysfunction, 
although surprisingly there were no apparent anatomical or physiological 
abnormalities [MacLennan et a l, 2001]. Interestingly, the zebrafish gene Mil 
(Miles Apart), which closely resembles the mammalian SIP2 gene, appears to be 
involved in cardiac development [Kupperman et a l, 2000].
The SIP3 receptor (formerly called Edg3) was initially isolated from human 
DNA and mapped to chromosome 9q22.1-22.2 [Yamaguchi et a l, 1996]. The 
gene encodes a 378 amino acid protein which was shown to bind SIP with high 
affinity (Kd = 26 nM) [Kon et a l, 1999]. SIP3 mRNA is expressed in many 
tissues including heart, brain, liver, lung, kidney, pancreas, thymus and spleen 
[Kluk and Hla, 2002]. SIP3 couples to multiple G proteins to exert its effects 
and the ability of this receptor to stimulate Gai, Gaq and G ai2/i3, but not Gas, 
has been demonstrated using [^^S]GTPyS binding [Windh et a l, 1999]. 
Activation of SIP3 by SIP promotes mobilisation of intracellular calcium via 
PLC activation, stimulation of ERK, cell migration, cytoskeletal organisation and
- 26 -
C hap te r 1
morphogenetic differentiation [reviewed by Kluk and Hla, 2002; Siehler and 
Manning, 2002]. In common with SIP2, SIP3 has been shown to activate nuclear 
factor kB (NF-kB) in response to SIP stimulation and this appears to reflect 
activation of Gq G proteins [Siehler et a l, 2001].
Deletion of the SIP3 gene in mice did not produce any obvious phenotypic 
abnormality [Ishii et a l, 2001]. This suggested a non essential role for SIP3 in 
murine development, however activation of PLC by SIP was significantly 
decreased in embryonic fibroblasts derived from SIP3 V mice. Generation of 
mice null for both SIP2 and SIP3 caused reduced litter sizes and significant 
infant mortality; although those pups which survived lacked any obvious 
phenotype [Ishii et al., 2002]. In vitro analysis of SIP signalling in SIP2SIP3 V 
embryonic fibroblasts showed severe defects in activation of Rho, PLC and 
calcium mobilisation. SIP receptor signalling therefore appears to be involved 
in perinatal survival and the signalling of SIP2 and SIP3 receptors is non- 
redundant.
The SIP4 gene was cloned from in vitro differentiated dendritic cells and was 
originally named Edg6  [Graeler et a l, 1998]. This receptor will be discussed in 
more detail in this chapter, section 3.5.
The final SIP receptor, SIP5 (previously named Edg8 /nrg-l) was cloned from rat 
PC 12 cells and encodes a 400 amino acid protein. SIP5 was shown to be another 
high affinity SIP receptor (Kd = 2 nM [Im et a l, 2000a]) and has differential 
expression patterns in rat and human. The human SIP5 gene is located on 
chromosome 19pl3.2 and its mRNA has been detected in skeletal muscle, heart, 
and kidney with lower expression in liver and placenta; in contrast, rat SIP5
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mRNA was predominantly expressed in brain [Niedemberg et a l, 2002]. 
Activation of SIP5 causes cell rounding, mobilisation of calcium, cell survival 
and inhibition of both adenylyl cyclase and ERK activation [Im et a l, 2000a; 
Niedemberg et a l, 2003a]. Differential effects on cell proliferation were 
observed between human and rat SIP5 : the rat receptor is antiproliferative whilst 
the human receptor is not [Niedemberg et a l, 2002]. SIP5 can couple to Gi and 
G12/13 G proteins and was reported by Niedemberg et a l, [2003a] to be 
constitutively active. Interestingly, constitutive inhibition of adenylyl cyclase 
was enhanced by SIP-induced receptor activation but the ability of SIP5 to 
inhibit basal ERK activity was not affected by SIP. These data were interpreted 
as suggesting that different signal transduction pathways are not equally 
activated through a constitutively active GPCR that couples to multiple G 
proteins. It is not clear whether this scenario is applicable to other SIP receptors.
The effect of deleting the SIP5 gene in mice has not been reported, but given the 
reported differences in expression pattems between human and rodent forms of 
SIP5 [Niedemberg et a l, 2002], it is unclear how useful analysis of SIP5 null 
mice would be in understanding the function of the human receptor.
Significant progress has been made in elucidating the in vivo function of the 
various SIP receptors and the generation of mice null for SI Pi demonstrated the 
critical involvement of the receptor in vascular maturation [Liu et a l, 2000]. 
Conditional knockout experiments and production of double knockout mice have 
been used to further address the question of the role of these receptors in 
physiology and disease. Additional work is required to fully unravel the 
significance of SIP receptor activation and to understand precisely how the
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different receptor isoforms, which can have similar or opposing functions, 
control the diverse effects of SIP in vivo.
1.3.4 The LPA receptor family
The LPA receptor family comprises three closely related GPCRs, which bind 
LPA with nM affinity. A fourth GPCR has recently been designated as LPA4  but 
this receptor is only distantly related and shares approximately 20 % sequence 
identity with the other LPA receptors (shown in Figure 1.2). This receptor 
(previously named P2Y9/GPR2 3 ) was found to bind LPA with high affinity (45 
nM Kd) and couples to mobilisation of intracellular calcium and stimulation of 
adenylyl cyclase activity [Noguchi et a l, 2003]. This LPA receptor has evolved 
from a different ancestor than that of the LPA1.3 receptors and the role of LPA4  
in vivo is currently unclear.
Unlike the SIP receptors, the LPA1.3 receptors contain an intron located within 
the middle of TM VI, the location of which is absolutely conserved between 
human and mouse [Contos and Chun, 1998; Contos and Chun, 2000; Contos and 
Chun, 2001]. This suggests that these LPA receptors were derived from a 
common ancestral gene. Significant progress has been made in this area since 
the identification of the first LPA receptor. Most notably, synthetic LPA 
mimetics have been developed, some of which show receptor subtype-selective 
activities [Im et a l, 2000b], whilst others act as competitive antagonists [Sardar 
et a l, 2002].
The ligand, LPA can be produced by several distinct enzymatic mechanisms. 
Intracellularly, the sequential actions of phospholipase D (which converts 
phosphatidylcholine to phosphatidic acid) and phospholipase A1 and A2
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enzymes (which deacylate phosphatidic acid) yield LPA. Phospholipase A2 may 
also be secreted from cells to produce extracellular LPA. An alternative route of 
production of extracellular LPA is via the lysophospholipase D enzyme, 
autotaxin, which acts within plasma to hydrolyse lysophosphatidylcholine and is 
believed to represent the principal route of production of extracellular LPA. 
Bioactive LPA is dephosphorylated by enzymes of the lipid phosphate 
phosphohydrolase family, some of which may possess ecto-activity. Finally, 
LPA may be produced from PA (and vice versa) by the action of the LPA acyl 
transferase enzyme.
LPA is released from activated platelets and is present in serum at low |xM 
concentrations. Although the term LPA is used to refer to the single entity 1- 
oleoyl LPA, it actually describes a family of molecules which can contain 
different fatty acyl chains with different levels of saturation. LPA is a potent 
signalling molecule which is involved in many physiological and 
pathophysiological process such as cell differentiation and proliferation, 
induction of apoptosis, cytoskeletal arrangements and cell invasion [reviewed by 
Y q et a l, 2002]. LPA affects a wide variety of cell types and reflects the 
widespread expression of the various LPA receptors. The LPA receptor family 
has been recently reviewed [Fukushima et a l, 2001; Fukushima and Chun, 
2 0 0 1 ]; each receptor will now be briefly discussed.
LPAi was identified as a result of studies designed to identify novel GPCRs 
associated with neuron production in mouse cerebral cortex. It was named 
ventricular zone gene (vzg-1) and assigned as the second Edg family member 
since it was similar to the orphan Edgl (SIPi) receptor. The human LPAi gene
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is located on chromosome 9p31.3-32 and encodes a protein of 364 amino acids 
[An et a l,  1997; Fukushima and Chun, 2001]. Analysis of heterologously 
expressed LPAi revealed that stimulation of the receptor caused cell 
proliferation, Rho-mediated actin rearrangement and stimulation of serum 
response elements via activation of Gai, Gttq and G an/n G proteins. The 
receptor was found to be widely expressed in the murine embryonic nervous 
system where it may play a role in neurogenesis and is also expressed in adult 
central nervous system (CNS) where it may be involved in the biology of 
myelinating cells. Receptor mRNA is also expressed outside the CNS, 
predominantly in testis and intestine, and moderately in heart, lung, kidney, 
spleen, thymus, muscle and stomach, as well as in several cancers. Disruption of 
the LPAi gene in mice was expected to cause nervous system defects. Targeted 
deletion of this gene resulted in approximately 50 % neonatal lethality due to 
decreased suckling, possibly caused by olfaction defects [Contos et a l, 2000]. In 
addition, LPAi ’/' mice were smaller and exhibited craniofacial abnormalities and 
increased apoptosis in peripheral nerves. This suggests a role for LPAi in 
nervous system development and survival of myelinating cells.
Functional LPAi has recently been detected at the cell nucleus [Gobeil et a l, 
2003]. Stimulation of nuclear LPAi caused activation of Gi/o G proteins, 
mobilisation of nuclear calcium and induction of pro-inflammatory gene 
expression. This observation suggests that the nucleus may be a potential 
organelle for intracrine signalling by lysophospholipids. It will be interesting to 
discover whether other LPA or SIP receptors are also active at the cell nucleus.
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The LPA2 receptor, which is located on human chromosome 19pl2, is a 351 
amino acid GPCR that shares approximately 46 % sequence identity with LPAi. 
Its sequence was discovered from database searches of human genomic DNA 
during attempts to identify LPAi receptor homologues [An et a l, 1998]. Several 
variants of this receptor have been detected in human cancer cells and in fact the 
original report describing the LPA2 (Edg4) receptor had cloned and characterised 
a mutant from an ovarian cancer cell line [An et a l, 1998]. This clone contained 
a base deletion which caused a frame shift and resulted in a mutant that 
contained an extended carboxy-terminal tail [Contos and Chun, 2000]. 
Subsequent comparison with the wild type receptor did not reveal any 
differences in G protein coupling; both wild type and mutant forms of the 
receptor couple to Goci, Gttq and G an/n G proteins [An et a l, 1998; Ishii et a l,
2000] and the role of mutant LPA2 receptors in cancer is unclear. Activation of 
LPA2 results in activation of PLC, stimulation of ERK, cell rounding and 
inhibition of adenylyl cyclase [Ishii et a l, 2000]. The gene is expressed in 
peripheral leukocytes, thymus, spleen, prostate and pancreas [An et a l, 1998]. 
Expression of LPAi and LPA2 has been shown to change after T cell activation 
and these receptors transduce opposing effects on T cell motility which may be 
relevant in vivo [Zheng et a l, 2001]. LPA2 knockout mice exhibited no obvious 
phenotypic abnormalities and failed to reveal any obvious behavioural, 
anatomical or histological defects [Contos et a l, 2002a]. Indeed, the same report 
describes analysis of mice null for both LPAi and LPA2, which displayed 
essentially the same phenotype as LPAi /’ mice. This suggests that the LPAi 
and LPA2 receptors have redundant functions in mediating multiple LPA 
responses.
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The discovery of a third LPA receptor was independently reported by two groups 
[Bandoh et ah, 1999; Im et ah, 2000b]. The LPA3 gene is present on human 
chromosome lp22.3-31.1 [Contos and Chun, 2001] and the resultant 353 amino 
acid receptor shares approximately 50 % sequence identity with LPAi and LPA%. 
LPA3 mRNA was found to be expressed in heart, pancreas, kidney, brain, 
prostate and testis, and less abundantly in ovary and lung [Bandoh et a l, 1999; 
Im et a l, 2000b]. An LPA3 variant (HOFNH30) which is highly expressed in 
placenta has also been identified and may be a splice variant of LPA3 [Fitzgerald 
et a l, 2000]. LP A-stimulation of LPA3 promoted mobilisation of calcium from 
intracellular stores which was mediated via activation of Gaq G proteins and was 
dependent on activation of PLC [Im et a l, 2000b]. The receptor has also been 
reported to couple to Gai G proteins although other groups have contradicted 
these findings [Fukushima et a l, 2001]. In marked contrast to the effects of 
LPAi and LPA2 stimulation, activation of LPA3 was found to promote neurite 
elongation and inhibited LPA-induced cell rounding in LPA1/2 expressing cells 
[Ishii et a l, 2000]. Analysis of in vivo LPA3 function by deletion in mouse has 
not yet been reported and the functional role of this receptor remains unclear.
1.3.5 SIP4 (Edg6 )
SIP4 (formerly named Edg6 ) was cloned in 1998 from in vitro differentiated 
dendritic cells, in an effort to discover novel chemokine receptors [Graeler et a l, 
1998]. It was categorised as the sixth member of the then named Edg receptor 
family, on the basis of sequence similarity with known members of this family. 
The sequence of this gene coded a 384 amino acid protein, which bore the 
hallmarks of being a GPCR since it possessed seven putative transmembrane 
domains. The translated SIP4 sequence also contained a putative N-
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glycosylation site in the amino-terminal tail as well as several sites for potential 
modification by PKC phosphorylation and palmitoylation within the carboxy- 
terminal region [Graeler et a l, 1998]. The SIP4 receptor shares greatest 
sequence identity with other SIP receptors and is less closely related to the LPA 
receptors, summarised in Table 1.4. It is also closely related to the cannabinoid 
receptors, sharing 20 % and 34 % sequence identity with CBl and CB2, 
respectively.
Receptor Sequence identity with SIP4
SlPi 39%
SIP2 36%
SIP3 40%
SIP5 37 94
LPAi 30%
LPA2 35%
LPA3 30%
Table 1. 4
Sequence identity between SIP4 and other SIP and LPA receptors.
SIP4  has a very distinct pattern of mRNA expression and is principally detected 
within the immune system. This is in marked contrast to that of the other SIP 
receptors (detailed in this chapter, section 3.3) and suggested that SIP4  may play 
a role in immune function. More recent studies of SIP4  expression have added 
to the initial findings, and are summarised in Table 1.5. In addition, the study of 
[Vassilatis et a l, 2003] detected low levels of SIP4  mRNA in murine cerebral 
tissues (e.g. brain stem, hippocampus, striatum, thalamus). Since no other 
studies have detected this transcript in these tissues, the significance of these 
findings is unclear.
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The pattern of SIP4 expression in various human tissues has been investigated 
using a polyclonal anti-SlP4 antibody in an immunohistochemistry study. The 
findings are summarised in Table 1.5 and Figure 1.8 shows some examples of 
SlP 4-expressing cells present within tissue sections.
Whilst significant advances were made with the other SIP receptors, progress 
with SIP4 was slow. Based on its similarity with other SIP receptors SIP was a 
candidate SIP4 ligand, but attempts to demonstrate this experimentally were 
frustrated by reported difficulties in expressing functional receptor [Im et a l, 
2001a]. However, in 2000, two independent groups showed that SIP bound to 
SIP4 with an apparent IQ of 12-63 nM [Van Brooklyn et a l, 2000; Yamazaki et 
a l, 2000]. Van Brooklyn et a l, [2000] expressed SIP4 in HEK293 cells and 
detected specific binding of SIP to the recombinant receptor. Bound SIP could 
be displaced by competition with the related lipids dihydroSlP (dhSlP) and 
sphingosylphosphorylcholine (SPC), although SPC could only compete for SIP 
binding when used at high (p-M) concentrations. This was in broad agreement 
with the ligand preference exhibited by other SIP receptors, except for the 
relatively low affinity with which SIP4 bound SIP. SIP4 expressed in CHO-Kl 
cells demonstrated pertussis toxin-sensitive activation of ERK in response to 
SIP, indicating that SIP4 coupled to Goti G proteins. The study of Yamzaki et 
a l, [2000] also detected specific binding of SIP which could be displaced by 
high concentrations of SPC. Additionally, this group reported that stimulation of 
SIP4 with SIP induced mobilisation of intracellular calcium via activation of the 
phospholipase C (PLC) enzyme. This response was partially sensitive to 
pertussis toxin treatment which suggested coupling of the receptor to Gai and
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Tissue/Cell Type Relative
level
Method Species Reference
spleen +++
thymus ++
peripheral leukocyte +++
lymph node ++
bone marrow ++ Northern blot human ^
foetal spleen +++
foetal liver +
foetal thymus +
foetal lung +
naïve CD4 T cell N.A. RT-PCR, 2 11 I- mouseWestern blotting
kidney +
lung +++
ovary +
peripheral leukocyte +++
prostate + RT-PCR mouse ^skin ++
spleen ++
stomach ++
thymus ++
thyroid +
lung +++
spleen +++ Northern blot mouse
thymus +
peripheral monocytes ++ RT-PCR human ^in vitro differentiated macrophages ++
platelet ++ RT-PCR human ^polymorphonuclear leukocytes +++
lymphocytes (subsets of) + to+++
mast cells +++
granulocytes +++ immunohisto- 7Langerhans cells +++ chemistry ^uman
lymph node interdigitating cells +++
neutrophils ++
eosinophils ++
Table 1. 5
Summary of tissues and cells reported to express SIP4.
Note: “relative level” refers to the level of signal obtained within that experiment 
and it would not be appropriate to compare relative SIP4  expression levels taken 
from different studies/publications.
+ faint signal; ++ medium signal; +++ strong signal; N.A. not appropriate. 
References:  ^ Graeler e/a/., 1998
Graeler and Goetzl, 2002 
Vassilatis et a l, 2003 
Contos et a l, 2002b 
Fueller et a l, 2003 
Motohashi et a l, 2000 
In house studies
36-
C h a p t e r  1
%
1» * 4 '
« ♦
t  "
mm#
m ^ i
i&sr4
mMsmm.
mm
Figure 1. 8
Expression of SIP4 detected in tissue sections.
Immunohistochemical studies have been performed using a rabbit polyclonal 
antibody, which recognises the human S1P4 protein. Affinity purified antiserum 
was used at a dilution of 1:250 on paraffin-embedded, formalin-fixed tissues. 
Cells positive for SIP4 expression stained fuschia-red. Tissue sections were also 
stained with haematoxylin and eosin. The identity of SIP4 positive cells was 
defined by histological analysis. This study was performed by LifeSpan 
Biosciences, Inc. (Seattle, WA., U.S.A.).
A Normal lymph node showing strong staining of interdigitating cells (40x)
B Inflamed lymph node showing strong staining of mast cells (40x)
C Inflamed skin showing strong staining of Langerhans cells (60x)
D Normal lymph node showing staining of lymphocytes within interfollicular 
zone(40x)
E Inflamed lymph node showing staining of neutrophils (60x)
F Small intestine with Peyer’s patches showing staining of lymphocytes (40x)
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possibly Gaq G proteins. However, untransfected cells were also observed to 
mobilise calcium in response to SIP stimulation, although the magnitude of 
response was smaller than for the SlP4-transfected cells. The ability of this 
receptor to promote a calcium flux has not been confirmed by other laboratories 
and therefore remains unclear.
Analysis of the SIP4 gene in mouse, found it to be present as a single copy 
comprising two exons with an intronless coding region, located on central 
chromosome 10, which is syntenic with human chromosome 19. The presence 
of a single, uninterrupted coding region is similar to that observed for the other 
SIP receptor genes and supports the theory that an ancestral SIP gene diverged 
to yield SIP4 and the other SIP receptor genes [Contos et a l, 2002b]. Within the 
same study, it was reported that the SIP4 gene is arranged in tandem with the 
murine G ai6 orthologue, Gai$ on mouse chromosome 10. Expression of the 
G ai5 and SIP4 genes primarily in haematopoietic tissues and their chromosomal 
proximity suggests that these transcripts may be co-expressed in the same cells. 
The authors therefore suggested that co-expression of Gais/ie and SIP4 proteins 
might imply this G protein to be the native coupling partner of SIP4 and that 
stimulation of SIP4 would result in increased concentration of intracellular 
calcium [Contos et a l, 2002b]. Direct analysis of the G proteins activated by 
SIP4 was performed by Graeler et a l, [2003] and revealed that this receptor 
coupled to GOi and G an/n subunits, but not Gaq or G ai5/i6. These observations 
were interpreted as suggesting that the previously reported tandem genomic 
arrangement of the SIP4 and G ai5/i6 genes may not be functionally relevant. In 
agreement with the well documented ability of this receptor to couple to Goti G
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proteins, the same study observed pertussis toxin-sensitive activation of PLC by 
SIP4 . Activation of SIP4 was also shown to potently activate Rho and promote 
stress fibre formation. The authors suggested this reflected the ability of 
stimulated SIP4 to cause pronounced activation of G ai2/i3 which could be 
relevant to the in vivo functions of this receptor [Graeler et a l, 2003]. SIP4 has 
also recently been shown to promote cell migration via activation of Cdc42 
[Kohno et a l, 2003].
There is some uncertainty as to whether SIP represents the true endogenous 
ligand for SIP4 . This lipid binds to the SIP4 receptor with significantly lower 
affinity than that with which it binds other SIP receptors and is a relatively poor 
agonist of SIP4 . In addition, phylogenetic analysis of the SIP receptor family 
(Figure 1.6) reveals that although this receptor family forms a discrete cluster, 
SIP4 is on the edge of this cluster, suggesting that it may be activated by a 
structurally distinct lipid. The molecule, phytosphingosine-1-phosphate (phSlP) 
was recently identified as a high affinity ligand for the SIP4 receptor, and is 
discussed further in this chapter, section 4.3.
There is still little data regarding the physiological role of the SIP4 receptor 
within the immune system. This is partly a consequence of the lack of receptor 
selective agonists, combined with the expression of multiple SIP receptor 
subtypes on haematopoietic and lymphoid cells. Disruption of the SIP4 gene in 
mice may indicate the processes in which the function of this receptor is 
required.
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1.3.6 Other lipid GPCRs
LPA and SIP receptors are not the only GPCRs to respond to lipid agonists. In 
addition to the well characterised GPCRs for platelet activating factor (PAF), 
cannabinoids and prostaglandins, several orphan receptors have recently been 
reported to respond to lipids which are structurally similar to SIP and LPA.
The ovarian cancer GPCR 1 (OGRl) receptor (previously named GPR6 8 ) is 
closely related to the PAF receptor and P2Y purinergic receptors but shares little 
homology with Edg family GPCRs. The gene was cloned from an ovarian 
cancer cell line and is expressed in placenta, lung, liver, testis, spleen, small 
intestine and peripheral leukocytes [Xu et a l, 2000]. OGRl is activated by nM 
concentrations of the lipid SPC, which had previously been identified as a low 
affinity SIP receptor agonist. Binding of SPC to OGRl stimulated activation of 
Gi and Gq G proteins, resulting in mobilisation of intracellular calcium, 
activation of ERK and inhibition of cell proliferation [Xu et a l, 2000]. The 
related GPR65 receptor, named T cell death-associated gene 8  (TDAG8 ) is 
expressed in spleen, lymph node and peripheral leukocytes [Im et a l, 2001b]. 
This receptor shares 41 % identity with OGRl and has been shown to respond to 
P-M concentrations of the glycosphingolipid, psychosine. Stimulation of TDAG8  
with psychosine promoted pertussis toxin-insensitive inhibition of cAMP, which 
was suggested to reflect activation of GoCz G proteins [Im et a l, 2001b]. The 
transcriptionally regulated gene, G2A (G2 accumulation G protein-coupled 
receptor), is predominantly expressed in lymphocytes and is also closely related 
to OGRl and TDAG8 . Genetic studies of this then orphan receptor suggested a 
role in peripheral lymphocyte homeostasis, since mice null for G2A developed 
secondary lymphoid organ enlargement and late-onset autoimmune syndrome
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[Le et a l, 2001]. Subsequently, the serum lipids lysophosphatidylcholine (LPC) 
and SPC were identified as G2A receptor agonists (Kd values of 65 nM and 230 
nM, respectively). The phenotype of the G2A knockout was particularly 
interesting given that the G2A receptor ligand, LPC is implicated in the 
pathogenesis of the autoimmune disease systemic lupus erythematosus. 
Stimulation of the receptor with LPC promoted mobilisation of intracellular 
calcium, activation of ERK and cell migration via GoCi G proteins [Kabarowski et 
a l, 2001]. Another GPCR closely related to the OGRl, TDAG8  and G2A 
receptors, GPR4, also responds to SPC and LPC. In contrast to the profile of 
ligand preference exhibited by G2A, GPR4 binds SPC with higher affinity (36 
nM) than it does LPC (159 nM) [Zhu et a l, 2001]. This receptor was found to 
couple to GoCi G proteins and stimulate activation of ERK, mobilisation of 
calcium from intracellular stores and DNA synthesis. These four lipid receptors 
form a distinct cluster (shown in Figure 1.2) and may represent a new 
lysophospholipid subfamily.
SIP has recently been shown to activate several non Edg family GPCRs. The 
closely related GPR3, 6  and 12 orphan receptors are predominantly expressed in 
cerebral tissues and are most similar to Edg and cannabinoid receptors (shown in 
Figure 1.2), sharing approximately 42 % sequence identity with these receptors. 
GPR3, 6  and 12 are constitutively active receptors and stimulate opposing Gtts 
and G(Xi G proteins. Treatment with low concentrations of SIP was found to 
further stimulate these receptors and although their physiological role is not 
currently understood, they have been identified as three additional SIP receptors 
[Uhlenbrock et a l, 2002].
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The mammalian orthologue of the Xenopus laevis PSP24 receptor, GPR63 was 
recently reported to be a low affinity SIP receptor [Niedemberg et a l, 2003b]. 
This receptor is expressed in stomach, small intestine and central nervous system 
and does not share significant sequence homology with Edg or other SIP 
receptors (Figure 1.2).
The existence of multiple receptors which respond to lysophospholipids and 
elicit diverse effects reinforces the importance of lipid mediators in biology.
1.4 Sphingolipid signalling
Sphingolipids are a major component of cell membranes and the sphingolipid 
metabolites ceramide, sphingosine and SIP play important roles in the regulation 
of cell proliferation, survival and death. The organisms in which these processes 
occur are diverse and include mammals, yeast and plants.
1.4.1 Sphingosine and ceramide
The bioactive lipids sphingosine and ceramide generally inhibit cell proliferation 
and promote apoptosis. The molecule sphingosine was named in 1884 after the 
Sphinx to reflect “the many enigmas which it has presented to the enquirer” 
[Smith and Merrill, 2002]. Ceramide may be produced via de novo synthesis or 
from the precursor sphingomyelin whilst sphingosine is produced via déacylation 
of ceramide by the family of ceramidase enzymes. The levels of ceramide and 
sphingosine found in resting cells are generally low since their production is 
tightly regulated.
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1.4.2 Sphingosine-l-phosphate
SIP (D-erp/Zzro-sphingosine-l-phosphate) is the principal phosphorylated 
sphingoid base in mammalian cells. In contrast to the pro-apoptotic actions of its 
precursors, ceramide and sphingosine, SIP is a cell survival factor. This 
bioactive lipid regulates a range of cellular responses, including cytoskeletal 
changes, cell movement, cell proliferation, angiogenesis and vascular maturation. 
SIP was originally thought to be an intracellular second messenger but the 
discovery of the SIP family of GPCRs, which bound this lipid with high affinity, 
redefined SIP as an extracellular receptor agonist. Despite the clear role for cell- 
surface SIP receptors in mediating many effects of SIP, the suggestion that this 
lysophospholipid also functions as an intracellular signalling molecule remains. 
Whilst some of the evidence to support this is compelling, the absence of 
identified intracellular targets has led to considerable debate in this area. The 
actions of SIP have been the subject of numerous reviews (for example see Pyne 
and Pyne, 2000a; Pyne and Pyne, 2000b; Maceyka et al., 2002; Spiegel et al., 
2002; Pyne and Pyne 2002; Hla, 2003; Spiegel and Milstien, 2003). Many of the 
micro-effects of SIP have already been discussed in the context of the GPCRs 
which respond to SIP (this chapter, section 3). The current section will discuss 
the mechanisms controlling SIP production and breakdown as well as the macro- 
effects induced by this bioactive lipid and the concept of SIP as a dual 
intracellular and extracellular signalling molecule.
As is common with many signalling molecules, SIP levels in cells tend to be low 
and are balanced by an equilibrium between its synthesis and degradation (Figure 
1.9). SIP is generated via the phosphorylation of sphingosine, which is 
catalysed by the sphingosine kinase (SK) enzyme. There are two different routes
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for SIP degradation: reversible dephosphorylation by SIP phosphatase, or 
irreversible degradation into hexadecenal and phosphoethanolamine via the 
actions of SIP lyase. Platelets are an exception and store high concentrations of 
SIP, which is not subject to degradation by SIP lyase since 
platelets do not express this enzyme. This stored SIP is released on cell 
activation and aggregation and represents the major source of SIP in serum and 
plasma.
Sphingosine kinase
Hexadecenal
Sphingosine
Phosphoethanolamine
SIP phosphatase
Figure 1. 9
Synthesis and degradation of SIP.
Sphingosine is converted to SIP by the actions of sphingosine kinase. 
Conversely, two different enzymes may degrade SIP: SIP phosphatase removes 
the phosphate to yield sphingosine; SIP lyase cleaves the C2-C3 bond of SIP to 
produce hexadecenal and phosphoethanolamine.
Extracellular SIP is albumin bound which is believed to prevent it from binding 
non-specifically to plasma membrane surfaces and is metabolically stable in this 
form [Yatomi et a l, 1997]. The concentrations of SIP in normal human plasma 
and serum have been reported to be approximately 200 nM and 485 nM, 
respectively [Yatomi et a l, 1997]. Release of SIP from activated platelets will 
significantly increase the concentration of circulating SIP. These concentrations 
are significantly higher than the dissociation constants for SIP binding to each 
isolated SIP-family receptor.
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Most cells produce SIP intracellularly which reflects the widespread expression 
of sphingosine kinase. It is not clear exactly how SIP is transported out of cells 
and the presence of the polar headgroup suggests SIP will not readily traverse 
the plasma membrane; candidate transporters include the P-glycoprotein lipid 
transporter Abcbl [Honig et a l, 2003]. SIP released from cells acts as an 
autocrine or paracrine mediator, stimulating cell-surface receptors on the cell 
from which it was released (autocrine) or on nearby cells (paracrine). In its 
putative intracellular role, SIP is proposed to function as a second messenger for 
growth factors and alters the activity of specific intracellular target proteins 
(discussed by [Pyne and Pyne, 2000b; Spiegel and Milstein, 2003]).
Sphingosine kinase catalyses formation of SIP and is a highly conserved enzyme 
present in organisms as diverse as plants, yeast, worms and mammals. It is 
activated in response to external stimuli such as growth and survival factors. 
Two human genes encoding sphingosine kinase enzymes have been cloned (SKI 
and SK2), which are the products of distinct genes. SKI and SK2 are cytosolic 
proteins of 384 and 618 amino acids, respectively, which contain five conserved 
catalytic domains and are most closely related to the diacylglycerol kinase 
family.
The SKI enzyme was originally from isolated from rat kidney [Olivera et a l, 
1998]. The importance of SIP as a signalling molecule is underscored by the 
existence of SK orthologues in many organisms ranging from mammals to yeast, 
plants and flies. The sequence of SKI contains putative calcium/calmodulin 
binding domains and consensus PKA and PKC phosphorylation sites, which may 
be involved in regulation of enzyme activity [Pyne and Pyne, 2000b]. Precise
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studies of the role of these enzymes in cellular processes have been hampered by 
the lack of specific inhibitors. Whilst compounds such as dimethylsphingosine 
(DMS) competitively inhibit SKI, DMS also inhibits PKC, which complicates 
interpretation of results since PKC may modify the activity of SKI.
Although this enzyme is believed to be cytosolic and contains no signal sequence 
or TM domains, constitutive export of SKI from endothelial cells has been 
observed [Ancellin et a l, 2002]. Many molecules have been reported to increase 
SKI activity, including ligands for GPCRs, agonists of growth factor receptor 
tyrosine kinases such as PDGF, epithelial growth factor (EGF) and nerve growth 
factor (NGF), as well as tumour necrosis factor-a (TNF-a), phorbol esters and 
even SIP itself [Maceyka et a l, 2002; Pyne and Pyne, 2002]. The activity of 
SKI is reported to be bimodal: prior to activation by exogenous stimuli the 
enzyme exhibits relatively high basal turnover which may be involved in 
housekeeping functions; after activation the catalytic activity of the enzyme 
increases approximately 2-fold resulting in a concomitant increase in SIP 
concentration [Pitson et a l, 2000]. In the same study, expression of a 
catalytically inactive dominant negative SKI mutant prevented activation of SKI 
in response to exogenous stimuli such as TNF-a and phorbol esters but did not 
affect basal SKI activity in these cells. Activation of SKI in response to TNF-a 
has been shown to involve a direct interaction between the TNF receptor- 
associated factor 2 (TRAF2) and SKI [Xia et a l, 2002]. SKI protects against 
apoptosis induced by ceramide, TNF-a, Fas ligand and other toxic agents via 
production of SIP, which inhibits the cytochrome-c release-dependent 
mitochondrial death pathway induced by these stimuli [Hla, 2003]. Production 
of SIP as a consequence of SK activation is accompanied by a decrease in
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ceramide levels and the fate of a cell appears to depend on the relative levels of 
these molecules, rather than their absolute concentrations. This system is a 
conserved stress mechanism that has been referred to as the “sphingolipid 
rheostat”, shown in Figure 1.10.
Ceramide
. i f .
Sphingosine
Pro-apoptotic
Anti-mitoaenic
Anti-apoptotic 
Mito genic 
S IP ,., ligand
Apoptosis Cell survival
Figure 1.10
The ceramide-SlP rheostat.
The sphingolipids ceramide, sphingosine and SIP are interconvertible and the 
balance between them determines cell fate. Ceramide and sphingosine are 
associated with arrest of cell growth and apoptosis whilst SIP promotes cell 
growth and survival.
The related SK2 enzyme has been less extensively studied, but in contrast to the 
pro-survival actions of SKI, this enzyme has been shown to enhance apoptosis 
via activation of caspase-3 [Liu et a l, 2003]. Induction of cell death by this 
enzyme was reported to be independent of SIP receptor activation but the 
presence of the Bcl-2 homology 3 (BH3) domain within SK2 was required. The 
BH3 domain is a nine amino acid sequence present in the group of “BH3 domain 
only” proteins, which are pro-apoptotic members of the Bcl-2 family. 
Interestingly, the SKI enzyme does not contain a BH3 domain and this
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difference may explain the opposing effects of these enzyme isoforms on cell 
fate.
Cellular effects of SIP may be divided into two broad categories: growth related 
functions or cytoskeletal functions. Effects on growth are often cell type 
dependent and include inhibition or stimulation of proliferation, altered 
differentiation, inhibition or activation of apoptosis and promotion of cell 
survival. Cytoskeletal SIP effects include chemotaxis, changes in cell 
morphology and aggregation. These varied responses are in part controlled by 
SIP receptor activation and the fate of a given cell is likely to depend on the 
profile of SIP receptors expressed and the presence or absence of costimulators 
such as PDGF.
Given its importance in regulation of cell signalling, SIP is liable to be involved 
in the pathology of many disease states. As was demonstrated by deletion of the 
SlPi gene in mice [Liu et a l, 2000], SIP is a key molecule in the progression of 
angiogenesis. This process is likely to be of key importance in tumour growth 
and other diseases where blood vessel formation is important, such as 
rheumatoid arthritis, diabetic retinopathy and psoriasis [reviewed by Pyne and 
Pyne, 2000a; Toman et a l, 2001]. SIP promotes cell survival and motility and 
may therefore be involved in tumour proliferation and invasion. Since SIP 
affects neuronal cells to promote survival, it has been suggested that the role of 
SIP in neurological disease states which are associated with deregulated 
apoptosis, such as Alzheimer’s and Parkinson’s diseases should be examined 
[Pyne and Pyne, 2000a].
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The presence of SIP in serum and its release from blood-borne cells suggests 
that this molecule may be a vasoactive and cardioactive mediator. Indeed, the 
SI Pi receptor was identified as an abundant transcript induced in endothelial cell 
differentiation [Hla and Maciag, 1990] and SI Pi and related receptors are 
expressed in cardiovascular tissues. There is a role for SIP in cardiac 
development, as demonstrated by the phenotype of the zebrafish Mil knockout 
[Kupperman et ah, 2000] and the observation that SIP activation of SI Pi 
promotes activation of eNOS and production of the potent vasodilator NO 
[Igarashi and Michel, 2001]. SIP induces well defined effects in vascular 
smooth muscle cells, particularly chemotaxis and proliferation, that are mediated 
by the SI Pi receptor [Hla, 2003].
SIP may also function as an immune system regulator. This lipid is important in 
allergic responses and the balance between sphingosine and SIP was shown to 
be decisive for mast cell activation after triggering of the immunoglobulin (Ig) E 
receptor [Prieschl et a l, 1999]. This effect reflects activation of SK activity in 
response to IgE receptor activation. SIP secretion into the lung is increased after 
allergen challenge and mediates airway smooth muscle cell contraction and 
proliferation which leads to the characteristic hypercontractility and remodelling 
seen in asthma (reviewed by Jolly et a l, [2002]). Graeler and Goetzl, [2002] 
reported that ligation of the T cell receptor on resting T cells regulates the 
expression of SlPi and SIP4 receptors. This suggests that SIP may modulate the 
function of naïve and activated T cells. The mode of action of the sphingosine 
analogue immunomodulatory drug, FTY720 implies a role of SIP as a regulator 
of immune cell trafficking (discussed further in this chapter, section 5).
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Of the numerous reports describing the effects of SIP on a given cell type, those 
concerning cells which express the SIP4 receptor are of particular interest since 
they may suggest a role for this receptor. Fueller et ah, [2003] observed SIP- 
induced mobilisation of intracellular calcium in human monocytes and 
macrophages. These cells express mRNA for SlPp2,4 receptors although it is not 
clear which of these receptors accounts for this response. The effects of SIP on 
migration of murine splenic T cells have also been investigated [Graeler and 
Goetzl, 2002]. Resting T cells express SI Pi and SIP4 receptors and activation of 
these receptors was proposed to account for the observed stimulation of T cell 
chemotaxis by SIP. Activated T cells did not respond to SIP in this manner and 
this was thought to be a consequence of the marked decrease in expression of 
SlPi/4 receptors after T cell receptor activation. The effects of SIP on T cell 
mobility were believed to be mediated via the SI Pi receptor, since transfection of 
this receptor into the HTC4 cell line (which does not respond to SIP) enhanced 
chemokinesis of these cells, whilst expression of recombinant SIP4 did not. 
Another recent study described the ability of SIP to dose-dependently inhibit T 
cell proliferation [Jin et a l, 2003]. SIP has also been shown to stimulate 
chemotaxis of natural killer (NK) cells. The receptor which mediated this effect 
was not identified, however sensitivity of this response to pertussis toxin 
suggests involvement of SI Pi [Kveberg et a l, 2002]. In contrast to the effects of 
chemokines, which recruit and activate NK cells, SIP recruits NK cells but 
inhibits their cytolytic activity against tumour cells [Maghazachi, 2003]. The 
effects of SIP on cells of the immune system suggest that this molecule is an 
important immunoregulator, which acts to maintain immune system homeostasis.
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In contrast to the clear role of SIP as an activator of specific cell-surface GPCRs, 
evidence to support the concept that SIP is a second messenger is less clear-cut 
(reviewed by [Pyne and Pyne, 2000b; Hla, 2003; Young and Nahorski, 2002; 
Spiegel and Milstien, 2003]). The idea that SIP was a second messenger arose 
from its ability to mobilise calcium from intracellular stores in a manner that was 
dependent on the activation of sphingosine kinase. Many cell stimuli elicit SIP 
production, although it is likely that many of the functions previously attributed 
to the “second messenger” actions of SIP actually reflect activation of Edg 
family receptors (discussed by Pyne and Pyne [2000b]). Much of the evidence 
supporting an intracellular role for SIP arose from agonist stimulation of SK and 
the use of SK inhibitors in mammalian systems. In support of the proposed dual 
effects of SIP, dhSlP, which binds to and activates SIP receptors with 
comparable affinity and potency to SIP itself, does not mimic all the effects of 
SIP, particularly those related to cell survival (reviewed by Pyne and Pyne 
[2 0 0 0 b]).
Calcium mobilisation occurs after stimulation of HEK293 cells with SIP. 
However, this response was found to be independent of PLC activation and 
correlated with activation of SK and the transient production of SIP [Meyer zu 
Heringdorf et a l, 2001]. This suggested the existence of an alternative pathway 
for calcium mobilisation in mammalian cells. It has been proposed that 
intracellular SIP has a general role in calcium mobilisation for many GPCRs 
since other GPCRs have been shown to mobilise calcium in a manner which was 
dependent on SK activation [Meyer zu Heringdorf et a l, 1998]. Although 
several other reports support this idea, the intracellular target of SIP, which is 
likely to be located in the endoplasmic reticulum, has not yet been identified.
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Sphingosine kinase orthologues exist in lower organisms that do not express 
lipid-responsive GPCRs. In yeast, deletion of the two SK genes was associated 
with decreased survival after heat stress [Hla, 2003]. SIP is also produced in 
plants and regulation of stomatal function was found to be dependent on SK 
activation [Coursol et a l, 2003]. These responses in yeast and plants, which 
occur after environmental stress, also involve calcium regulation, suggesting that 
SIP might have a universal role in calcium regulation [Spiegel and Milstien, 
2003]. This is an interesting concept since calcium itself has been suggested as a 
regulator of SK activity [Pyne and Pyne, 2000b]. Identification of the 
intracellular SIP targets in plants or yeast will be valuable in understanding the 
role of SIP as a second messenger in mammalian cells.
SIP is a bioactive lipid, which mediates myriad effects in diverse cell types. 
These effects are influenced by the repertoire of cell-surface-expressed SIP 
receptors and the presence or absence of co-stimulatory signals. It seems likely 
that the site of action of intracellular SIP will be identified, confirming SIP as an 
extracellular agonist of SIP receptors and an intracellular second messenger 
involved in calcium mobilisation. This is not unprecedented since the lipid 
mediators leukotriene B4 (LTB4) and LPA have been shown to activate both cell- 
surface and nuclear receptors [Yokomizo et a l, 1997; Gobeil et a l, 2003].
1.4.3 Phytosphingosine-l-phosphate
The related compound, phSlP (D-n6 o-phytosphingosine-1 -phosphate) shown in 
Figure 1.11, was recently found to be a high affinity ligand for the SIP4 receptor 
[Rios Candelore et a l, 2002]. In phSlP, the double bond present in SIP has 
been reduced to yield an extra hydroxyl group on the C4 carbon atom.
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Figure 1.11 
Structure of phSlP.
Although the exact route of synthesis of phSlP has not been shown in vivo, the 
likely precursor (phytosphingosine) is produced in mammalian cells by the 
recently identified alkaline ceramidase aPHC [Mao et a l, 2001]. The activity of 
certain alkaline and neutral ceramidases may be regulated by growth factors and 
cytokines, which is suggestive of a role in mediation of cell signalling. It is 
probable that phytosphingosine is a substrate for the sphingosine kinase enzymes 
and it is through this route that phSlP is produced. Traditionally, phytoceramide 
(and phSlP) have been thought of as only being present in high concentrations in 
lower eukaryotes, such as Sacchromyces cerevisiae, however the recent detection 
of trace amounts of phytoceramide in mammalian tissues such as skin, liver and 
kidney coupled with the expression of aPHC mRNA in these tissues suggests 
that phSlP may have an important physiological role to play in these 
environments [Mao et a l, 2001]. These researchers suggested that the relevance 
of phSlP as a ligand for SIP4 might be linked with the restricted expression 
pattern of aPHC. The presence of aPHC mRNA and its product 
(phytosphingosine) in skin has been highlighted as particularly interesting since 
Langerhans cells are skin-specific dendritic cells which strongly express SIP4 .
PhSlP binds to human SIP4 with a Kd value of approximately 2 nM and is 
displaced by competition with dhSlP, SIP and FTY720-P, suggesting a shared 
binding pocket. The ability of phSlP to act as an agonist of SIP4 was shown
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using microphysiometer analysis. In this system, SIP was defined as a full 
agonist and had an E C 5 0  of approximately 12 nM, whilst phSlP was a partial 
agonist with an E C 5 0  of approximately 30 nM.
The physiological relevance of phSlP has yet to be investigated and the 
possibility that this compound represents the true in vivo ligand for SIP4 is 
speculation. It has not been reported whether phSlP is a high affinity ligand 
solely for SIP4 , or whether it can bind strongly to the other SIP receptors, 
although given the structural similarity with SIP, it seems likely that phSlP 
would bind to other SIP receptors.
1.5 FTY720 and SIP receptors
Immunosuppressant drugs, such as cyclosporin A (CsA), are used in the 
prevention of organ transplant rejection and for the treatment of autoimmune 
diseases including rheumatoid arthritis and psoriasis. The mode of action of this 
class of compound is to suppress immune responses by inhibiting production of 
the cytokine interleukin-2 (IL-2) by antigen-stimulated T cells. However, their 
use is associated with severe side effects, including hepatic and renal toxicity.
Recently, the compound FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-propane- 
1,3-diol) has been identified as a potent immunomodulatory compound (shown 
in Figure 1.12). This compound has a highly novel mechanism of action and is 
believed to exert its effects via activation of SIP receptors. FTY720 is a 
synthetic structural analogue of a fungal metabolite derived firom Isaria 
sinclairii, which has been used as a traditional Chinese herbal medicine for 
thousands of years and is considered as one of the three oriental medicines that 
bestow eternal youth [Im, 2003]. The development of FTY720 is a classic
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example of ethnopharmacology, wherein the biological mechanism for a 
traditional therapeutic herbal agent has been elucidated and has resulted in the 
chemical optimisation of a novel class of compound.
Figure 1.12 
Structure of FTY720.
FTY720 functions in vivo to promote reversible lymphopenia via retention of 
circulating B and T cells in secondary lymphoid organs [Chiba et a l, 1998]. The 
effect of T cell redistribution is to reduce the numbers of these cells at sites of 
inflammation and hence to attenuate the immune response. The compound has 
been extensively profiled in animal transplantation models, including skin, islet 
and solid organ allograft (reviewed by Brinkmann and Lynch [2002]) and 
synergises with traditional immunosuppressive agents, allowing combination 
therapy of FTY720 with subclinical doses of compounds such as CsA. FTY720 
monotherapy in models of adjuvant- and collagen-induced arthritis and systemic 
lupus erythmatosus has also been successfully applied. Low doses of FTY720 
can reportedly be used as a prophylactic or a therapeutic in the model of multiple 
sclerosis, experimental autoimmune encephalomyelitis. Efficacy of this 
compound has been shown in human phase II trials for the prevention of acute 
rejection in de novo renal patients on baseline immunosuppression [Brinkmann 
and Lynch, 2002].
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Administration of FTY720 promotes sequestration of naïve and activated CD4 
and CDS T cells and B cells from the circulation into lymph nodes and Peyer’s 
patches [Xie et aL, 2003]. Although the effects of this compound had been 
known for some years, its mode of action was unclear. Sensitivity of the 
lymphocyte homing effect to pertussis toxin suggested the involvement of a Goti 
coupled GPCR and the chemokine receptor CCR7 was proposed as a potential 
candidate. CCR7 and its chemokine ligands, ELC (EBV-induced molecule 1 
ligand chemokine) and SLC (secondary lymphoid tissue chemokine) are known 
to play a critical role in the migration of B and T cells into secondary lymphoid 
organs. It was subsequently shown that FTY720 did not act via this chemokine 
receptor, since the compound was still able to promote lymphopenia in both 
CCR7 deficient and pit mice, which do not express either ligand for CCR7 
[Henning et a l, 2001], although the kinetics of FTY720-induced lymphocyte 
homing in these mice were delayed compared to wild type control animals.
The breakthough in determining the way in which FTY720 elicits its response 
came with the observation that FTY720 is rapidly metabolised in vivo by 
addition of phosphate to the terminal alcohol group to yield the compound 
FTY720-P (shown in Figure 1.13). The structure of this metabolite bears 
noticeable resemblance to that of SIP and it was proposed that FTY720-P may 
act at SIP receptors. Two independent groups recently identified this compound 
as a high affinity (IQ's 0.2-6 nM), potent agonist at four of the five SIP receptors 
(SIPi,3,4,5) [Mandala et a l, 2002; Brinkmann et a l, 2002], but not the SIP2 
receptor. FTY720 was shown to be rapidly converted in vivo to the phosphate, 
and this conversion could also be mediated via the isolated sphingosine kinase 
enzyme, albeit more slowly. Since T cells express mRNA for SI Pi,4,5 receptors.
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the implication of these studies was that activation of one or more SIP receptors 
present on T cells promoted sequestration of circulating T cells to secondary 
lymphoid organs. FTY720 is the first example of the application of a 
sphingomimetic compound as a therapeutic agent (reviewed by Kester and 
Kolesnick [2003]).
HO I O
HO
Figure 1.13
Structure of FTY720-P.
In a subsequent study, the effect of FTY720 on T cell chemotaxis in vitro was 
investigated [Graeler and Goetzl, 2002]. FTY720 did not stimulate movement of 
murine T cells when tested at concentrations of 1-100 nM, but could dose- 
dependently inhibit SIP-induced T cell chemotaxis in vitro. These results were 
interpreted as suggesting that FTY720 has no direct chemotactic activity but can 
suppress the stimulatory effects of SIP on T cell migration. The apparent 
contradiction between these results and the previous findings that the 
lymphopénie action of FTY720 was a consequence of its actions as a high 
affinity SIP receptor agonist highlight the need for further research in this area.
The report of Brinkmann et al., [2002] identified the phosphorylated form of the 
(R)-isomer of the related compound, AAL-P (2-amino-4-(4-heptyloxyphenyl)-2- 
methylbutanol) [Figure 1.14] to be another potent agonist of SlPi,3,4,s receptors. 
This compound was a more potent agonist of S I P 4  than FTY720-P ( E C 5 0  = 4 nM 
compared to 63 nM for FTY720-P [Brinkmann and Lynch, 2002]). The
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unphopshorylated AAL compound exhibited similar in vivo lymphopénie effects 
to those of FTY720.
HO
OH NH
Figure 1.14
Structure of (R)-AAL-P.
Although it seems highly likely that the lymphopénie effect of FTY720 
administration occurs, at least in part, as a result of activation of SIP receptors 
expressed on T cells, the precise manner in which the T cells are recruited to, and 
held in lymph nodes and Peyer’s patches is unclear. Recent advances have 
suggested that FTY720 has dual effects to promote increased intrinsic mobility 
of peripheral B and T cells and to increase endothelial integrity, thereby 
preventing egress from secondary lymphoid organs.
These exciting observations have significantly increased interest in the SIP 
receptors as potential therapeutic targets and have also identified highly potent 
agonists against four of the five receptors. The actions of FTY720-P have 
suggested an important role for SIP in lymphocyte trafficking and control of the 
immune response.
1.6 Project aims
When the work described in this thesis was started, SIP4 was the orphan receptor 
named Edg6 . From sequence similarities with other Edg receptors, it seemed 
likely that the Edg6  orphan would be activated by the lysophospholipid SIP and 
would couple to 0%  G proteins. Therefore, the first aim of this work was to
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express SIP4 in mammalian cells and investigate whether the receptor coupled to 
this class of G proteins and could be activated by SIP. It was known that other 
members of the SIP and LPA receptor families were widely expressed in 
mammalian cells and that their presence could lead to the production of 
interfering signals in functional assays. A fusion protein between SIP4 and a 
mutated, pertussis toxin-insensitive variant of the Ga^ G protein was also used 
in these investigations so that potential interference due to activation of 
endogenous Edg receptors present in host cells could be eliminated via treatment 
with pertussis toxin.
Since it was expected that the host cells used for expression of the recombinant 
SIP4 and SlP4-GoCii fusion proteins would express endogenous Edg family 
receptors, the second aim of this work was to use the technique of RT-PCR to 
determine the profile of LPA and SIP receptors endogenously expressed within 
these cells.
Many GPCRs exhibit the phenomenon of constitutive activity, and results 
generated in the early stages of this thesis using a [^^SJGTPyS binding assay to 
detect SIP4 activation suggested this receptor to be constitutively active. At the 
time of these investigations, no inverse agonists were available for this class of 
GPCRs and so it was necessary to use an alternative approach to further 
characterise agonist-independent signalling by this receptor. Therefore, the 
relationship between the expression level of SIP4 and the level of basal 
signalling was investigated using an mammalian inducible expression system.
As would be expected, many laboratories are working on the SIP receptor family 
and significant findings were reported during the course of the investigations
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described in this thesis. As a consequence, the aims of this project developed as 
new observations concerning this receptor family were published. The final aim 
of the work presented in this thesis was to examine the nature of ligand 
preference exhibited SIP4, in the light of published observations. Firstly, the 
activity of newly identified agonists such as phSlP was determined using the 
[^^SJGTPyS binding assay. Novel information regarding the role of the 
conserved residue present in the SIP receptor family was then used to 
further understand the nature of SIP4 ligand preference. The role of the this 
residue in SIP receptors has been investigated using the SI Pi receptor to 
exemplify this receptor family. Mutation of this residue to glutamine (present at 
this position in the LPA receptor family) was found to influence ligand 
selectivity and allowed activation of SI Pi by LPA, whilst preventing its response 
to SIP [Wang et a l, 2001]. The second part of this final aim was to further test 
the hypothesis that the conserved E^ ^^  residue of SIP receptors is key in 
controlling ligand selectivity. This was achieved by introduction of the 
equivalent mutation in the SIP4 receptor and evaluation of its consequences on 
activation of [^^SJGTPyS binding by SIP and LPA after expression of the mutant 
receptor in mammalian cells.
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Chapter 2 -  Materials and Methods
2.1 General chemicals and materials
General laboratory chemicals were purchased from Sigma Aldrich Company 
Ltd., (Gillingham, Dorset, U.K.) or BDH Ltd., (Poole, Dorset, U.K.) unless 
stated otherwise. Ethanol and Biphenol/Tris were from Hayman Ltd., (Witham, 
Essex, U.K.) and Camlab Ltd., (Cambridge, U.K.), respectively. Bacto-tryptone, 
bacto-agar and bacto-yeast extract were from Difco Ltd., (Detroit, MI., U.S.A.).
Restriction endonucleases, dNTPs, DNA molecular weight markers, T4 DNA 
ligase, calf intestinal phosphatase and amplification grade deoxyribonuclease I 
were purchased from New England Biolabs Ltd., (Hitchin, Herts., U.K.) or 
Roche Diagnostics Ltd., (Lewes, East Sussex, U.K.). DNA sequences were 
cloned into pCR4-T0P0, pIRESpuro or pIND expression vectors, Invitrogen 
Ltd., (Paisley, Scotland, U.K.). QIAGEN Miniprep, Maxiprep, QIAquick Gel 
Extraction, PCR purification, DNeasy genomic DNA and RNeasy Mini RNA 
purification kits were from Qiagen Ltd., (Crawley, West Sussex, U.K.). 
Apparatus for horizontal gel electrophoresis was supplied by Invitrogen Ltd., 
(Paisley, Scotland, U.K.).
Big Dye Terminator Cycle Sequencing Ready Reaction DNA sequence kit and 
Amplitaq DNA polymerase were obtained from Applied Biosystems, 
(Warrington, Cheshire, U.K.). Sequencing reactions were carried out using a 
Biometra Trio-Thermoblock (Anachem Ltd., Luton, Herts., U.K.) or Primus 96 
Plus (MWG-Biotech Ltd., Milton Keynes, Bucks., U.K.). All other PCR 
reactions were performed using Biometra Personal Cycler (Anachem Ltd., 
Luton, Herts., U.K.) or Primus 96 Plus (MWG-Biotech Ltd., Milton Keynes,
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Bucks., U.K.) PCR machines. Advantage RT-for-PCR, Advantage 2 and 
Advantage-GC 2 PCR kits were from Clontech Laboratories Inc., (Palo Alto, 
CA, U.S.A.).
Media and supplements for tissue culture and transfection reagents were supplied 
by Invitrogen Ltd., (Paisley, Scotland, U.K.); non-enzymatic cell dissociation 
solution was from Sigma Aldrich Company Ltd., (Gillingham, Dorset, U.K.); 
foetal bovine serum was from Helena Biosciences Ltd., (Sunderland, U.K.) or 
PAA Labs GmbH., (Linz, Austria) and tissue culture plastics were from BD 
Falcon (Brembodegem, Belgium). CHO-Kl and HEK-293 cells were from 
ECACC (CAMR, Porton Down, Wilts., U.K.) and CHO-EcR cells were supplied 
by Invitrogen Ltd., (Paisley, Scotland, U.K.).
Sphingosine-1 -phosphate was obtained from Biomol Research Laboratories Inc., 
(Plymouth Meeting, PA., U.S.A.) and UK14304 was from Tocris Cookson Ltd., 
(Bristol, U.K.). Pertussis toxin was purchased from CN Biosciences Ltd., 
(Nottingham, U.K.). Lysophosphatidic acid (18:1, 16:0 and 14:0) was from 
Avanti Polar Lipids Inc., (Alabaster, AL., U.S.A.). Other chemicals (FTY720 
and AAL) were synthesised by the Medicinal Chemistry department of Celltech 
R&D Ltd.
The radiochemical guanosine 5 ' - S]triphosphate, triethylammonium salt 
([^^SJGTPyS) had a specific activity of > 37 TBq/mmol and was purchased from 
Amersham Biosciences (Amersham, Bucks., U.K.).
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Tris-Glycine SDS Page gels and SeeBlue prestained protein markers were 
supplied by Invitrogen Ltd., (Paisley, Scotland, U.K.). Immobilon-P PVDF 
membrane was from Millipore Ltd., (Watford, Herts., U.K.).
Small scale centrifugation was performed using Eppendorf 5415D (Anachem 
Ltd., Luton, Herts., U.K.) or Hettich refrigerated EBA12R (Andreas Hettich 
GmbH & Co.KG, Tuttlingen, Germany) benchtop microcentrifuges; Sorvall 
RC3B or RC5B refrigerated centrifuges were used for large scale centrifugation.
2.1.1 Media for bacterial growth
LB Agar
SOC
2x TY Broth
1 % (w/v) Bacto-tryptone 
0.5 % Bacto-yeast extract 
171 mMNaCl
1.5 % (w/v) Bacto-agar 
pH 7.0
2 % (w/v) Bacto-tryptone 
0.5 % Bacto-yeast extract
8 . 6  mM NaCl 
25 mM KCl 
10 mM MgCl2 
20 mM glucose 
pH 7.0
2 % (w/v) Bacto-tryptone 
1 % Bacto-yeast extract 
171 mM NaCl 
1.5 % (w/v) Bacto-agar 
pH 7.0
2.1.2 Buffer formulations
PBS
TAE
137 mM NaCl 
2.68 mM KCl
10.1 m M N a2HP0 4  
1.76 mM K H 2 P O 4  
pH 7.4
40 mM Tris-acetate pH 8.0
2.5 mM EDTA
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TE
Hi TNE
lOmMTris-HCl pH 7.4 
1 mM EDTA
65 mM Tris-HCl pH8 
15 mM EDTA 
4 M NaCl
5x DNA loading buffer
0.25 % (w/v) bromophenol blue, 30 % (w/v) glycerol 
2x protein sample buffer
125 mM Tris-HCl pH 6.8, 0.715 M 2-mercaptoethanol, 20 % (w/v) glycerol, 
4 % (w/v) SDS, 0.1 % (w/v) bromophenol blue
5x ligation buffer
250 mM Tris-HCl pH 7.4, 5 mM ATP, 100 mM DTT, 50 mM MgCl:
Clontech Advantage PCR and RT buffers
lOx Advantage 2 PCR buffer
5x Advantage-GC 2 PCR buffer
5x Advantage RT-for-PCR buffer
400 mM Tricine-KOH, pH 9.2 at 25 °C 
150 mM potassium acetate 
35 mM magnesium acetate
37.5 pg/mL BSA
0.05 % (v/v) Nonidet P-40 
0.05 % Tween-20
200 mM Tricine-KOH, pH 9.2 at 25 °C 
75 mM potassium acetate
17.5 mM magnesium acetate 
25 % (v/v) DMSG
18.75 pg/mL BSA 
0.025 % (v/v) Nonidet P-40 
0.025 % Tween-20
200 mM Tris-HCl, pH 8.3 
375 mM KCl 
15 mM MgCl]
-64
C hap ter
QIAGEN kit purification buffers
Buffer AB (elution buffer)
Buffer AL (lysis buffer)
Buffer AW 1 (wash buffer 1)
Buffer AW2 (wash buffer 2)
Buffer EB (elution buffer)
Buffer N3 (neutralisation buffer) 
Buffer PI (resuspension buffer)
Buffer P2 (lysis buffer)
Buffer P3 (neutralisation buffer) 
Buffer PB (binding buffer)
Buffer PE (wash buffer)
Buffer QBT (equilibration buffer)
Buffer QC (wash buffer)
Buffer QF (elution buffer)
10 mM Tris-HCl, pH8.5
Contains chaotropic salts *
50 mM Tris-HCl, pH 8.0
lOmMEDTA
100 pg/mL RNase A
200 mM NaOH 
1 % (w/v) SDS
3.0 M potassium acetate, pH 5.5 
Contains chaotropic salts *
750 mM NaCl 
50 mM MOPS, pH7.0 
15 % (v/v) isopropanol 
0.15% (v/v) Triton X-100
1.0 M NaCl
50 mM MOPS, pH7.0
15 % (v/v) isopropanol
1.25 M NaCl
50 mM Tris-HCl, pH 8.5
15 % (v/v) isopropanol
Buffer QG (solubilisation buffer)
Buffer RLT (lysis buffer)
Buffer RWl (wash buffer 1)
Buffer RPE (wash buffer 2)
* The composition of these QIAGEN buffers is withheld by the manufacturer.
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2.1.3 Sources of cDNA
The human peripheral blood mononuclear (PBMC) cDNA library had been 
previously prepared at Celltech R&D Ltd. Gotii(C^^^I) and AAR-Gcqi(C^^^I)
constructs were kindly provided by Professor Graeme Milligan (University of
Glasgow, Scotland, U.K.).
2.1.4 Bacterial strains
Routine propagation of recombinant plasmids was performed using Novablue 
chemically competent E. Coli cells (endAl hsdR17(rYiu supE44 thi-1
recAl gyrA96 relAl lac¥"[proA^B^ lacPZ M15::TnlO (Tc^)]), supplied by 
Novagen Inc., (Madison, WL, U.S.A.). TOPO cloning reactions were 
transformed into TOP 10 chemically competent E. Coli cells {F mcrK ^(mrr- 
hsdRMS-mcrBC) (|)8G/flcZAM15 AlacX.14 deoKrecAl amDl39 A(ara-leu)l691 
gal\J galK. rpsL (Str^) endKX nupG), supplied by Invitrogen Ltd., (Paisley, 
Scotland, U.K.).
2.1.5 Antibodies
High affinity rat anti-HA monoclonal antibodies (unconjugated and Fluorescein- 
conjugated), which recognises the HA epitope tag (YPYDVPDYA) were from 
Roche Diagnostics Ltd. Rabbit polyclonal anti-Gap (sc-391) and anti GoCi 1/2/3 
(sc-262) antibodies were supplied by Autogen Bioclear Ltd., (Caine, Wilts., 
U.K.). The rabbit polyclonal SGI antibody was raised against the decapeptide 
KENLKDCGLF [Grant et a l, 1997] and cross-reacts with Gotii/2 . Peroxidase 
conjugated anti-rat and anti-rabbit IgG antibodies were purchased from Jackson 
ImmunoResearch Laboratories Inc., (West Grove, PA., U.S.A.). Isotype 
matched negative control antibody for use with the rat anti-HA-Fluorescein
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antibody was FITC conjugated rat IgGl,K and was supplied by BD Pharmingen 
(Brembodegem, Belgium). The anti-SlP4 antibody was a rabbit polyclonal 
antibody that was raised against a peptide corresponding to amino acids 226-243 
of the human SIP4 sequence (Lifespan Biosciences, Inc., Seattle, WA., U.S.A.).
2.1.6 Oligonucleotides
Oligonucleotides were designed using sequences in the Genbank nucleotide 
sequence database. Shown below are sequences for oligonucleotides that were 
used for PCR cloning, PCR mutagenesis and RT-PCR; vector specific and 
sequencing oligonucleotides are not shown.
Human SIP4 (Edg6) -  Genbank accession number AJ000479
F7240 (forward)
5 ’-GAGAGAGCGGCCGCCACCATGAACGCCACGGGGACC-3 ’
Notl Start
F7241 (reverse)
5 ’-GAGAGAGAATÎÇTTATCAGATGCTCCGCACGCTGGAG-3 ’
EcoBl Stop Stop
F12582 (forward)
5 ’-GAGAGAGCGGCCGCCACCATGTATCCATATGATGTTCCAGATTAT 
Notl Start HA-tag
GCTAACGCC ACGGGGACCCCGGTG-3 ’
F12581 (reverse)
5 ’-GAGAGACCATGGTGGCAAAGCGCTCCCC-3 ’
Ncol
F27384 (forward)
5 ’-GAGAGAGGATCCTGGCCCTGGCCGTC-3 ’
BamYil
F36663 (reverse)
5 ’-GAGAGAGAATIÇGGCGATGCTCCGCACGCTGGAGATG-3 ’
Ecom  A(aa)
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110A (forward)
5’-GAGAGAGAATTCGCCACCATGTATCCATATGATG-3’
EcoRI Start
111 A (reverse)
5’-GAGAGAGAGCGGCCGCTTATCAGATGCTCCGCACGCTG-3 ’ 
Notl Stop Stop
58A (forward)
5’-CAGTGGTTCCTACGGCAGGGCCTGCTCTTCAC-3’
59A (reverse)
5 ’-GTGAAGAGC AGGCCCJGCCGTAGGAACCACTG-3 ’
•gl22Q
Gotii -  Genbank accession number M17527
Oligonucleotides were designed to allow PCR amplification of Gttii, which had 
previously been modified to contain the C^ ^ I^ mutation, which confers 
insensitivity to pertussis toxin [Bahia et ah, 1998]; the presence of this mutation 
affected design of the reverse primer and its location in this primer is shown.
F36661 (forward)
5 ’-GAGAGAGAATTÇGCCACCATGGGCTGCACACTGAGCG-3 ’ 
EcoiBl Start
F36662 (reverse)
5’-GAGAGAGGATCCTTAGAAGAGACCGATGTCTTTTAG-3 ’ 
Barnm  Stop
Cloning of partial sequences of Edg receptor genes from Chinese hamster 
genomic DNA was achieved using the following oligonucleotide pairs, which 
had been designed using alignments of nucleotide and protein sequences from 
available species. The suffix B indicates oligonucleotides which were used for
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cloning fragments of Chinese hamster Edg receptor genes; those designated with 
the suffix C were used for RT-PCR.
Chinese hamster SlPi (Edgl)
1170B (forward)
5 ’-GCTGGGTC ATCTCCCTC ATCCTGG-3 ’ 
1171B (reverse)
5 ’-GGTC AGAGTGTAGATGATGGGGTTG-3 ’ 
1364C (forward)
5 ’-CCATC ATGGGCTGGAACTGCATC-3 ’ 
1365C (reverse)
5 ’-ACCTGAGTTCAGC AC AGCC AGAA-3 ’
Chinese hamster SIP2 (Edg5)
1176B (forward)
5 ’-AAC AGCAAGTTCCACTC AGC AATGTA-3 ’ 
1177B (reverse)
5 ’-GC AGCCAGC AGAYGATRAARACRCC-3 ’ 
1372C (forward)
5 ’-CTGTTCCTCGGCAACCTGGCAG-3 ’
1373C (reverse)
5 ’ -C AGT ACG ATGGTG ACTGTCTTG AG-3 ’
Chinese hamster SIP3 (Edg3)
1215B (forward)
5 ’-CTGATGGTTTTGATTGCC ATCTGGA-3 ’ 
1217B (reverse)
5 ’-CCAGCGTGTAGATGACNGGGTTCA-3 ’ 
1368C (forward)
5 ’-AACAATAAATTTCACAACCGCATGTAC-3 ^
- 6 9
C hapter 2
1369C (reverse)
5 ’-GATGAACACACTCACTACTATCACG-3 ’
Chinese hamster SIP4 (Edg6 )
53B (forward)
5 ’-GAGAGTGGGGCCACCAAGACCAGCCG-3 ’ 
54B (reverse)
5 ’-CCTCACGGCTGCGGAAGGAGTAGATGA-3 ’ 
1374C (forward)
5 ’-GTGTATGGTTGCATCGGGCTGTG-3 ’
1375C (reverse)
5 ’-GGGTTGATGGCAGAGTTGAGTACG-3 ’
Chinese hamster SIP5 (Edg8 )
1182B (forward)
5 ’-GGTTTGCGCCGNGARGGRGGYGTC-3 ’ 
58B (reverse)
5 ’-GTCCGGCAGGTCKCGGTTGGTGA-3 ’ 
1378C (forward)
5’-GTGGCACTGGCCGCATCGGTG-3’ 
1379C (reverse)
5 ’-GAACGTGTAGATGATGGGATTCAG-3 ’
Chinese hamster LPAi (Edg2)
45B (forward)
5 ’-CACAGCCCCAGTTCACAGCCATG-3 ’ 
46B (reverse)
5 ’-GTTGAAAATGGCCCAGAAGACTAAG-3 = 
1366C (forward)
5 ’-CGAACCCCAGTGCTTCTACAACG-3 ’
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1367C (reverse)
5 ’-GTAGGAGTCACTATAGAGGGGTG-3 ’
Chinese hamster LPA2 (Edg4)
49B (forward)
5 ’-GGCCAGTGCTACTACAACGAGACCA-3 ’ 
1174B (reverse)
5 ’-AGACAAGCAGGCTSGAYAGRGCCCA-3 ’ 
1370C (forward)
5 ’-ATTGGCTTTTTCTAC AATAAC AGTGG-3 ’ 
1371C (reverse)
5 ’-CACAGCCAGGTATGAGCGGCTG-3 ’
Chinese hamster LPA3 (Edg7)
1178B (forward)
5 ’-GAGTGTCACTATGAC AAGCNCATGG-3 ’ 
1180B (reverse)
5 ’-C AGTCATC AC YGTCTTCATTAGCTTCA-3 ’ 
1376C (forward)
5 ’-GACTTTTTTTACAACAGGAGCAACTC-3 ’ 
1377C (reverse)
5’-AGCCCTCCGGCGGCTGATGGA-3 ’
Chinese hamster GAPDH -  Genbank accession number X52123
59C (forward)
5 ’-GGTCGGCGTGAACGGATTTGGCCG-3 ’ 
60C (reverse)
5 ’-CGC ATTGCTGACAATCTTGAGGGAG-3 ^
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2.1.7 Mammalian cell lines
CHO-Kl cells (85051005) and HEK-293 cells (85120602) were from ECACC 
(CAMR, Porton Down, Wilts., U.K.) and CHO-EcR cells were supplied by 
Invitrogen Ltd., (Paisley, Scotland, U.K.).
2.2 DNA methods
2.2.1 PCR amplification of DNA fragments
Due to its high GC content, amplification of S I P 4  sequences was performed
using Advantage-GC 2 PCR kit. Typically, PCR reactions were carried out in a 
total volume of 20 pL and contained approximately 100 ng cDNA, genomic 
DNA or plasmid DNA template, 10 pmoles each oligonucleotide, 4 fiL 
Advantage-GC 2 PCR buffer, 0.5 M GC Melt, 0.2 mM dNTP mix (dATP, dCTP, 
dGTP, dTTP), 1 pL Advantage 2 Polymerase and sterile dHiO.
Other PCR reactions were performed using the Advantage 2 PCR kit. Reactions 
were typically set up in a final volume of 20 pL and comprised approximately 
100 ng cDNA or plasmid DNA template, 10 pmoles each oligonucleotide, 2 pL 
Advantage 2 PCR buffer, 0.2 mM dNTP mix (dATP, dCTP, dGTP, dTTP), 1 pL 
Advantage 2 Polymerase and sterile dH2 0 .
When PCR reactions were performed to generate DNA for use in cloning, 
reactions were scaled up to 50 pL, with the components in the same proportions 
as described above for 20 pL reactions.
Oligonucleotides were normally designed to have a melting temperature (Tm) of 
at least 6 8  °C.
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Reactions were cycled under the following conditions:
“ 2  step program”
95 °C 1 minute
95 °C 30 seconds
6 8  °C 3 minutes
6 8  °C 3 minutes
4°C constant
x35 cycles
The two step PCR program was used for general PCR amplification and cloning 
activities. Amplification of partial Edg receptor sequences from Chinese hamster 
genomic DNA, and from first strand cDNA prepared from Chinese hamster 
RNA, used either this two step program, or the three step program shown below; 
details of which program was used for amplification of which partial sequence 
are shown in Table 2.1.
“3 step program”
x30 cycles
94 °C 1 minute
94 °C 15 seconds
60 °C 30 seconds
6 8  °C 1 minute
6 8  °C 5 minutes
4°C constant
Post-reaction, samples were analysed using agarose gel electrophoresis.
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Forward
oligonucleotide
Reverse
oligonucleotide PCR program
SlPi 1170B1364C
1171B
1365C
2  step 
2  step
SIP] 1176B1372C
1177B
1373C
3 step 
2  step
S1 P3 1172B 1173B 3 step1368C 1369C 3 step
S1 P4 53B1374C
54B
1375C
2  step 
2  step
S1 P5 1182B1378C
58B
1379C
2  step
3 step
LPAi 45B1366C
46B
1367C
2  step 
2  step
LPA] 49B 1174B 3 step1370C 1371C 3 step
LPA3 1178B 1180B 3 step1376C 1377C 3 step
Table 2.1
Oligonucleotides and PCR programs used to amplify SIP and LPA receptor 
gene fragments from Chinese hamster genomic DNA or first strand cDNA.
The suffix B denotes oligonucleotides used for cloning gene fragments from 
Chinese hamster genomic DNA; the suffix C denotes use in RT-PCR with first 
strand cDNA. Sequences of these oligonucleotides are shown in this chapter, 
section 1 .6 .
2.2.2 Analysis of DNA fragments by gel electrophoresis
DNA samples were analysed by horizontal electrophoresis, typically using 1 % 
(w/v) agarose gels in TAE buffer, which were run at 100 V/cm. Appropriate size 
markers were included on each gel. Ethidium bromide was added to both gel and 
running buffer, to a final concentration of 30 pg/mL. DNA bands were 
visualised using uv transillumination at 254 nm. Agarose gel electrophoresis 
was also used for the purification of DNA fragments for cloning; this was 
performed in the same manner as analytical gel electrophoresis.
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2.2.3 Spin column purification of PCR products
Purification of PCR products which were to be ligated into expression vectors 
(after digestion with appropriate restriction enzymes) was performed using 
QIAGEN QIAquick PCR Purification Kit, in accordance with the manufacturer’s 
protocol; all centrifugation steps were performed using a benchtop centrifuge at 
maximum speed (16,100 x g). Briefly, 5 volumes buffer PB were added to
1 volume of PCR reaction and mixed; the sample was then applied to a
QIAquick spin colunm and centrifuged for 1 minute; the flow-through was 
discarded. Column-bound DNA was washed with 0.75 mL buffer PE and 
centrifuged for 1 minute, the flow-through discarded and the column centrifuged 
for a further minute. 30 pL buffer EB was applied to the centre of the column, 
which was allowed to stand for 1 minute at room temperature prior to 
centrifugation for 1 minute; this eluted the DNA solution.
2.2.4 Purification of DNA fragments from agarose gels
DNA fragments were purified from agarose gels using QIAGEN QIAquick Gel 
Extraction Kit, in accordance with the manufacturer’s instructions; all 
centrifugation steps were performed using a benchtop centrifuge at maximum 
speed (16,100 x g). Briefly, the desired band was excised from the agarose gel 
and weighed; 3 volumes buffer QG were added per gel volume (and the 
assumption was made that 100 mg gel was approximately equal to 100 pL 
volume). The sample was incubated at 50 °C for 10 minutes in order to melt the 
agarose and mixed well; 1 volume isopropanol was mixed with the sample 
before it was applied to a QIAquick spin column and centrifuged for 1 minute. 
The flow-through was discarded and the column washed with 0.5 mL buffer QG
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and centrifuged for 1 minute. Column-bound DNA was washed with 0.75 mL 
buffer PE and centrifuged for 1 minute, the flow-through discarded and the 
column centrifuged for a further minute. 30 pL buffer EB was applied to the 
centre of the column and allowed to stand for 1 minute at room temperature prior 
to centrifugation for 1 minute; this eluted the DNA solution.
2.2.5 Analysis of DNA fragments by restriction enzyme digest
For general restriction enzyme analysis, 1-2 pg DNA was incubated in an 
appropriate enzyme buffer with 5 units of each restriction enzyme for 2-4 hours 
at 37 °C. One unit is defined as the amount of enzyme required to completely 
digest 1 pg of substrate DNA in 1 hour. When the DNA was to be used in 
subsequent sub-cloning procedures, the PCR product (which had been purified 
according to this chapter, sections 2.3-2.4), or approximately 10 pg plasmid 
DNA was incubated with 20 units of each restriction enzyme, overnight at 37 °C; 
it was then subject to phenol-chloroform extraction prior to purification by gel 
extraction (this chapter, sections 2.4 and 2.7).
2.2.6 Alkaline phosphatase treatment of digested vector
Prior to ligation with DNA fragments, vector that had been digested with 
appropriate restriction enzymes was treated with alkaline phosphatase to prevent 
religation of partially digested vector. The reaction comprised approximately 
10 pg DNA, an appropriate volume of lOx phosphatase buffer and alkaline 
phosphatase (100 units). One unit is defined as the enzyme activity which 
hydrolyses 1 pmol of 4-nitrophenyl phosphate in 1 minute at 37 °C. After 
incubation at 37 °C for 30 minutes, a further 100 units alkaline phosphatase were
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added and the reaction incubated for another 30 minutes at 37 °C. The treated 
DNA was then purified by phenol-chloroform extraction (this chapter, section 
2.7).
2.2.7 Phenol-chloroform extraction of DNA
After digestion with restriction enzymes or alkaline phosphatase treatment, DNA 
was subject to extraction with phenol/chloroform/isoamyl alcohol. Briefly, to a 
100 pL reaction, 20 pL Hi TNE buffer, 80 pL TE buffer and 700 pL 
phenol/chloroform/isoamyl alcohol (25:24:1) were added and mixed well. 
Centrifugation (1 minute at 16,100 x g) was used to separate the aqueous and 
organic layers. The aqueous layer was carefully removed into a clean tube and 
the phenol/chloroform/isoamyl alcohol re-extracted after the addition of 20 pL 
Hi TNE buffer and 80 pL TE buffer. The aqueous layer was combined with the 
first aqueous fraction and extracted with chloroform. DNA in the resultant 
aqueous layer was then precipitated by the addition of 2.5 volumes of 100 % 
ethanol and incubation at -20 °C for 1 hour. The DNA was collected by 
centrifugation at 16,100 x g  for 10 minutes, washed once with cold 70 % ethanol 
and resuspended in an appropriate volume of TE buffer.
2.2.8 Ligation of DNA fragments
Ligation of DNA fragments was performed in a total reaction volume of 20 pL, 
comprising 4 pL 5x ligation buffer, 400 units T4 DNA ligase, approximately 
50 ng vector DNA and a molar equivalent of insert fiagment(s). Control 
reactions, containing no insert DNA, were routinely performed to allow 
assessment of the background of uncut vector as well as the efficiency of
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transformation. Ligation reactions were incubated overnight at 16 °C before 
transformation of a proportion of the reaction into competent E. Coli cells.
2.2.9 Transformation of DNA into competent E. Coli cells
Novablue competent E. Coli cells were transformed in accordance with 
manufacturer’s recommendations. Briefly, 50 pL Novablue cells were gently 
thawed on ice and 1-2 ng DNA was added. The cells were incubated on ice for 
5 minutes, heat-shocked at 42 °C for 30 seconds then incubated on ice for a 
further 2 minutes. 800 pL SOC medium was added and cells were incubated on 
a shaker platform at 37 °C for 30 minutes. An appropriate volume of sample was 
then plated out onto LB Agar plates supplemented with 100 pg/mL ampicillin, 
which were then grown overnight at 37 °C.
2.2.10 TOPO cloning of PCR products
PCR products which were amplified with the specific purpose of sequencing (i.e. 
partial sequences of SIP- and LPA-receptor coding sequences which were 
amplified from Chinese hamster genomic DNA) were cloned into pCR4-T0P0 
vector using the TOPO TA Cloning Kit for Sequencing, in accordance with the 
manufacturer’s recommendations. Briefly, PCR products were purified from 
agarose as described in this chapter, section 2.4 and cloned into the TOPO TA 
vector in a 5 minute reaction. 2 pL of each reaction was then transformed into 
TOP 10 One Shot chemically competent cells, which were incubated on ice for 
5 minutes, heat shocked at 42 °C for 30 seconds and returned to ice. 250 pL 
SOC medium was added and the tube incubated on a shaker platform for 1 hour 
at 37 °C after which time appropriate volumes were plated out onto LB Agar
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plates supplemented with 100 pg/mL ampicillin; these plates were then grown 
overnight at 37 °C.
2.2.11 Isolation of plasmid DNA using QIAGEN Miniprep columns
Miniprep columns were used to prepare recombinant plasmid DNA for 
subsequent analysis via restriction enzyme digest or DNA sequencing. The 
method used was broadly in accordance with the manufacturer’s 
recommendations and centrifugation steps were performed using a benchtop 
centrifuge at maximum speed (16,100 x g), unless stated otherwise. Briefly, a 
single colony of transformed E. Coli was picked from a selective LB Agar plate 
and used to inoculate a 10 mL 2x TY culture (containing 100 pg/mL ampicillin). 
The culture was grown overnight at 37 °C and bacteria collected by 
centrifugation (1,500 x g for 15 minutes). The cell pellet was resuspended in 250 
pL buffer PI, then 250 pL lysis buffer P2 was added and mixed by gentle 
inversion. The lysis reaction was neutralised by the addition of 350 pL buffer 
N3 and was immediately mixed by gentle inversion. Centrifugation (10 minutes) 
was used to clear the cell lysate and the supernatant fraction was applied to a 
QIAprep spin column. The column was placed in a 2 mL collection tube and 
centrifuged for 1 minute. Bound DNA was washed with 0.5 mL buffer PB then 
with 0.75 mL buffer PE; centrifugation for 1 minute followed each wash step. 
After an additional 1 minute centrifugation to remove any remaining PE buffer, 
DNA was eluted from the column in 180 pL buffer EB, which was collected by 
centrifugation, into a clean tube. The DNA was then precipitated by the addition 
of 20 pL Hi TNE buffer and 600 pL 100 % ethanol with incubation at -20 °C for
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1 hour. Precipitated DNA was collected by centrifugation for 10 minutes, 
washed once with 70 % ethanol and resuspended in 30 pL buffer EB.
2.2.12 Isolation of plasmid DNA using QIAGEN Maxiprep kit
Larger quantities of plasmid DNA were prepared from overnight cultures 
(200 mL 2x TY medium containing 100 pg/mL ampicillin) using QIAGEN-tip 
500, following the manufacturer’s guidelines; centrifugation steps were 
performed using Sorvall RC5B refrigerated centrifuge. In brief, cells were 
collected by centrifugation (4,600 x g  rpm for 15 minutes) and the cell pellet 
resuspended in 10 mL buffer PL 10 mL buffer P2 was added and mixed gently 
to lyse the cells. After an incubation of 5 minutes at room temperature, 10 ml 
buffer P3 (which had been chilled to 4 °C) was added and the lysate was 
immediately poured into a QIAfilter cartridge and incubated for 10 minutes at 
room temperature. The cell lysate was then filtered through the QIAfilter 
cartridge and applied to a QIAGEN-tip 500 (which had been previously 
equilibrated using 10 mL buffer QBT) and allowed to flow under gravity 
pressure. Bound DNA was washed twice with 30 mL buffer QC then eluted with 
15 mL buffer QF. 10.5 mL isopropanol was added to the eluted DNA and mixed 
well then centrifuged (17,000 x g, at 4 °C for 40 minutes). Precipitated DNA 
was washed once with 70 % ethanol, air-dried and resuspended in an appropriate 
volume of TE buffer.
2.2.13 Optical density measurement of DNA
The concentration of DNA was determined via measurement of the optical 
density at 260 nm, using a quartz cuvette. A Genova uv/vis spectrophotometer
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(Jenway Ltd., Dunmow, Essex, U.K.) was used and an optical density reading of
1.0 was assumed to be equivalent to a concentration of 50 pg/mL.
2.2.14 DNA sequencing
DNA sequencing reactions were performed in 0.2 mL thin-walled tubes 
(Anachem Ltd.) for analysis using either 3 73A or 3100 automated DNA 
sequencer (Applied Biosystems, Warrington, Cheshire, U.K.)
For analysis using 373A sequencer, each reaction comprised 5 pmol sequencing 
primer, 1.0-1.5 pg plasmid DNA, 1.5 pL sequencing buffer and 1.5 pL Big Dye 
Terminator Reaction Ready sequencing premix (Applied Biosystems). Distilled 
water was added to bring the volume to 7.5 pL and the reaction was cycled under 
the following conditions:
96 °C 30 seconds
96 °C 10 seconds
50 °C 5 seconds
60 °C 4 minutes
X 25 cycles
4 °C constant
The DNA was then precipitated by the addition of 2 pL 3 M sodium acetate 
(pH 4.6) and 50 pL 95 % ethanol. Samples were incubated on ice for 10 minutes 
and centrifuged at maximum speed (16,100 x g) for 15 minutes. The supernatant 
was removed and the pellet was air-dried, then resuspended in sample loading 
buffer.
For analysis using 3100 sequencer, reactions were prepared in the same manner 
as described above, except that 250 ng DNA was used per reaction. After 
cycling, samples were batch precipitated by the addition of 0.76 pL 3 M sodium 
acetate (pH 4.6) and 19.23 pL 95 % ethanol to each tube. Samples were
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incubated at room temperature for 15 minutes and centrifuged at 1,500 x g  for 
45 minutes at 4°C. The resultant pellets were washed with 70% ethanol, air 
dried and resuspended in 10 pL formamide.
2.2.15 Isolation of genomic DNA from mammalian cells
Genomic DNA was prepared from CHO-Kl cells using QIAGEN DNeasy kit, in 
accordance with the manufacturer’s recommendations; centrifugation steps were 
performed using a benchtop centrifuge at maximum speed (16,100 x g). In brief, 
approximately 5 x 10  ^ cells were resuspended in 200 pL PBS then 20 pL 
proteinase K and 200 pL buffer AL added to the sample which was mixed by 
vortexing before incubating for 10 minutes at 70 °C. 200 pL absolute ethanol 
was added and mixed by vortexing and the sample applied to a DNeasy spin 
column, which was placed in a collection tube and centrifuged for 1 minute. 
Bound DNA was washed first with 500 pL AWl then with 500 pL AW2 buffers; 
before each wash step the spin column was placed into a fresh collection tube 
and centrifuged for 1 minute (AWl wash) or 3 minutes (AW2 wash). DNA was 
eluted from the column by the application of 200 pL buffer AE and was 
collected by centrifugation after an incubation of 1 minute. The elution step was 
repeated and the eluates combined. Genomic DNA was stored at 4 °C.
2.2.16 Isolation of total RNA from mammalian cells
Total RNA was prepared from CHO-Kl cells using QIAGEN RNeasy Mini kit, 
in accordance with the manufacturer’s recommendations; centrifugation steps 
were performed using a benchtop centrifuge at maximum speed (16,100 x g). 
Briefly, approximately 4 x 10  ^ cells, which had been washed with PBS, were 
lysed in 350 pL buffer RET (which had been supplemented with 143 mM
- 8 2 -
C hap ter 2
2-mercaptoethanol) and mixed by vortexing. The lysate was homogenised by 
application to a QIAshredder column, which was placed in a 2 mL collection 
tube and centrifuged for 2 minutes. 350 pL 70 % ethanol was added to the 
homogenised lysate, mixed by pipetting and then applied to an RNeasy Mini 
colunrn, which was placed in a 2 mL collection tube. The sample was bound to 
the column by centrifugation for 15 seconds and then washed with 700 pL buffer 
RWl followed by 2 X 500 pL washes with buffer RPE; centrifugation followed 
each wash step. Bound RNA was eluted by the application of 50 pL RNase-ffee 
water and collected by centrifugation for 1 minute; the elution was repeated and 
the eluates were pooled.
Purified total RNA was treated with amplification grade deoxyribonuclease I 
(DNase I) to eliminate any contaminating genomic DNA. Approximately 5 pg 
RNA was treated in a 50 pL reaction, which also contained 5 pL lOx DNase I 
reaction buffer, 5 units DNase I and an appropriate volume of DEPC-treated 
water. After incubation at room temperature for 15 minutes, the reaction was 
terminated by the addition of EDTA to a final concentration of 2.2 mM, followed 
by heat inactivation of the enzyme at 65 °C for 10 minutes.
2.2.17 Synthesis of first strand cDNA by RT-PCR
First strand cDNA was prepared from CHO-Kl total RNA (preparation of which 
is described in this chapter, section 2.16) using Advantage RT-for-PCR kit, 
following the manufacturer’s protocol. In essence, approximately 1 pg total 
RNA was mixed with oligo dT primer and heated for 2 minutes at 70 °C then 
immediately cooled on ice. 5x reaction buffer, dNTPs, recombinant RNase 
inhibitor and MMLV reverse transcriptase were added to give a 20 pL reaction
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which was incubated at 42 °C for 1 hour then heated at 94 °C to terminate the 
reaction, denature RNA-cDNA hybrids and destroy DNase activity. The 
resultant cDNA was stored at -80 °C until use and 2 pL used as template in 
20 pL gene specific amplifications, which were carried out as described in this 
chapter, section 2 .1 .
2.3 Cell culture and cell biology methods
2.3.1 General cell culture
HEK-293 and CHO-Kl cell lines were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM), supplemented with 2 mM L-glutamine, 10 % (v/v) foetal calf 
serum and Ix non essential amino acids (“complete DMEM”). The CHO-EcR 
cell line was maintained in Ham’s F-12 Nutrient Mix, supplemented with 10 % 
(v/v) foetal calf serum, 2 mM L-glutamine and 250 pg/mL Zeocin (“Complete 
F12”). Stable cell lines were cultured in the appropriate medium, to which
7.5 pg/mL Puromycin (CHO-Kl) or 500 pg/mL Geneticin (CHO-EcR) had been 
added.
CHO and HEK cells adhere to tissue culture plastics and were normally cultured 
in T175 flasks. Routine passage of cells was performed using trypsin-EDTA to 
dislodge the adherent cell monolayer; medium was removed from the flask and 
the adherent cells were washed once with 10 mL Dulbecco’s PBS before 3 mL 
trypsin-EDTA in Hank’s Balanced Salt Solution was added. Cells were 
incubated at 37 °C for approximately 5 minutes until cells could be dislodged by 
tapping the flask. 7 mL “complete DMEM” was added and an appropriate 
volume of cell suspension transferred to a fresh flask together with 40 mL 
medium which was incubated at 37 °C with 5 % CO2 . Cells were subcultured at
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a ratio which achieved confluence after approximately 4 days: CHO-Kl cells 
were split 1 in 100; CHO-EcR were split 1 in 50; HEK-293 were split 1 in 10.
Cell lines were cryopreserved for long term storage. Cell monolayers were 
removed by trypsinisation, centrifuged, the cell pellet was resuspended in 
freezing medium (90 % (v/v) foetal calf serum + 10 % (v/v) DMSO) and 
dispensed into cryovials. Aliquots of cells were packed in expanded polystyrene 
and chilled to -70 °C before transfer of the aliquots to liquid nitrogen.
2.3.2 Transient transfection of HEK-293 cells
HEK-293 cells were transiently transfected to express aiAAR-Gaü fusion 
protein, which was to be used as a positive control in the [^^S]GTPyS binding 
assay. Cells were seeded into poly-D-lysine coated T175 flasks (2 x 10  ^
cells/flask) on the day prior to transfection. The resulting sub-confluent cells 
were transfected using Lipofectamine reagent (Invitrogen Ltd.) in accordance 
with the manufacturer’s protocol. Briefly, 36 pg plasmid DNA was mixed with
1.8 mL Opti-Mem Reduced Serum Medium to yield Solution A; 144 pL 
Lipofectamine was mixed with 1.8 mL Opti-Mem to produce solution B. 
Solutions A and B were combined and incubated at room temperature for 
30 minutes to allow DNA-liposome complexes to form. 14.4 mL Opti-Mem was 
added to the complexes and mixed gently. Diluted complexes were overlaid 
onto the cells (which had been washed once with Opti-Mem) and incubated for 
6  hours at 37 °C with 5 % CO2 after which time they were removed and 50 mL 
fresh “complete DMEM” added to the cells. Cells were grown for 2-3 days at 
37 °C with 5 % CO2 before being harvested.
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2.3.3 Generation of stable cell lines
CHO-Kl cells were stably transfected to express HA-SIP4, HA-SlP4-Gaii(C^^^I) 
or HA-SlP4(E^^^Q)-Gaii(C^^^I) proteins. Cells were transfected essentially as 
described in this chapter, section 3.2 with the following modifications: 0.67 x 10  ^
cells were seeded into a T25 flask on the day prior to transfection, such that they 
were 50-80 % confluent on the day of transfection. Solution A was prepared by 
mixing 5.3 pg plasmid DNA with 267 pL Opti-Mem Reduced Serum Medium;
21.3 pL Lipofectamine reagent was mixed with 267 pL Opti-Mem to yield 
Solution B. After the combination of solutions A and B and incubation to allow 
formation of complexes, 6.4 mL Opti-Mem was added and the diluted complexes 
laid over cells which had been washed once with Opti-Mem. Cells were 
incubated with the complexes for 6  hours at 37 °C with 5 % CO2 then the 
complexes were removed and replaced with 5 mL “complete DMEM”. 2-3 days 
post transfection, cells were detached using trypsin, counted, resuspended in 
“complete DMEM” supplemented with 7.5 pg/mL Puromycin and seeded into a 
number of 96-well plates (200 pL/well); seeding densities of 10, 100 and 1000 
cells/well were used. The plates were incubated at 37 °C with 5 % CO2 for 2-3 
weeks before inspection of wells to identify those containing a single colony of 
Puromycin-resistant cells. Such colonies were detached into 200 pL trypsin and 
expanded into 24-well plates (1 mL/well); when confluent, cells were seeded into 
2  copies of a 6 -well plate (one copy was then used to test for expression of the 
recombinant protein of interest). Positive clones (identified using FACS 
analysis, described in this chapter, section 3.5) were then expanded into T175 
flasks (via T25 flasks) and frozen stocks prepared. A mock transfection was set 
up in parallel to each transfection; this was to ensure that Puromycin-resistant
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colonies were the result of transfection with plasmid containing Puromycin- 
resistance gene.
The CHO-EcR cell line was stably transfected to express HA-SIP4 using 
Lipofectamine 2000 (Invitrogen Ltd.) as the transfection reagent and following 
the manufacturer’s protocol. Essentially, CHO-EcR cells were seeded in T75 
flasks such that they were 90-95 % confluent on the day of transfection. 114 pL 
Lipofectamine 2000 was mixed with 1.9 mL Opti-Mem Reduced Serum Medium 
and incubated for 5 minutes at room temperature; this was Solution A. 38 pg 
plasmid DNA was mixed with 1.9 mL Opti-Mem to form Solution B. Solutions 
A and B were mixed and incubated at room temperature for 20 minutes to allow 
formation of DNA-liposome complexes. Cells were washed once with Opti- 
Mem medium and 8  mL fresh Opti-Mem was added to the cells before the 
complexes were laid onto cells. The cells were incubated with complexes for 
6  hours at 37 °C with 5 % CO2 after which time complexes were removed and 
15 mL “complete F12” medium added to each flask. 2-3 days post-transfection, 
cells were trypsinised, counted and seeded into 96 well plates in “complete F12” 
medium supplemented with 500 pg/mL Geneticin and single colonies isolated 
and expanded as described previously in this chapter. A mock transfection was 
set up in parallel.
2.3.4 Induction of HA-SIP4 expression in ecdysone-inducible CHO- 
EcR cell line
Small scale experiments used to profile this expression system were set up in 24- 
well tissue culture plates using CHO-EcR cells which had been stably transfected 
to express H A - S I P 4  under the control of the ecdysone receptor. Cells were 
normally seeded on the day prior to an experiment with 1 .6  x 1 0  ^ cells per well,
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in “complete F12” medium. Plates were placed on an orbital shaker for 
30 minutes to aid even settling of the cells and then transferred to 37 °C with 5 % 
CO2 for 3 hours to allow attachment to the tissue culture plastic. Medium was 
then removed and the attached cells washed once with PBS before serum-free 
F12 medium containing the appropriate concentration of induction agent was 
applied to the cells. The induction agents, ponasterone A and muristerone A, 
were prepared as 10 mM DMSO stocks. Cells were then assayed to determine 
cell-surface receptor expression (this chapter, section 3.5) 24 hours after 
application of the induction agent. For expression timecourse experiments, cells 
were seeded in 24 well plates at 0.6 x 10  ^cells per well three days prior to assay 
and medium replaced with serum-free F I2 medium containing induction agent at 
appropriate timepoints. Cells were assayed to determine cell-surface receptor 
expression as normal.
2.3.5 Detection of cell-surface proteins (FACS analysis)
Cells ( > 1  X 1 0 ^ ) were detached from tissue culture plastics using cell dissociation 
solution (Sigma) and mixed with FACS buffer (PBS containing 3 % (v/v) FCS, 
0.1 % (w/v) NaNg) in 5 mL polypropylene Falcon tubes (BD Biosciences, 
Cowley, Oxon., U.K.). After collection by centrifugation (4 minutes at 400 x g), 
cells were resuspended in 100 |iL FACS buffer in the presence of approximately 
0.5 pg/mL rat anti-HA-Fluorescein antibody or an isotype matched control 
antibody, and incubated for 1 hour at 4 °C, in the dark. Cells were washed with 
3 mL chilled FACS buffer and resuspended in 200 pL of the same. Staining data 
was measured using FACScan or FACScalibur flow cytometers (BD
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Biosciences); staining with the specific antibody was compared to that obtained 
with the isotype matched control antibody.
2.3.6 Fluorescence microscopy
Cells were non-enzymatically detached from tissue culture plastics using cell 
dissociation solution and seeded into 8  chamber tissue culture treated glass slides 
(2 X 10"^  cells/chamber) in the appropriate complete medium. Where appropriate, 
the induction agent ponasterone A was added to medium. 24 hours after seeding, 
cells were washed well with medium and stained in complete medium containing 
the rat anti-HA-Fluorescein antibody (0.5 pg/mL) for 30 minutes in the dark. 
The nuclear stain DAPI (4',6'-diamidino-2-phenylindole hydrochloride) was 
added to the medium for the final 10 minutes (10 pg/ml). Cells were washed 
with medium and the slides mounted using ProLong Antifade Kit (Molecular 
Probes, Leiden, Holland). Fluorescent images were observed using a Leica 
DMRXA fluorescence microscope with oil immersion lenses. Fluorescein was 
excited at 495 nm (520 nm emission) and excitation of the DAPI stain was at 420 
nm (345 nm emission). Images were manipulated using Openlab 2.2.0 
deconvolution software (Improvision, Coventry, U. K.).
2.4 Protein methods
2.4.1 Preparation of cell membranes
CHO cell lines for use in SlP-receptor activation assays were grown in T175 
flasks or 2 L roller bottles and transferred to serum-ffee medium approximately 
24 hours prior to harvest. Briefly, medium was aspirated and cells washed twice 
with PBS before replacement with serum-ffee DMEM (containing 100 pg/mL 
pertussis toxin, where appropriate). HEK-293 cells, which had been transiently
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transfected to express a 2AAR-Gotii(C^^^I) fusion protein, were grown in 
“complete” DMEM. To harvest cells, growth medium was removed and the 
adherent cells washed with PBS. Cells were dislodged from culture vessels 
using cell dissociation solution and collected by centrifugation; the resultant cell 
pellet was washed with PBS. Cells were resuspended in an appropriate volume 
of membrane preparation buffer (20 mM HEPES (pH 7.4), 100 mM NaCl, 
10 mM MgCl2, “complete” protease inhibitors (Roche Molecular 
Biochemicals)). For small scale membrane preparations, cells were ruptured by 
35 strokes using a hand held Wheaton tight fit glass douncer; larger scale 
preparations were homogenised in a nitrogen cavitation chamber (500 psi for 20 
minutes). Unbroken cells and nuclei were removed by centrifugation (500 x g, 
10 minutes at 4 °C) and the supernatant fraction was centrifuged at 45,000 x g 
for 45 minutes at 4 °C. Membrane pellets were resuspended in membrane 
preparation buffer, titurated through a fine gauge needle, aliquotted and stored at 
-80 °C until required.
2.4.2 Determination of protein concentration
The protein concentration of membrane preparations was determined using 
Micro BCA Protein Assay Reagents (Perbio Science U.K. Ltd., Tattenhall, 
Cheshire, U.K.) in accordance with the manufacturer’s protocol. Membrane 
preparation buffer (this chapter, section 5.2) was used as the diluent for BSA 
standards and samples.
2.4.3 Immunological detection of protein (Western blotting)
Samples (typically membrane preparations) were prepared for Western blot 
analysis by the addition of an equal volume of 2 x protein sample buffer and
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incubation for 1 hour at room temperature. Approximately 10 pg each sample 
was loaded onto 4-20 % Tris-Glycine pre-cast polyacrylamide gel alongside 
prestained molecular weight markers. Gels were electrophoresed at 100 V / 35 
mA for approximately 90 minutes, until the dye front had reached the bottom of 
the gel. Proteins were transferred to Immobilon-P PVDF membrane, which had 
been pre-wetted in methanol, overnight at 80 mA; the use of prestained 
molecular weight markers allowed judgement of the success of protein transfer. 
The resultant blot was blocked in PBS containing 2.5% (w/v) Marvel for 1 hour 
at room temperature, with constant agitation. Antibodies were prepared in PBS 
containing 1 % (w/v) Marvel and 0.1 % (v/v) Tween-20. The membrane was 
incubated with the primary antibody for 4 hours at room temperature, then 
washed three times in PBS containing 0.1 % (v/v) Tween-20 (5 minutes per 
wash) before incubation with the appropriate horseradish peroxidase-conjugated 
secondary antibody for approximately 2 hours at room temperature. After a 
further three washes (10 minutes per wash), the blot was developed using Pierce 
SuperSignal reagents (Perbio Science), in accordance with the manufacturer’s 
instructions. The signal was detected using x-ray film, which was processed 
using an X-OMat automatic developer (Kodak Ltd., Hemel Hempstead, Herts., 
U. K.).
2.5 Receptor activity assays
2.5.1 Handling of receptor agonists
Lysophospholid solutions were handled using siliconised Eppendorfs and pipette 
tips to minimise losses due to adhesion to plastics. Sphingosine-1-phosphate was 
dissolved in methanol to give a 1 pM solution, this required heating at 60 °C and
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repeated vortexing and sonication to disperse the solid. 100 pL aliquots 
(equivalent to 0.1 pmoles compound) were dispensed into 2 mL Wheaton brown 
glass vials (Sigma) and the solvent gently evaporated under a stream of nitrogen. 
Aliquots were then stored at -80 °C prior to use. To reconstitute an aliquot of 
SIP, 250 pL “assay buffer” (this chapter, section 5.2) supplemented with 1 % 
(w/v) fatty acid free BSA was added and incubated at 37 °C for 30 minutes, with 
repeated vortexing. A further 1 in 4 dilution in assay buffer supplemented with 
1 % (w/v) fatty acid free BSA yielded a 100 pM solution of SIP for use in 
receptor activation assays.
Lysophosphatidic acid (18:1) was prepared as a 2 mM DMSO solution (repeated 
vortexing and sonication were used to disperse the solid) and aliquotted for 
storage at -20 °C. 16:0 and 14:0 lysophosphatidic acids were prepared in 1:1
ethanol:water as 2 mM stock solutions, aliquotted and stored at -20 °C until use. 
Dilution of these stock solutions with “assay buffer” (this chapter, section 5.2) 
supplemented with 1 % (w/v) fatty acid free BSA gave a solution of LPA, which 
could be used in assays.
The tt2AAR agonist, UK14304 was prepared as a 5 mM stock solution in 1:1 
DMSO:water and aliquots stored at -80 °C.
Compounds FTY720 and AAL were synthesised by the medicinal chemistry 
department of Celltech R+D using synthetic schemes described previously 
[Kiuchi et ah, 2000]. Each compound was then prepared as ImM stock solution 
in ethanol and stored at -20 °C. In vitro phosphorylation of FTY720 and AAL 
was achieved via incubation with rabbit blood (essentially as described by
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Mandala et al., [2002]). Heparinised venous rabbit blood was mixed with three 
volumes of RPMI medium (supplemented with 10 % FCS, 2 mM L-glutamine 
and Ix non essential amino acids). FTY720 or AAL compounds were added to 
the diluted blood and the phosphorylation reaction incubated for the stated time 
at 37 °C, without additional CO2 . Post reaction, four volumes of acetonitrile 
were added and mixed well before centrifugation at approximately 2 0 0 0  x g  for 
15 minutes. The supernatant was then analysed by liquid chromatography-mass 
spectrometry (LC-MS).
2.5.2 [^^SjGTPyS binding assay
[^^S]GTPyS binding experiments were performed in accordance with the method 
described by Stevens et ah, [2001]. Reagents were prepared in “assay buffer” 
(20 mM HEPES (pH 7.4), 3 mM MgCl2, 100 mM NaCl). Membranes 
( 2 0  pg/point) were incubated with or without ligand for an appropriate time at 
30 °C in “assay buffer” containing [^^S]GTPyS (100 nCi/point), and an 
appropriate concentration of GDP, in a final volume of 100 pL/point. Where 
indicated, saponin (20 pg/point) was included. Lysophospholipid ligands were 
prepared in “assay buffer” supplemented with 1 % (w/v) fatty acid free BSA (this 
chapter, section 5.2), such that the final BSA concentration in the assay was 
0.1 % (w/v). UK14304, an 0C2AAR agonist, was diluted in “assay buffer” and 
used at a final concentration of 1 pM.
Following incubation, 500 pL chilled “assay buffer” containing “complete” 
protease inhibitors was added to each tube and membranes collected by 
centrifugation (14,000 rpm (16,100 x g) for 15 minutes at 4 °C). Membranes 
were solubilised for 1 hour at 4 °C, mixing end-over-end, in 50 pL 0.4 % (w/v)
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SDS in chilled “solubilisation buffer” (100 mM Tris-HCl (pH 7.4 at 4 °C), 
200 mM NaCl, 1 mM EDTA, “complete” protease inhibitors and 1.25 % (v/v) 
NP-40). This solution was then precleared by the addition of 60 pL/point of a 
mixture containing normal rabbit serum (diluted in “solubilisation buffer” to give 
1 in 100 final concentration) and protein G Sepharose beads ( 6  pL/point diluted 
in “bead buffer” (2 % (w/v) BSA, containing 0.1 % (w/v) NaNg and “complete” 
protease inhibitors)) and mixed for 1 hour at 4 °C. Beads were pelleted by 
centrifugation (14,000 rpm for 5 minutes at 4 °C) and the supernatant was 
immunoprecipitated with SGI antiserum, which directed against Gaii/2 G 
proteins. 50 pL of a mix containing SGI (diluted to give 1 in 200 final 
concentration in “solubilisation buffer”) and protein G Sepharose beads 
(5 pL/point diluted in “bead buffer”) was added to each tube and mixed 
overnight at 4 °C. Beads were collected by centrifugation and washed twice with 
500 pL “solubilisation buffer”. 1 mL Ultima Gold XR scintillation fluid (Perkin 
Elmer, Cambridge, U.K.) was added to each tube and bound radioactivity 
measured using liquid scintillation spectrometry. Non-specific binding in the 
presence of 100 pM GTPyS was also determined in each experiment.
2.5.3 Data analysis
Analysis of numerical data was performed using Graphpad Prism, version 3.00. 
Data were corrected for non-specific binding and where appropriate, fitted using 
nonlinear (sigmoidal dose-response, fixed slope) regression. This method is 
reliant on the presence of at least two data points on the top and bottom sections 
of the curve, and at least one data point on the sigmoidal section of the curve in 
order to generate a dose-response curve; where this does not occur, interpretation
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of the resultant E C 5 0  value should be cautious. Results were expressed as the 
mean of triplicate determinations ± SEM. Typically, assays were performed at 
least three times, using membranes prepared from at least two individual cell 
passages. Statistical tests applied to data were one-way ANOVA, with Dunnett’s 
multiple comparison post test. Investigations of the statistical relationship 
between two data sets were performed using Pearson’s correlation.
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Chapter 3 -  Cloning of Human SIP4 and Production 
of Expression Constructs
3.1 Introduction
This chapter describes the cloning and construction of plasmids for expression in 
mammalian cells and the application of RT-PCR to determine the profile of 
endogenous SIP and LPA receptor mRNA expression in CHO-Kl cells.
The S1P4 receptor was cloned from a human PBMC cDNA library and modified 
to contain an amino-terminal HA epitope-tag. It was also constructed as an in­
frame fusion between HA-tagged SIP4 and a pertussis toxin resistant Gaii(C^^’l) 
G protein. These constructs were made using the plRESpuro mammalian 
expression vector (Figure 3.1). HA-SIP4 and the HA-SlP4-Gaii(C'^^'l) fusion 
protein were stably expressed in CHO-Kl cells and used in functional assays as 
described in chapters 4 and 6 .
II rvs I 1RES
S a p l
Figure 3. 1
Schematic diagram of the pIRESpuro mammalian expression vector.
The vector is approximately 5.2 kb in size and includes the internal ribosome 
entry site (1RES), which permits the translation of two open reading frames from 
one mRNA. This expression cassette contains the human cytomegalovirus 
(CMV) major intermediate early promoter/enhancer which drives expression of 
cloned genes; a multiple cloning site for insertion of cloned genes; a synthetic 
intervening sequence (IVS) intron to enhance mRNA stability; the 
encephalomyocarditis virus (ECMV) 1RES followed by the Puromycin resistance 
marker; bovine growth hormone polyadenylation signal for proper processing of 
the 3’ end of the cloned mRNA. The vector backbone also contains the 13- 
lactamase gene to confer resistance to ampicillin and the pBR322 origin of 
replication for propagation in E. Coli.
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HA-tagged SIP4 was also constructed in the plND expression vector (Figure 3.2) 
and stably transfected into CHO-EcR cells for the inducible expression studies 
described in chapter 5.
R e a l
Amp-^  I 5xE/GRE| P^ hsp BGH pA |  fl ori ]SV40 ori] Neo*^  ]SV 40pA | pUCori
Figure 3. 2
Schematic diagram of the pIND ecdysone-inducible mammalian expression 
vector.
This vector is approximately 5.0 kb in size and contains five 
ecdysone/glucocorticoid receptor elements (E/GRE), which allow binding of the 
modified ecdysone-receptor for activation of gene transcription and inducible 
expression of the gene of interest. Its other essential elements include the 
minimal heat shock promoter, which drives expression of the gene of interest; a 
multiple cloning site; bovine growth hormone (BGH) polyadenylation signal to 
allow efficient transcription termination and polyadenylation of cloned mRNA; 
fl origin of replication; SV40 early promoter and origin of replication to drive 
high level expression of the neomycin resistance gene, which confers resistance 
to the antibiotic Geneticin and SV40 polyadenylation signal. The vector also 
contains (3-lactamase gene and pUC origin for high copy number replication and 
propagation in E. Coli.
Residue (glutamic acid) of SIP4 was mutated to glutamine to allow 
investigation into the role of this residue in the ligand preference of SIP4 . This 
mutant was constructed with an HA-epitope tag as an in-frame fusion with the 
pertussis toxin resistant mutant of Gaü(C^^'l) G protein, using the plRESpuro 
expression vector. These proteins were then stably expressed in CHO-Kl cells 
and their response in functional assays measured as described in chapter 6 .
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3.2 Results
3.2.1 Cloning of HA-tagged SIP4
In order to clone SIP4 , the published sequence (Genbank accession number 
AJ000479) was used to design primers F7240 and F7241 to allow amplification 
of the coding sequence of the SIP4 gene. The 5’ oligonucleotide, F7240, 
contained a Notl restriction site to facilitate cloning and a partial Kozak 
translational initiation sequence for optimal gene expression, upstream of the 
initiator methionine. F7241, the 3’ oligonucleotide, contained the terminal 
coding sequence of SIP4, an additional stop codon and an EcoRI restriction site. 
SIP4 was amplified from a human peripheral blood mononuclear cell (PBMC) 
cDNA library using PCR. Since the SIP4 sequence was GC rich (approximately 
67 % GC content), it was necessary to use a “GC-rich” PCR kit to amplify this 
sequence. The resultant PCR product was digested with the appropriate 
restriction enzymes to yield a fragment of approximately 1152 bp. This 
fragment was gel-purified and ligated into the mammalian expression vector, 
plRESpuro (Figure 3.3 (A)), which had been digested with Notl and EcoBl, then 
transformed into chemically competent E. Coli. Single colonies were cultured 
and plasmid DNA purified and the presence of insert verified by restriction 
digest and analysis by gel electrophoresis. The entire insert was sequenced using
a combination of sequencing primers designed from the published SIP4
sequence, and vector-specific primers. A number of clones were sequenced and 
were all found to contain PCR errors, which may have been due to the use of 
modifiers in the PCR mix and were necessary for amplification of this GC rich 
sequence. These were identified as PCR errors since they were random errors
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Figure 3. 3
Construction of SlPVpIRES.
S I P 4  was amplified from a human peripheral blood mononuclear cell (PBMC) 
cDNA library using the 5’ oligonucleotide F7240, which contained the Notl 
restriction site and a partial Kozak sequence, and the 3’ oligonucleotide F7241, 
which contained an EcoKl restriction site. The fragment was digested with Notl 
and EcoKl and ligated into pIRES (A). Due to the presence of PCR errors in the 
clones which were sequenced, it was necessary to generate an authentic construct 
via restriction digest and three-way ligation of two clones, each containing a 
single random PCR error either side of the unique Ncol site located at position 
437, into the pIRES vector (C). Two unique restriction sites located within the 
S I P 4  gene: Ncol and BamRl, are also shown. These sites were used to facilitate 
construction of this construct, epitope-tagged S I P 4 ,  a fusion of S I P 4  with the 
Gail G protein and a fusion of S1P4(E^^^Q) with the pertussis toxin-insensitive 
Gaii(C^^'l) G protein.
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that were not present in every clone sequenced. Two clones were identified 
which each contained a single error: clone number 1 0  had an error at position 
348, whilst in clone number 5 there was a single error at position 642. A unique 
Ncol restriction site at position 437 was utilised to produce a complete error free 
construct. DNA from each clone was digested with appropriate restriction 
enzymes (clone 5 with NotUNcol-, clone 10 with NcoVEcoBS) to excise the error- 
free section of the amplified sequence (Figure 3.3 (B)). These 5’ and 3’ portions 
were then ligated into plRESpuro, which had been digested with Notl and EcoBl 
enzymes. DNA sequencing was used to confirm the absence of errors in the 
resultant construct and the sequence obtained was identical to that described by 
Graeler et al., [1998] and this plasmid was named PIRES/SIP4 , (Figure 3.3 (C)).
It was necessary to epitope tag the SIP4 sequence since no antibodies to this 
receptor were available and, being an orphan GPCR at the time this work was 
undertaken, there was no possibility of detecting expression of protein using a 
functional assay. Therefore, PIRES/SIP4 was modified by PCR. The 5’ 
oligonucleotide F12582 contained a Notl restriction site for cloning, a partial 
Kozak sequence and the HA-epitope (YPYDVPDYA) inserted between the first 
and second codons of the SIP4 coding sequence. The 3’ oligonucleotide, 
F12581, was designed across the unique Ncol site present in the SIP4 sequence 
such that only the 5’ end of the gene would be amplified (Figure 3.4 (A)). The 
product of this PCR was digested with Notl and Ncol restriction enzymes to 
yield a 449 bp fragment. The 3’ end of the SIP4 coding sequence with which 
this 5’ fragment was to be ligated was produced by digestion of the pIRES/ SIP4 
plasmid with Ncol and EcoBJ restriction enzymes and gel purification (Figure
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Figure 3. 4
Construction of HA-SlPVpIRES.
SIP4 was HA-epitope tagged by PCR amplifieation of the 5’ portion of the 
sequence, using the forward oligonucleotide F12582, which contained the HA 
epitope sequence (YPYDVPDYA) immediately after the initiator methionine, as 
well as a partial Kozak sequence and Notl restriction site, and the reverse 
oligonucleotide F125 81 which utilised the unique Ncol site present in the SIP4 
sequence. This fragment (A) was joined with fragment (B), produced by 
Ncol/EcoRl restriction digest of SIP4/PIRES, in a three-way ligation reaction 
with Notl/EcoRl digested pIRES to yield HA-SIP4/PIRES (C).
3.4 (B)). The complete construct was then generated by three-way ligation 
reaction of the PCR-generated HA-tagged 5’ fragment, the restriction digest- 
produced 3’ fragment and Ao^EE'coRI-digested pIRES. Plasmid DNA was 
extracted from transformed E. Coli colonies and digested with restriction
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enzymes to check for the presence of insert. The entire insert was sequenced 
with vector- and insert-specific primers and was found to be error free. This 
construct was named HA-SIP4/PIRES (Figure 3.4 (C )).
3.2.2 Generation of HA-tagged SlP 4-Caii(C^^^I) fusion construct
The construct to express HA-SIP4 fused to GOii, where the G protein contained 
the mutation and was therefore resistant to ADP-ribosylation by pertussis 
toxin, was produced in several stages. Initially, PCR was used to remove the 
stop codon present at the 3’ end of the HA-SIP4 coding sequence in the 
previously produced HA-SIP4/PIRES construct. The forward oligonucleotide, 
F27384, which encompassed a unique BamYll restriction site within the SIP4 
sequence, was used in conjunction with the reverse oligonucleotide, F36663, 
which allowed mutation of the stop codon to alanine and also contained the 
EcoRl restriction site. The resultant PCR product was digested with BanïHl and 
EcoRl enzymes and gel purified to yield a fragment of approximately 290 bp 
(Figure 3.5 (A)). Digestion of HA-SIP4/PIRES with Notl and BaniRl yielded the 
910 bp 5’ fragment of HA-SIP4 (Figure 3.5 (B)) which was gel purified before 
three-way ligation with the PCR-generated 3’ fragment and plRES which had 
been cut with Notl and EcoRl. This ligation reaction was transformed into 
chemically competent E. Coli and plasmid DNA extracted from cultures of 
single colonies was analysed by restriction digest and gel electrophoresis to 
check for the presence of insert. The entire insert of a single clone was 
sequenced on both strands and found to be error free. This intermediate 
construct was named HA-SlP4(No Stop)/plRES and is shown in Figure 3.5 (C).
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Figure 3. 5
Construction of HA-SIP4(No Stop)/pIRES.
A construct of HA-SIP4 which lacked the 3’ stop codon was generated by PCR 
amplification of a 3’ fragment of HA-SIP4 using the forward primer F27384, 
which encompassed a unique BamHl site within the SIP4 sequence, and the 
reverse oligonucleotide F36663, which mutated the stop codon to alanine and 
contained an EcoRl restriction site to facilitate cloning. Restriction digest and 
gel purification of the PCR product yielded a fragment of approximately 290 bp 
(A). This was ligated in a three-way reaction with fragment (B), which had been 
produced by NotVBamlW digestion of HA-SIP4, and Aorl/EcoRI-digested 
pIRES, to produce HA-SlP4(No Stop)/pIRES (C).
The Gaii(C^^'l) G protein was modified by PCR such that it contained restriction 
sites which would allow in-frame fusion with the HA-SlP4(No Stop) sequence. 
The forward oligonucleotide F36661 introduced an EcoRI restriction site before 
the initiator methionine, and the reverse oligonucleotide F36662 created a
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BamUl site after the stop eodon of Gaii(C^^'l). Digestion of the PCR produet 
with appropriate restriction enzymes and subsequent gel-purifieation, yielded a 
fragment of approximately 1083 bp which was ligated into pIRES, which itself 
had been digested with EcoRl and BamRl. Chemically competent E. Coli were 
transformed with this ligation reaction and plasmid DNA extracted from cultures 
grown from single colonies. Analysis of this DNA by restriction digest and gel 
electrophoresis confirmed the presence of the insert, after which the insert of a 
single clone was sequenced on both strands, using Gttii- and veetor-specifie 
sequencing primers. This clone was found to be error free and was named 
Gaii(C^^^I)/pIRES (shown in Figure 3.6).
■ IVS I
F36662
5a/jl
r j u u u .  BamlW
1083 bp
Figure 3. 6
Construction of Gotii(C^^^I)/pIRES.
Gaii(C^^'l) was modified using PCR such that it contained an EcoRl restriction 
site at the 5’ end and a BamHl restriction site at the 3’ end. These sites were 
present in the forward oligonucleotide, F36661, and the reverse oligonucleotide, 
F36662, respectively. Digestion of the PCR product with EcoRl and BamHl 
yielded a fragment of approximately 1083 bp, which was ligated into pIRES, 
which had also been cut with EcoRl and BamHl. This produced the 
Gaii(C^^^)/pIRES construct.
The in-frame fusion between HA-SlP4(No Stop) and Gaii(C^^^I) was generated 
via restriction digest and three-way ligation. The 1200 bp HA-SlP4(No Stop) 
insert was released by Notl/EcoRl digest of the HA-SlP4(No Stop)/pIRES
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construct (Figure 3.7 (A)), whilst the GOii(C^^^I)/pIRES plasmid was digested 
with EcoRl and BamHl to yield the Gaii(C^^^I) insert, which was approximately 
1083 bp in size (Figure 3.7 (B)). These two fragments were gel-purified and 
combined with pIRES, which had been cut with Notl and BamHl restriction 
enzymes, in a three-way ligation reaction, which was transformed into competent 
E. Coli bacteria. Single colonies were cultured and plasmid DNA extracted. 
Analysis of this DNA by restriction digest and gel electrophoresis confirmed the 
presence of the expected insert and one of the clones was designated HA-SIP4- 
GoCii(C^^^I)/pIRES (Figure 3.7 (C)). The use of this cloning strategy resulted in 
the addition of a five amino acid artificial linker between the two elements of the 
fusion, which is shown in Figure 3.7 (C).
3.2.3 Generation of HA-tagged SIP4 construct for inducible expression
In order to control the level of HA-SIP4 expression in mammalian cells, a 
construct was made for use with the ecdysone-inducible mammalian expression 
system (Invitrogen Ltd.).
The insert of the HA-SIP4/PIRES construct was modified by PCR such that the 
5’ end of the sequence contained an EcoRl restriction site, and a Notl site was 
present at the 3’ end. These restriction sites were present in the forward and 
reverse oligonucleotides, 1 lOA and l l lA , respectively (see Figure 3.8 (A)). The 
PCR product was digested with the appropriate restriction enzymes and gel- 
purified before being ligated into the pIND vector, which had also been digested 
with EcoRl and Notl restriction enzymes. Chemically competent E. Coli were 
transformed and single colonies cultured before plasmid DNA was purified and
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Figure 3. 7
Construction of HA-SlP4-Gan(C^^ I)/pIRES.
The insert of the HA-SlP4(No Stop)/pIRES construct was released by digest 
using Notl and EcoRl restriction enzymes (A). Fragment (B) was produced by 
restriction digest of the Gaii(C^^'l)/pIRES with EcoRl and BamHl enzymes. 
Ligation of these fragments into pIRES, which had been digested with Notl and 
BamUl restriction enzymes, produced HA-SlP4-Gaii(C^^’l)/pIRES (C).
analysed by restriction digest and gel electrophoresis to confirm the presence of 
the expected insert. The insert of a single clone was sequenced over both 
strands, using a combination of the previously designed S1 P4-specific and
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vector-specific sequencing primers. This clone was error free and was 
designated HA-SlPVpIND (shown in Figure 3.8 (B)).
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Figure 3. 8
Construction of HA-SlPVpIND.
PCR was used to modify the restriction sites at the 5’ and 3’ ends of the HA- 
S1P4 insert such that they were compatible with the pIND vector. The forward 
oligonueleotide, 11OA contained a partial Kozak sequence and introduced an 
EcoK\ restriction site prior to the initiator methionine; the reverse 
oligonucleotide, l l lA  contained a Notl site after the stop codon of HA-SIP4. 
The HA-SIP4/PIRES eonstruet was used as a template and the resultant PCR 
product (A) was digested with EcoKV and Notl restriction enzymes. Ligation 
into pIND, which had also been digested with EcoRI and Notl produced the 
construct named HA-SIP4/PIND (B).
3.2.4 Generation of HA-tagged S1?4(E^^^Q) mutant fused with 
pertussis toxin-insensitive Gaii(C^^ I^)
The mutation was introduced into EIA-SIP4 using PCR. Two
complementary oligonucleotides, 58A and 59A, were designed across residue 
Each oligonucleotide contained the necessary base modifications to mutate 
glutamic acid to glutamine. Parallel PCR reactions were set up, each using
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HA-SlPVpIRES as template DNA. The first reaction used oligonucleotides 
F12582 and 59A to produce a fragment of approximately 405 bp; the second 
reaction was performed using oligonucleotides 58A and F7241 and yielded a 
fragment of approximately 795 bp. After gel purification, equimolar amounts of 
these PCR products were mixed and a further reaction performed, using 
oligonucleotides F12582 and F7241. This product was gel purified then digested 
of with Notl and Ncol restriction enzymes, gel purified to yield the 5’ fragment 
of approximately 476 bp, which included the desired mutation (Figure 3.9 (A)). 
Digestion of the previously produced HA-SlP4(No Stop) construct with Ncol 
and EcoRl restriction enzymes was followed by gel purification and yielded a 3’ 
fragment, of approximately 727 bp (Figure 3.9 (B)). The GOii(C^^^I)/pIRES 
plasmid (produced in this chapter, section 2.2) was digested with EcoRl and 
BamUl to yield the GoCii(C^ ^^ I) insert, which was approximately 1083 bp (Figure 
3.9 (C)). An in-frame fusion between the mutant of HA-SIP4 and
Gaii(C^^^I) was generated via four-way ligation of these fragments into 
Aotl/EcoRI-digested pIRES. Single colonies of transformed E. Coli were 
cultured and restriction digestion followed by gel electrophoresis used to check 
for the presence of insert in the purified plasmid DNA. The HA-SIP4 insert of a 
single clone was sequenced on both strands and was found to contain the desired 
mutation and to be free from PCR errors. This construct was named HA- 
SlP4(E^^^Q)-GOii(C^^^I)/pIRES and is shown in Figure 3.9 (D). In common with 
the wild type HA-SlP4-G0Cii(C^ ^^ I) fusion protein, HA-SlP4(E^^^Q)-Gotii(C^^^I) 
contained an artificial five amino acid linker present between the two elements of 
the fusion protein, which was a consequence of the cloning strategy used.
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Figure 3. 9
Construction of HA-SlP4(E'^^Q)-GOii(C^^'l)/pIRES.
Mutation of glutamic acid at position of SIP4 to glutamine was achieved by 
parallel PCR reactions. The 5’ portion of the sequence was amplified using the 
oligonucleotides F12582 (forwards) and 59A (reverse), whilst the forward 
oligonucleotide 58A and the reverse oligonucleotide F7241 were used to amplify 
the 3 ’ portion of the sequence. The PCR products were combined and a further 
amplification performed using the oligonucleotides F12582 and F7241. This 
product was digested with Notl and Ncol restriction enzymes (A). Other 
fragments to produce this construct were generated by restriction digest: (B) 3’ 
Ncol/EcoRl fragment of HA-SlP4(No Stop) and (C) EcoRl/BamHl insert from 
Gaii(C^^'l)/pIRES. These fragments were ligated into Notl/BamHl digested 
pIRES to yield HA-SlP4(E '“ Q)-Ga„(C” ‘l)/pIRES (D).
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3.2.5 Determination of expression of endogenous SIP and LPA 
receptors in CHO-Kl cells by RT-PCR
Untransfected CHO-Kl cells respond to exogenous SIP in a variety of in-vitro 
assays, which is thought to be due to the expression of endogenous SIP receptors 
by these cells. Although several mammalian cell lines have been characterised 
with respect to expression of endogenous SIP and LPA (Edg) receptors 
(examples in Graeler et a l, 1998; Motohashi et a l, 2000; Fueller et a l, 2003), 
very little data of this nature has been reported for the CHO-Kl host. This may 
be due to this cell line being derived from Chinese hamster. Very few gene 
sequences have been published for this species and of those which had been 
deposited at the time of the current investigation, none were of SIP or LPA 
receptors.
Such a lack of sequence data meant that the design of oligonucleotides for use in 
RT-PCR experiments to determine which of the SIP and LPA receptors were 
endogenously expressed by CHO-Kl cells was not straightforward. Human and 
rodent sequences for each of the eight Edg receptors were aligned, both at the 
nucleotide and protein level, and areas of high similarity between species were 
identified as the optimal areas over which oligonucleotides could be designed. It 
was noted that, for each of the Edg receptors, there was a strong degree of 
conservation between species at the protein level, although this was less obvious 
in nucleotide sequences since there were often changes at the 3-position between 
different species, which were silent with respect to the protein sequence. Hence, 
it was necessary to design primers which contained a degree of redundancy. The 
LPA receptors were known to contain an intron in TM VI, the location of which 
is absolutely conserved between human and mouse [Contos and Chun, 1998;
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Contos and Chun, 2000; Contos and Chun, 2001]. Oligonucleotides to amplify a 
fragment of each of the LPA receptor genes were designed such that this intron 
boundary was not spanned by the expected product. Table 3.1 shows the identity 
of the forward and reverse primers designed to amplify each of the SIP and LPA 
receptor genes from Chinese hamster.
Forward
oligonucleotide
Reverse
oligonucleotide
Expected 
fragment (bp)
SlPi 117GB 1171B 44G
S1P2 1176B 1177B 56G
S1P3 1172B 1173B 61G
S1P4 53B 54B 485
S1 P5 1182B 58B 625
LPAi 45B 46B 61G
LPA2 49B 1174B 59G
LPA3 1178B 118GB 72G
Table 3.1
Oligonucleotides used to clone fragments of SIP and LPA receptor genes 
from Chinese hamster genomic DNA.
Oligonucleotides were tested using genomic DNA prepared from CHO-Kl cells 
as template in PCR reactions (Figure 3.10); products of the expected sizes were 
obtained for each primer pair. PCR products were cloned into the TOPO TA 
Cloning Kit for Sequencing vector and transformed into TOPIC chemically 
competent E. Coli. Plasmid DNA was purified from cultures grown from single 
colonies and digested with EcoRl to confirm the presence of an insert. Vector- 
specific primers were used to sequence the entire insert of four clones of each 
receptor construct and the consensus sequence obtained for each Chinese 
hamster gene fragment aligned with known human and rodent sequences for that 
gene, at both the nucleotide and protein levels. Alignments of translated partial
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Chinese hamster gene fragment sequences with translated coding sequences of 
human, mouse and, where available, rat genes are shown in Figure 3.11 (A-H).
Figure 3.10
PCR amplification of partial SIP and LPA receptor sequences from Chinese 
hamster genomic DNA.
Oligonucleotides to amplify a fragment of each Chinese hamster SIP and LPA 
receptor were designed using sequences of human, mouse and, where available, 
rat SIP and LPA receptors. Genomic DNA was prepared from CHO-Kl cells 
and used as template in PCR reactions with these oligonucleotides pairs and the 
PCR products analysed using gel electrophoresis. This Figure is representative 
of three independent experiments.
Lane 1 
Lane 2 
Lane 3 
Lane 4 
Lane 5 
Lane 6  
Lane 7 
Lane 8  
Lane 9
SlPi
S I P 2
S IP 3
S I P 4
S I P 5
LPAi
L P A 2
L PA 3
L P A 3 (no DNA)
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S1P1(rat)(175) L GGL PIH G W H C I S S  L S S  CS T V L P L Y H ItH Y IL F C T T V F T  LLL L S I  V I L Y C  R I Y S  LVRT R 
 Se et on 5
(233)____________ 240_____________ *^-*0   390
SI PI (m ouse)(232)  S RRL TF R K N IS K A S  R S S  EKS LAL L K T V I I V L S V F  lACW APL F I L  L LLDV G C K A K T C D I  
SI PI (hamster) (57) S R R L T F P K H I S K A S R S S E K S L A L L K T V I I V L S V F I A C H A P L F I L L L L D V G C K A K T C S I  
S1P1 (human)(232) S R P .L T F R K H I S K A S R S S E K S L A L L K T V I I V L S V F I A C H A P L F I L L L L D V G C K V K T C D I  
S1P1(rat)(233) S RRL TF R K H I S K A S  R S S  EKS LAL L K T V I I V L S V F  lACW APL F I L  L L LD V G C K A K T C D I
---------------------------------------------------------------------------------------------------------------------------------------------------------------------- Se et on 6
( ^ 1 )  291 — 320________  330________________________ 348
S1P1(mouse)(29CÔ L Y K A E Y F L V L A V L H S G T H P I I Y T L T H K E H R R A F I R l S s C C K C P H G D S A G K F K R P I I P G
SI PI (hamster)(115) LYKAEYFL V L A V L H S G----------------------------------------------------------------------------------------------------------
S1P1 (human)(290) L ^ A E Y F L V L A V L H S G T H P I I Y T L T H K E M R R A F I R I H S C C K C P S G D S A G K F K R P I I A G  
S1P1(rat)(291) L Y K A E Y F L V L A V L H S G T H P I I Y T L T H K E H R R A F I R l | s C C K C P H G D S A G K F K R P I I P G
---------------------------------------------------------------------------------------------------------------------------------------------------------------------- Se et on 7
(348) ^ _____________ 360_____________ 370________________ 383
S I  PI (m ouse)(348)  MEFS R SK S D H S SHP QKDDGDHP E T I N S  S GHVHS S S
SI PI (hamster)( 1 3 1 ) -------------------------------------------- --------------------------------------------
S1P1 (human)(348) MEF S R SK S D H S SHP QKDDGDHP E T I N S  S GHVHS S S 
S1P1(rat)(349) HEF S R SK S D H S SHP QKDDGDHP E T I H S  S GHVHS S S
Figure 3.11
Alignment of human, mouse and rat SIP and LPA receptor protein 
sequences with translated partial hamster sequences obtained from PCR 
reactions using Chinese hamster genomic DNA.
Amplification of a portion of the coding sequence of each of the SIP and LPA 
receptors present in the genome of the Chinese hamster was achieved via PCR 
using oligonucleotide pairs which had been designed using alignments of human, 
mouse and, where available, rat SIP and LPA reeeptor sequences. The products 
of these PCR reaetions were eloned and sequenced. The translated sequence was 
aligned with protein sequences of human and rodent S1P and LPA reeeptors and 
the alignment annotated to show the location of each transmembrane (TM) 
domain.
A SlPi(Edgl)
- 113 -
C hapter ?
B
---------------------------------------------------------------------------------------------------------------------------------------------------------------------- Se et  on 1
(1) 1 10 20 30
SI  P2 (mouse)  (1) HGGL YS EYLNP EKVL EHYNYTKE TLDHQ ET T S R K V À S A F I I I L C  C À I W E N L  L VL l A V
SI P2 (hamster) ( 1 ) --------------------------------------------------------------------------------------------------------------------------------------------------
S1P2 (human) (1) HG£ LYS EYLNPIIKVQ EHYNYTKE T L | t Q ET T S R Q V A S A F l i l L C C  A I  W E N L  L V L I A V  
S1P2(rat)  (1) HGGLYS EYLNP EKVQ EHYNYTKE TLDHQET P S R KV AS A F I I I L C C  A I  W E N L  L V L I A V
---------------------------------------------------------------------------------------------------------------------------------------------------------------------- Se et  on 2
S 1 P2 (m ous e) (59) A RN SK F H S  AHY L FL GN L A A S D L L  AG VA F VAN TLLSGHt-’ T L S L T P
SI P2 (hamster) ( 1 ) ------------------------ Y L F L G N L A A S D L L A G V A F V A H T L F S G P V T L S L T P
S 1 P 2 (human) (59) A R N S K F H S A H T L F L G N L A A S D L L A G V A F V A N T L L S G S V T L R L T P  
S1P2(rat)  (59) A R N S K F H S A H ' f L F L G H L A A S D L L A G V A F V A N T L L S G P V T L S L T P I
Q N F A R E G S A F I T L
Q W F AR E G S A F I T L
Q N F A R E G S A S I T L
QWF AR E G S A F I T L
----------------- Se et on 3
S 1 P 2 (m o u se ) (1 1 7 )  S A S V F S  LL A I A I E R Q  V A i A K V K L Y G S D K S C R H L H L I  G A S W L I S L I  LGGL P I L  GWHCLN 
S1P2 (harreter) (49) S AS V F S L L  A I A I  ERQ V A I A K V K L Y G S D K S C R H L H L I  GASWl S s L I  LGGL P I L  GOTICLD 
S1P 2(hum an)(117) S A S V F S L L A I A I E R H V A I A K V K L Y G S D K S C R H L # L I G A S W L I S L ^ L G G L P I L G W N C L G  
S1P2(rat)(117) S A S V F S L L A I A I E R Q V A I A K V K L Y G S D K S C R H L H L I G A S W L I S L I L G G L P I L G W N C L D
--------------------------------------------------------------------------------------------------------------------------------------------------------------------- Se et on 4
( 1 »* 5)  ^  3 " 3  ^^  ^^0 232
S I P 2 (m o u se ) (175) Q L E A C S T V L P L Y A K H Y V L C V V T I F S V I L L A I V A L Y V R I Y F V V R S S H A D V A G P Q T L A L L  
SI P2(harreter)(107) H L E A C S T V L P L Y D K I yV L C V V T I F S V I  L L A I V A L Y V R I Y F V V R S S H A D | a GPQTLALL  
S 1 P 2 (human)(175) H L E A C S T V L P L Y A I t H Y V L C V V T I F S g l L L A I V A L Y V R I Y C V V R S S H A D g A g P Q T L A L L  
S 1P2 (r af) ( 175) H L E A C S T V L P L Y AKH YV L C V V T I F  S V I L  L A I  VA L YV R I  Y F VV RS S HADVAGP QTLALL  
--------------------------------------------------------------------------------------------------------------------------------------------------------------------- Se et on 5
S 1 P 2 (m o u se ) (233) K T V T I V L G V F I I C W L P A F S I L L L D S T C P V R A C P V L Y K A H Y F F A F A T L H S L L N P V I Y T W
SI P2 (harreter)(165) K T V T I V L ---------------------------------------------------------------------------------------------------------------------------------
S1P2 (human)(233) K T V T I V L G V F l ë c W L P A F S I L L L D Y A C P V H i c P Ï L Y K A H Y F F A V i l L N S L L N P V I Y T W  
S1P2(rat)(233) K T V T I V L G V F I I C W L P A F S I L L L D S T C P V R A C P V L Y K A H Y F F A F A T L N S L L N P V I Y T W
--------------------------------------------------------------------------------------------------------------------------------------------------------------------- S e c t  on 6
(291) ’^ 1 ___________ 300_____________310_____________3 ^ _____________ 3 30________________________ 3 ^
S I P 2 (m o u se ) (291)  R S R D L R R E V L R P L Q C W R R G K G V T G R R - G G H P G H R L L P L R S S S S L E R G H H H P T S P T F L E
SI P2 (hams ter) ( 1 7 2 ) ---------------------------------------------------------------------------------------------------------------------------------------------------
S1P2(hum an)(291) R SR D L R R E V L R P L Q C W R P G V G V Q G R R R V G T P G H H L L P L R S S S S L E R G H H H P T S P T F L E  
S1P2(rat)(291) R SR D L R R E V L R P L LC W R Q G K G A T G R R - G G N P G H R L L P L R S S S S L E R G j L H H P T S P T F L E
--------------------------------------------------------------------------------------------------------------------------------------------------------------------- Se  et on 7
(349) 349 353  
S I P 2 (m o u se ) (348) GNTVV  
S1P2 (hameter)(172) — —— ——
S1P2(human)(:349) GNTVV  
S1P2(rat)(34S) GNTVV
Figure 3.11 (continued)
Alignment of human, mouse and rat SIP and LPA receptor protein 
sequences with translated partial hamster sequences obtained from PCR 
reactions using Chinese hamster genomic DNA.
Amplification of a portion of the coding sequence of eaeh of the SIP and LPA 
receptors present in the genome of the Chinese hamster was achieved via PCR 
using oligonucleotide pairs which had been designed using alignments of human, 
mouse and, where available, rat SIP and LPA receptor sequenees. The products 
of these PCR reactions were eloned and sequenced. The translated sequence was 
aligned with protein sequenees of human and rodent SIP and LPA receptors and 
the alignment annotated to show the location of each transmembrane (TM) 
domain.
B SIP2 (Edg5)
1 1 4 -
Chapter 3
C
----------------------------------------------------------------------------------------------------------------------------------------------   SedionJ
s 1F3 (m ous e) (1) HATTH.kQGHQPVLGu!lÉTLREHYDYVGKLAGRLiÉ!pPEGGllLiTTiLFLVTCSFIVLBN
S1P3 (harretef) ( 1 ) ----------------------------------------------------------------------------------------------------------------------------------------
S1P3(human) (1) M A T A L P P R L Q P V R G # T L R E H Y Q Y V G K L A G R L # A S E G -# T g T T # L F L V IC S F I V L E N
S1P3(rat) ( 1 ) -----------------------------------------------------------------------------------------------------------------------------------------
 Se'ZÜon 2
S1P3 (mouse) (59) LHVL lAIWKNNKFHNRHYF FIGNLALCD LL AGI AYKVWILHS GRKTF SL S PTVTJF LRE
SI P3 (ha meter) ( 1 ) ------------------ KNNK FHN PII YF FIGNLALCDLl | gIAYKVWILHSGRKTFSLSPT VTJF L R E
S 1P3 (h uma n) (58) LMVLIAIWKNNK FHN PHYF FIGNLALCD LL AGI AYKVNILMS g| k  TFSLSPTVWFLRE
S1P3(rat) ( 1 ) ------------------------------------PMYFFIGNLALCDLLAGIAYKVNILHSGRKTFSLSPTVWFLRE
----------------------------------------------------------------------------------------------------------------------------------------------------------- Se et on 3
(11 7) 1 43 150
S1P3(mouse)(117) GSHFVALGASTCSLLAIAIERHLTMIKHRPYDANïtKHRVFLLIGHCWLIAFSLGALPI  
S1P3 (hamster) (51) G SH F VA L G A S T C S L L A I A I E PH L TM IKM RP YD ANI-3ÎHP V F L LIGM CW L IA  F S L GA L P I  
S1P3(hum,an)(116) GSMFVALGASTCSLLAIAIERHLTMIKMRPYDANK#HRVFLLIGMCWLIAF|#LGALPI  
S1P3(rat) ( 4 4  GSM FV ALGASTCSLLAIAIEPHLTHIKMRPYDANKKHPVFLLIGHCULIAFSLGALPI
----------------------------------------------------------------------------------------------------------------------------------------------------------- Sect on 4
r 1751 175 180 193 200 TM V 210 220 232
S1P3 (mouse)(175) LGWNCLENF PD C S T I LP L Y SK K YIAFL I S I  F T A IL V T I V IL  YARIYC LVKSSS RRVAN 
S1P3(hamster)(109) L G W N C L E N F P D C ST IL P L Y S K K Y IA F L IS IF T A IL V T IV IL Y A R IY F L V K S S S R R V A N  
S1P3 (human)(174 LGWNCLHNL PD C S I  IL P  LYSKKYIAFCI S I  F T A IL V T I V IL  YARI YF LVKSSS p | v A N  
S1P3(rat)(102l L G W N C L E H F P D C S T IL P L Y S K K Y IA F L IS IF T A IL V T IV IL Y A P IY F L V K SS S R R V A N
----------------------------------------------------------------------------------------------------------------------------------------------------------- Se et on 5
(233) iï.W6en*iïïfr^«s^Wiw3§ÛUwiwiiB^  ^ 270 280
S1P3 (mouse) (233) H N- S E R SH A L L P TVVIVVS V F IA C W SP L F IL F L  ID  V AC P - ^  E c i l l  L F KS QWFIML AV L 
S1P3(hamster)(167) H N -S  ERSHALL P TVVIVVS VFIACWSP L F I L FL IDVAC p f e E C P  ILFKSQWFIMLAVL  
S1P3(human)(^2) HNNS ERSHALL RTVVIVVSVFIACWSP L F I  L FL IDVAC PRQ AGP I  LFfJ I q WF i S l AVL 
S1P3(rat)(160) H N -SE R SH A L L R T V V IV V SV FIA C W SP L FIL F L ID V A C R A K E C iiL F K SQ W F IH L A V L
----------------------------------------------------------------------------------------------------------------------------------------------------------- Se et on 6
(291) 2 9 - L - T ^ I . E m ¥ ^ = _________310____________ ^ _________  330_______________________3 ^
S1P3(mouse)(290) NSAHNPVIYTLASKEMRPAF FRLVC GCLV gG Ë G TQ A SPgO PA LD P SR SK SSSSN N SSH
SI P3(hamster)(224) N S A ----------------------------------------------------------------------------------------------------------------------------------
S1P3(hum,an)(290) NSAHNPVI YTL ASKEMRPAF FRLVCNCLv S gI gA P A S P I qP A L D P S R S K S S S S N N S S H
S1P3(rat)(217) NSAHNP---------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------------------------------------------------- Se et on 7
(349) 349_____________ 360________________________ 379
SI P3(mouse)(348) s  PKVKEDL P PVATS S C I Ï D K N pJ f q Ng S l CK
S1P3(hamster)(227)--------------------------------------------------- --------------------
S 1P3 (h uma n) (348) g PKVKED L P H T D P S S C I # )  K N A |  L Q N G |f CN 
S1P3 (rat) ( 2 2 3 ) -------------------------------------------------------------------------
Figure 3.11 (continued)
Alignment of human, mouse and rat SIP and LPA receptor protein 
sequences with translated partial hamster sequences obtained from PCR 
reactions using Chinese hamster genomic DNA.
Amplification of a portion of the coding sequence of eaeh of the SIP and LPA 
receptors present in the genome of the Chinese hamster was achieved via PCR 
using oligonucleotide pairs which had been designed using alignments of human, 
mouse and, where available, rat SIP and LPA reeeptor sequences. The products 
of these PCR reaetions were cloned and sequenced. The translated sequence was 
aligned with protein sequences of human and rodent SIP and LPA reeeptors and 
the alignment annotated to show the loeation of eaeh transmembrane (TM) 
domain.
C SIP3 (Edg3)
- 115
C hapter  3
...........................................................................................................................      Section 1
i  iO 20 30  4Li
D
S1P 4  (m ouse)  (1) H U i S  TW S T L VT P E S C HP L A A S GH S L L I V  LH YKH S GPLAS PG GSED GGGL GML PGP SVA
S 1 P 4 (harreter) (1) -     -------------------------------------------------------------------------------------------------------------------------------------------
S1P4(human) (1) -  - # N A T G T P V A P E S C Q Q L A A G G H S R L IV L H Y N H S G R L A G P G G P E -D G G L G A L R G L S V A  
---------------------------------------------------------------------------------------------------------------------------------------------------------------------- Section 2
S1P 4  (m ouse)  (59,  A G C L W L E  N a É V  L A A I A  l i w  RS R RWVYY C L I n I T L S D L L T G L  A Y i  VN VL L S G T R T F Q L
8 1 P4 (harreter) ( 1 ) ---------------------------------------------------------------------------------------------------------------------------------------------------
S1P4(human) (56) A S C L W L E H L B v L A A I T S g H R S R R W V Y Y C L ^ H I T L S D L L T G A A Y g A N V L L S G A R T F R L  
---------------------------------------------------------------------------------------------------------------------------------------------------------------------- Section 3
(117) 117___________ — _ _ 1 3 Q— — __________150_____________.160 -2 4
S1F'4 (mouse)(117) |  PVHWF LREGLL FMA L A AS T F S L L F T A G E A F AT H VR -  V A E S GAT K T S  RVY GCIGLCWL
8 1 P 4  (harreter) ( 1 ) ------------------------------------------------------------------------------------------------------------------------- V Y G C IG L  CWL
S 1 P 4 (h u m a n ) ( 1 1 4  |P A Q W F L R E G L L F T A L A A S T F S L L F T A G E R F A T H V P P V A E S G A T K T S R V Y G F I G L C W L  
------------------------------------------------------------------- ;--------------------------------------------------------------------------------------   Section 4
8 1 P 4 ( m o u s e ) ( 1 7 4  L A A lL G L L  P L L G t a N C V C A F P R C S S L L P L Y S K G Y V L F C V V V F A L I L V A I L S L Y G A I  FRV  
8 1 P4(harreter) (11) LAAT LGLL PLL GWNCVC AF P R C S S L L P  L Y SK G Y V L F C V V V F A L I  L V A I L G L Y G A I F R V  
8 1P4(hum an)(172) L AAlL GfiiL  PLL G W W cic  AFD PC S S L  L P L Y S K R Y | l F C 0 v 1 f  A gI l AT i I g L Y G A I FRK
 Section 5
(233) 240 25G 2S0 29 m)
S1P 4 (m o u se ) (2 3 2 )  VR.&.NGQKSPPPPAR RK’fi PR L LN T VL H I  L VA F C WG P L F GL L L AD I F GS HËtiTAQ E Y L P  
8 1 P 4 (harreter) (69) V R*kN GQ KS P PA P AR PKA PR L LN T VL H I  L VA F W  C WG P L F GL L L AD I F GS n |  W A Q E YL P 
8 1P4 (huma n)(230) V QA 3 GQ F ^ P  RPAARRFIARPL LK T VL H I  L # A  F | v  CWGPLF GL L LADËF GS HgWA QEYLR
 Section 6
( 291) 29 1 3 0 0  T M V n  310 320_____________3 3 0  _348
8 1 P4 (m ouse)  (290) GHD U I L  A L A V F N  SA I  N p I i  Y S F R  SR EV Q PA V l I f  L C CG C LW L GLIr GP G D C L T R I T  EAH
8 1 P4(harreter) (  127) G H D W I L A L A V L N S A I H P -------------------------------------------------------------------------------------------------------
8 1P4(hum an)(288) G H D W I L A L A V L N S A M H P E lY S F R S R E V C R A V L ^ F L C C G C L R L G jK R G P G D C L A R A V E A H
 Section 7
( 34@r, 3 ^ ______________ 360_____________370_______________________ 387
8 1 P 4 ( m o u s e ) (348) S G A S T T D S S L R P P D S F R T S R S L S F R H R E P L S S I S S V R S T
8 1 P 4 (ha rreter) ( 1 4 4 --------------------------------------------------------------------------------------------------
8 1P4(hum an)(346) S G A S T T D S S L R P R D S F R G S R S L S F R H R E P L S S I S S V R S I
Figure 3. 11 (continued)
Alignment of human, mouse and rat SIP and LPA receptor protein 
sequences with translated partial hamster sequences obtained from PCR 
reactions using Chinese hamster genomic DNA.
Amplification of a portion of the coding sequence of eaeh of the SIP and LPA 
receptors present in the genome of the Chinese hamster was achieved via PCR 
using oligonucleotide pairs which had been designed using alignments of human, 
mouse and, where available, rat SIP and LPA receptor sequences. The products 
of these PCR reactions were cloned and sequenced. The translated sequence was 
aligned with protein sequences of human and rodent SIP and LPA receptors and 
the alignment annotated to show the location of each transmembrane (TM) 
domain.
D SIP4 (Edg6 )
- 1 1 6 -
C hapter 3
E
---------------------------------------------------------------------------------------------------------------------------------------------------------------------- Section 1
(i) 1 10 2D 30
S I P 5 (m ouse)  (1) H E P G L L R P A P V S E V I V L H Y N Y T G K L R G A R Y Q P G A G L R A D A A V C L A V C A F IV L E N L A V L
SI P5 (hamster) ( 1 ) ---------------------------------------------------------------------------------------------------------------------------------------------------
S 1 P 5 (human) (1) H E S G L L R P A P V S E V I V L H Y N Y T G K L R G A R Y Q P G A G L R A D A V V C L A V C A F I V L E N L A V L  
S 1P5 (rat) (1) M E S G L L R P A P V S E V I  VL HYN YT GKL RG A RY Q P G A CL RAD A A V C L A V C A F I V L E N L A V L  
---------------------------------------------------------------------------------------------------------------------------------------------------------------------- Section 2
S I P 5 (m ouse)  (SSTt L V L V P J IP R F H A P H F L L L G S L T L S D L L A G A A Y A T N I L L S G P L T L R L S P A L W F A R E G G V F
SI P5 (harreter) ( 1 ) ------------------------------------------------------------------------------------------------------------------------------------------------- F
S 1 P 5 (human) (59) L V L G R H P R F H A P H F L L L G S L T L S D L L A G A A Y A -- .N IL L S G P L T L g L S P A L W F A R E G G V F  
S1P5(rat) (59) L V L G R H P R F H A P M F L L L G S L T L S D L L A G A A Y A T N I L L S G P L T L R L S P A L W F A R E G G V F
---------------------------------------------------------------------------------------------------------------------------------------------------------------------- S ections
S 1P5 (m OUS e) ( 117) V AL A AS VL S  L L A I A  L B RHL T HA R RG P A P AA S PA R T L AH A VA A WG A S L L L G L L P AL GWN 
SI P5 (hamster) (2) VAL A AS VL S  L L A I A  L E R HL T HA R RG PA P AA S PA R T L AH AVAAWG A S L L L G L L P A L  G¥H  
S1P5 (human)(117)  VAL T ASVL S LL A I A L  ERSL THARRGPAP v t i s  p I r TL AMAAAAWGVSL LL GLL PAL GWH 
S 1P5 (rat) (117) VAL A AS V L S L L A I A L E  RHL T HA R RG PA P A A S PA RT L AH A VAAWG L SL LL G LLPA LG W H  
---------------------------------------------------------------------------------------------------------------------------------------------------------------------- Section 4
(175) 4 7 5  ISO 190 220 232
SI P5 (m ouse)  (175) C L G R L E | c  S T V L P L YAKAYV L F C V L A F L G I L A A I C A L Y A R I Y C Q  V RANA RRLRAGPGS  
SI P5 (harreter) (60) C L G R L e | c S  T V L P L YAKAYV L F C VL AF L G I L  AA I C A  LY A RI Y C Q V PAHA R RL Rà B p  G S 
S1P5 (human)(175) C LGRli^î iC  S TVL PL YAKAYVLF C V L A F ^ G I  L A A I C A L Y A R I Y C Q V P A N A R R L  P a | p g |  
S1P5(rat)(175) C L G R L E A C S T V L P L Y A K A Y V L F C V L A F L G IL A A IC A L Y A R I Y C Q V P À N A R R L R A G P G S
---------------------------------------------------------------------------------------------------------------------------------------------------------------------- Se et on 5
(233)  233  243_____________2 5 0     g G Û J Ü Ü I _______ 220_______  2 8 0 _290
S I P 5 (m o u se ) (233)  R R A T S S S R S P H T P R S L A L L R T L S W L L A F V A C W G P L F L L L L L D V A C P A R A C P V L L Q A D  
S1P5(harreter)(118) R R A T S S S R S P H T P R S L A L L R T L S W L L A F V A C W G P L F L L L L L D V A C P A R A C P V L L Q A D  
S1P 5(hum an)(233) A G - t S s | p.^ R P K P R S L A L L R T L S W L L A F V A C W G P L F L L L L L P V A C P A R T C P V L L Q A D  
S1P5(rat)(233) R R A T S S S R S P H T P R S L A L L R T L S W L L A F V A C W G P L F L L L L L D V A C P A R A C P V L L Q A D
---------------------------------------------------------------------------------------------------------------------------------------------------------------------- S e c t  on 6
(29 1) 32Ü_____________3 3 0  348
S 1 P 5 (m o u se ) (291) P F L G L A H A H S L L N P I I Y T F T N R D L R H A L L R L L C C G R G P C N Q D S S N S L Q R S P S A A G P S G
SI P5 (ha mster)( 176) P F L G LAHAHSL L N P I I Y T F ---------------------------------------------------------------------------------   - -
S 1 P 5 (human)(290) P FL G L AH ANSL  L N P I  lY T L T N R D  L R H A L L R L ic C  GRHSC GPD PS GSQ Q - -  i ' I ^ A l E l i S  
S 1 P 5 (r a t ) ( ^ 1 )  P F L G L A H A H S L L N P I I Y T F T N R D L R H A L L R L L C C G R G P C N Q D S S H S L Q R S P S A V G P S G
---------------------------------------------------------------------------------------------------------------------------------------------------------------------- Se et on 7
(349) _______________æ O _____________370_____________380_____________ g O ____________ 401
S 1P 5 (m o u se ) (3 4 9 )  G G L R R C L P P T L D R S S S P S E H L S P Q Q D G V D T S C S T G S P G V A T A H R S L V P T A T D -
S1P5 (h a m s t e r ) ( 1 9 Q --------------------------------------------------------------------------------------------------------------------------------------
S1P5(hum an)(346) G G L R R C L P P G L D G S F S G S E R S S P Q R D G £ D T S G S T G S P G A P T A A R T L V S |P J iJ ! .D  
S1P5(rat)(3% ) G G L R R C L P P T L D R S S S P S E H S C P Q R D G H D T S C S T G S P G A A T A N R T L V P E A T D -
Figure 3. 11 (continued)
Alignment of human, mouse and rat SIP and LPA receptor protein 
sequences with translated partial hamster sequences obtained from PCR 
reactions using Chinese hamster genomic DNA.
Amplification of a portion of the coding sequence of each of the SIP and LPA 
receptors present in the genome of the Chinese hamster was achieved via PCR 
using oligonucleotide pairs which had been designed using alignments of human, 
mouse and, where available, rat SIP and LPA receptor sequences. The products 
of these PCR reactions were cloned and sequenced. The translated sequence was 
aligned with protein sequences of human and rodent SIP and LPA receptors and 
the alignment annotated to show the location of each transmembrane (TM) 
domain.
E SIP5 (EdgS)
- 1 1 7
C hapter 3
—— — — ——  Se et on 1
(1) 1______________ 10______________ g ______________ 30 ______________^
LPAI (m ouse)  (1) M AAA S T S S P V I S  Q P Q F T AHN e | q C F YM E S I A  F F YNR SGKYL À TE WNT VS K L VH GL GI T
LPAI (hamster) ( 1 ) ------------------------------------------------N EP Q CF YWE S I  AFF Y H R SG K Y L ATEWNTVSKLVMGL GI T
LPAI (human) (1) H A A I S T S I P V I S Q P Q F T A H N E P Q C F Y N E S I A F F Y N R S G K i L A T E W N T V S K L V H G L G I T  
LPAI (rat) (1) M AA A S T S S P V I S Q P Q F T A H H eI q C F Y W E SIA F F Y H R S G K Y LA T K M H T V SK  L VH GL G IT
LP Al (m OUS e) (59) V C V F I H  L AN L L VHV A I Y  VN R RF H F P I Y  Y LH ANL A AAD F F AG L AY F YL HF N T G P NT RR L 
LPAI (harreter) (43) V C V F IH L A N L L V M V A I Y V N R R F H F P I Y Y L H A N L A A A D F F A G L A Y F Y L H F N T G P N T  RRL 
LPAI (huma n) (59) V C 0 F  I H  LAN L L VHVA l Y  VN R RF H F P l Y  Y LHANL A AAD F F AG L AY F YL HF N TG P NT RR L 
LPAI (rat) (59) V C V F I H L A N L L V H V A I Y V N R R F H F P  lY Y L H A N L A A A D F F A G L A Y F Y L H F N T G P N T  RRL
 Se et on 3
(117) 117 150
LPAI (m ous e) ( 117) T VN T ¥ L  L R Q GL I D  T S L T AS VAN L L A I A I E  R H I T  V F RHQ L HT RHS N RR W  V V I V  V I  NT H 
LP A l  (ha rreter ) (98) T VS T TJL L R Q GL I D  T S L T AS V AH L L A I A I E  R H I T  V F RHQ L HT RHS N RR W  V V IV V I W T H  
LP A l  (h uma r.) ( 117) T VS T WL L R Q GL I D  T S L T AS V AH L L A I A I E  R H I T  V F RHQ L HT RHS N R R W V V I V V I W T H  
LF-Al (rat) ( 117) T VS T WL L R Q GL I D  T S L T AS V AN L L A I A I E  RH I T  V F RHQ L HT RHS N R R W V V I  VVIW TH
-------------------------------------------------------------------;----------------------------------------------------------------------- -— ; Se et on 4
( iy  5) 90 200 232
LPAI (m ouse)  (175) A I  VH Ga | p  |  VG WNC I  CD I D H C S N H A P L Y S D S Y L V F W A I F N L V T F  V VH W  L Y A H IF  GYV
LF'AI (harreter)( 156) A I V H G A I P S V G W N C I C D I D H C S N H A P L Y S D S Y -----------------------------------------------------------------
LF-A1 (h uman)(175) A I V H G A I P S  VGWNCI CD l i l l  C S  NHA P L Y SD S YL V FW A I  F NL V T F V VH W  L Y A H I F  GYV 
LPA 1 (rat) ( 17 5) A I  VH G A IP  S VG WNCI CD I D  H C S NHA P L Y SD S YL V FW A I  F NL V T F V V H W  L Y A H I F  GYV
 Se et  on 5
(233) 233________Z43_____________2 5 0 __________________________________________________  29 U
LPAI (m o u se ) (233) R Q R T H R H S R H S S G P R R N R D T H H S L L K T V V IV L G A F IV C W T P G L V L L L L D V C C P Q C D V L
LF'AI (h a rr e te r ) f l8 8 ) ---------------------------------------------------------------------------------------------------------------------------------------------------
LPAI (human)(233) R Q R T H R H S R H S S G P R R N R D T H H S L L K T V V IV L G A F iS c W T P G L V L L L L D V C C P Q C D V L  
LPAI (rat)(233) R Q R T H R H S R H S S G P R R N R D T M H S L L K T V V IV L G A F IV C W T P G L V L L L L D V C C P Q C D V L
---------------------------------------------------------------------- —   Se et on 6
(2^ 1) 29 1 320 3 3 0  348
LPAI (m o u se ) (291) A Y E K F F L L L A E F N S A H N P I I Y S Y R D K E H S A T F R Q I L C C Q P J J E N P N G P T E G S D R S A S S L
LPAI (h arreter) (188)---------------------------------------------------------------------------------------------------------------------------------------------------
LPAI (human)(291) A Y E K F F L L L A E F N S A H N P I I Y S Y R D K E H S A T F R Q I L C C Q R S E N P T G P T E G S D R S A S S L  
LPAI (rat)(291) A Y E K F F L L L A E F N S A H N P I I Y S Y R D K E H S A T F R Q I L C C Q R N E N P N G P T E G S D R S A S S L
 Se et on 7
(349) 3 ^ ___________________ 36 4
LPAI (m o u se ) (349) N H T I L A G V H S N D H S V V
LF'AI (h a m ster ) (1 8 8 ) ----------------------------------------
LPAI (human)(349) NHT I  L AG VH SNDH SVV  
LPAI (rat)(349) NHT I  L AG VH SNDH SVV
Figure 3.11 (continued)
Alignment of human, mouse and rat SIP and LPA receptor protein 
sequences with translated partial hamster sequences obtained from PCR 
reactions using Chinese hamster genomic DNA.
Amplification of a portion of the coding sequence of each of the SIP and LPA 
receptors present in the genome of the Chinese hamster was achieved via PCR 
using oligonucleotide pairs which had been designed using alignments of human, 
mouse and, where available, rat SIP and LPA receptor sequences. The products 
of these PCR reactions were cloned and sequenced. The translated sequence was 
aligned with protein sequences of human and rodent SIP and LPA receptors and 
the alignment annotated to show the location of each transmembrane (TM) 
domain.
F LPA, (Edg2)
- 1 1 8 -
C hapter 3
----------------------------------------------------------------------------------------------------------------------------------------------------------------------Se et on 1
( p  1 10 20 30
LPA2 (m ouse)  ( 1 )  H GQ C Y YNE T I G  F F YHW S GK E L S LHW RP KD VV W  AL G L T V  S V L VL L T H L L V l À  A I A
LFA2 (harreter) ( 1 )   I G F F Y N N S G K E L S  LHW RPKDVVW AL G L T V S V L  VL L T H L L V I A A I A
LPA2 (h uma n) (1) H V I H  GQ C Y YNE T I G F  F Y N N S G K E L S S H W R P K D V V W A L G L T V S V L V L  L T H L L V I A A I  A
----------------------------------------------------------------------------------------------------------------------------------------------------------------------Se et on 2
i'59) 50 70 T M I I  80 90 100 116
LPA2(m ouse)  (56) S N R R F H Q P I Y Y L L G N L A A A D L F A G H A Y L F L H F H T G P R T A R L S I K G W F L R Q G L L D T S L T  
LPA2 (ha mster) (47) S NR R FH Q P I Y Y  L L GN LA AAD L F A GH AY L F L M FH T GP RT A  RL S I K  G WF L R Q GL L D T S L T 
LPA2(human) (59) S N R R F H Q P I Y Y L L G N L A A A D L F A G liL Y L F L H F H T G P R T A R L S iE G W F L R Q G L L D T S L T
----------------------------------------------------------------------------------------------------------------------------------------------------------------------Se'Zton 3
r 1171 117 T M  n i  130 143 150 160 T M  IV 174
L P A 2 (m o u se ) ( 1 1 4  A SV A T LL A IA V E R H R S V H A V Q L H S R L P R G R V V T L IV G V W A A A L G L G L L P A H F W H C L C D  
LPA2 (ha mster) ( 105) A S V A T L L A I  AV E RH R S VHA V Q L H S R L P R GR V VT L I V  GVW VA A  L GLGLLPAHFWHCLCD  
LPA2 (h uma n)( 117) A SV A  T L L A I  AV E PH R SVMA V Q L H S R L P R GRVLTILIVGVWVAA L G L GL L P AHS WHC L C A 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------Se et on 4
(17Î)  1 ' IS'O 210 220  232
LPA2(m o u se ) (172) L D S C S R l îV P L F S R S Y L A À W A L S S L L V F L L M V A V Y T R IF F Y V R R R V E R M A E H V S C H P R Y
LP'A2 (ha rreter) (163) L D R C S RHV P L F S RS Y LAV-----------------------------------------------------------------------------------------------------
Lf A 2 (human)(175) LDRCSRH.“. P L L S R S Y L A V W A L S S L L V F L L H V A V Y T R IF F Y V R R R V Q R H A E H V S C H P R Y
----------------------------------------------------------------------------------------------------------------------------------------------------------------------Se  et  on 5
(233) 233 ^ *^ 3  ^70
LPA2(m o u se ) (230) R E T T L S L V K T V V I IL G A F V V C W T P G Q V V L L L D G L D C K S C H V L A V E K Y F L L L A E A N S L V
LP" A2 (ha ms ter) ( 1 8 1 ) ---------------------------------------------------------------------------------------------------------------------------------------------------
LPA2(human)(233) R E T T L S L V K T V V I IL G A F V V C W T P G Q V V L L L D G L G C E S C N V L A V E K Y F L L L A E A N S L V
----------------------------------------------------------------------------------------------------------------------------------------------------------------------Se et on 6
(281) .2 9 X l à L Y I L »  3 0 0 _____________310_____________ 3 æ _____________3 3 0 _________________________^
LP A2 (m ous e)  (208)  N AV V YS C RD AE H RR T F R RL L C C H C L RW SÉ H K  S A R YSA!s  AQT GAS T RIML P ENGRP LMD
LPA2 (hamster) ( 1 8 1 ) ---------------------------------------------------------------------------------------------------------------------------------------------------
LP.A2 (h uma n) (291)  N AA V Y S C RD AE H RR T F R RL L C C A C L RQ s i  R E S VH y | S s  A QGGAS T RIML P EHGHP LMD
----------------------------------------------------------------------------------------------------------------------------------------------------------------------- S ee ton  7
(349) G5361 
L P ^ (m o u se ) (346) ST L
LP A2 (ha ms ter) ( 1 8 1 ) ------
LP.A2(human)(349) ST L
Figure 3. 11 (continued)
Alignment of human, mouse and rat SIP and LPA receptor protein 
sequences with translated partial hamster sequences obtained from PCR 
reactions using Chinese hamster genomic DNA.
Amplification of a portion of the coding sequence of each of the SIP and LPA 
receptors present in the genome of the Chinese hamster was achieved via PCR 
using oligonucleotide pairs which had been designed using alignments of human, 
mouse and, where available, rat SIP and LPA receptor sequences. The products 
of these PCR reactions were cloned and sequenced. The translated sequence was 
aligned with protein sequences of human and rodent SIP and LPA receptors and 
the alignment annotated to show the location of each transmembrane (TM) 
domain.
G LPA2 (Edg4)
- 1 1 9 -
C hapter
H
 Se et on 1
(1) 1 10 aO 3 0  58
LP A3 (m  OUS e) (1) MNE C HYDK RHT ■ F F YW R S N T D T A D E W T G T K L V I V L C V G T F F C L F I F F S H S L V I À Â V I T N
LP A3 (hamster) ( 1 ) ------------------------ D F F Y H R S  h | d  T AD EW | g T KL V I V  L C V GT F F C L F I  F F S N S L V I A  AV I T  N
LFA3  (h uma n) (1) MNE CHYDKKMr.' F FYN RS NT D T V D i ^  T G T K L V I V L C V G T F F C L F I F F S N S L V I A A V I K N  
LP A3 (rat) (1) HNE C HYDK RHL' F F YN RS HT D T AD E W T G T KL V I V  L C V GT F F C L F I  F F S NS L V I A  AV I T  N
 Se et on 2
fSSn ^ JOUI  @0________@0— 100
LP A3 (m ouse)  (59) RKFH FP FYYLLAHL AAADF F A G I A Y V F  LH FH T G P VS K T L  TVHRWF LRQGL LD T SL TAS  
LP A3 (hamster) (49) R K FH FPF Y Y L L A H L  A AAD F F A G I A Y V F  LMFHTGPVSKT L TVHRW#LRQGL LD T S L  TAS  
LP A3 (human) (59) RKFH FP FYYLLAHLAAA.DF F A G I A Y V F  LMFHTGPVSKT L TVHRWF LRQGL Ld I s L TAS  
LP A3 (rat) (59) RKF H F P FYYLLAHL A AAD F F A G I  AY VF L HF H T G P VS KT L TVH RW i L R Q G L L D T S L T A S
 Seeton  3
(11 7) 130 1 40 ¥%¥¥'¥¥%¥¥¥**;%%% 1 / 4
LP A3 (m ous e) ( 117) L AN L L V I A  V E R H H SIH R H R  VHS H L T KK R VT L L I L  LVWAI A I  F HG A VP T L G WN C L C H I  S 
LPA3(hamster)(107) LANL L V I A V E R H i s  IHRHRVHSHLTKLLRVT L L I  LLVWAI A I  FHGAVP TLGWNC L C H I S  
LP A3 (h uma n) ( 117) L TH L L V I A  V E RHHS I  HRHR VHS H L T K K R V T L L IL  L V ¥ A  I  A I  F HG A VP T L GWH C L C H I  S 
LPA3(rat)(117) L A I I L L V I A V E R H H S I H R H R | h S H L T K K R V T L L I L L V W A I A I  FH G AVP T LG W H C L C H IS  
 S ee ton  4
(175) 175 180____________ ________ I I L W Q Q _________  210_____________220______________ ^
LP A3 (m ous e ) (  175) A C S S L A P I Y  S R S YL I  F ¥  TV S HL L A F F I H  VA V W  R I  YM*/VKRKTH V L S P H T S G S I S R R R  
LF-A3 (ha rreter) ( 165) A C S S L A P I Y  S R S YL I  FTiJ T V S HL L AF F I H  W  V YV RIYMY VKRK TH V L S PH T S G S I S  RR R 
LP.A3 (h uma n) ( 175j A C S S L A P I Y  S R S YL Ü FW TV S HL S  A F LIM  W  V y | r  I  Yfri'VKRK TH V L S PH T S G S I S  RR R 
LF-A3 (rat) ( 175) A C S S L A P I Y  S R S YL I  F ¥  T V S HL L AF F IM  W  V YV RIYMY VKRK TH V L S PH T S G S I S  RR R
 Seeton  5
(233) 233  ____________________________________________ 270
LP A3 (mous e) (233) A PHK LHKT VHT V L G A F V VC W T P G L V VL LLDGLHCKQCHVQHVKRWFLLLALLHSVHHP
LPA3(harreter)(223) A P ----------------------------------------------------------------------------------------------------------------------------------------------
LF’A3 (h uma n) (233) T PHK LHKT VHT V L GA FV VC W T P G L V VL L LD G LH c i o  C G V QHVKRW F L L L A L L H S v W p  
LP A3 (rat) (233) A PHK LHKT VHT V L GA F V VC ¥  T P G L V VL L LD G LH C KQ CH V QHVKRW FLLLALLHSVHHP
 Seeton  6
(291) - 30 0 _____________310_____________320_____________3 3 0 _________________________343
LPA3( m o u se ) (291) I I Y S Y K D E D H Y H T H R K H I C C A L Q D S H T E R R P S R H P S T I H S R S Ï T G S Q Y L E D S I S Q G P V
LPA3 (harreter)(225)---------------------------------------------------------------------------------------------------------------------------------------------------
LP .A 3(hum an)(a i)  I I Y S Y K D E D H Y G T H K K H I C C F S O l ï - H P E R R P S R I P S T ^ i L S R S D T G S Q Y l E D S I S Q G A V  
LP A3 (rat) (291) I I Y S Y K D E D H Y H T H R K H I C C A P H D S H A E R H P S R I P S T I H S R S D T G S Q Y L E D S I S Q G Q V  
 S ee ton  7
(349) 349 354
LPA3(m o u se ) (349) CHKMGS
LP A3 (ha rreter) ( 2 2 5 ) --------------
LP A3 (human) (346) C H K S J S  
LP.A3(rat)(349) C H K s I s
Figure 3. 11 (continued)
Alignment of human, mouse and rat SIP and LPA receptor protein 
sequences with translated partial hamster sequences obtained from PCR 
reactions using Chinese hamster genomic DNA.
Amplification of a portion of the coding sequence of each of the SIP and LPA 
receptors present in the genome of the Chinese hamster was achieved via PCR 
using oligonucleotide pairs which had been designed using alignments of human, 
mouse and, where available, rat SIP and LPA receptor sequenees. The products 
of these PCR reactions were cloned and sequenced. The translated sequence was 
aligned with protein sequences of human and rodent SIP and LPA receptors and 
the alignment annotated to show the location of each transmembrane (TM) 
domain.
H LPA] (Edg?)
- 120-
C hap ter  3
Both nucleotide and protein sequences of the partial Chinese hamster sequences 
were found to be very similar to those from human, rat and mouse. Percent 
identities were calculated for novel Chinese hamster sequences compared to 
human, mouse or rat orthologues using pairwise comparisons of sequences at the 
nucleotide (Table 3.2 (A)) and translated protein level (Table 3.2 (B)).
SlPi
S I P 2
S IP 3
S I P 4
S IP 5
L P A i
L P A 2
L P A ]
B
% identity
Human Mouse Rat
88.7 95.0 94.6
82.6 90.6 92.5
89.5 93.1 94.0
83.3 91.1
81.9 91.0 90.7
90.9 93.2 93.7
8 6 .1 92.0 *
87.3 90.1 90.3
% identity
Human Mouse Rat
94.6 97.7 97.7
90.6 94.2 97.1
95.2 98.9 99.4
81.8 95.8 *
88.7 99.5 98.5
97.9 97.9 99.5
95.0 98.3 *
93.3 97.8 98.2
SlPi
SIP2
SIP]
S1P4
S1P5
L P A i
L P A 2
L P A ]
Table 3. 2
Summary of similarities between cloned partial Chinese hamster SIP and 
LPA receptor sequences and those from mouse, rat and human.
Pairwise comparisons of the cloned Chinese hamster sequence of each SIP and 
LPA receptor gene fragment with the mouse, rat or human orthologues were 
performed and the percentage identity determined for the range of the partial 
Chinese hamster sequence.
* - sequence not available from National Centre for Biotechnology Information 
(NCBI) Entrez database.
A Summary of nucleotide sequence identities
B Summary of protein sequence identities
-121 -
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The cloned Chinese hamster gene fragments shared a high degree of identity 
with their mouse, rat and human orthologues, showing between 81.9 and 95.0 % 
identity at the nucleotide level and between 81.8 and 99.5 % at the protein level. 
In general, the level of identity was higher for the protein sequence than the 
nucleotide sequence for a given receptor gene, although this was not the case for 
the comparison between human and hamster S I P 4  (where the level of identity at 
the nucleotide level was slightly higher than at the protein level). It was 
observed that many differences in the nucleotide sequences of a given S I P  or 
LPA receptor gene from each of the species examined, occurred at the third 
position of a codon and hence were not observed as a difference in the protein 
sequence. Chinese hamster S I P  and LPA receptor gene fragments always shared 
greater sequence identity with mouse and rat orthologues than with human.
Each Chinese hamster gene consensus sequence was then used to facilitate 
design of non-redundant oligonucleotides for use in the RT-PCR experiment. 
The identity of these oligonucleotides is shown in Table 3.3.
Forward
oligonucleotide
Reverse
oligonucleotide
Expected 
fragment (bp)
SlPi 1364C 1365C 380
S1P2 1372C 1373C 510
S1P3 1368C 1369C 560
S1P4 1374C 1375C 425
S1P5 1378C 1379C 580
LPAi 1366C 1367C 560
LPA2 1370C 1371C 540
LPA] 1376C 1377C 670
Table 3.3
Oligonucleotides used for RT-PCR analysis of CHO-Kl mRNA to identify 
endogenously expressed SIP and LPA receptor genes.
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Total RNA was prepared from CHO-Kl cells and treated to remove 
contaminating genomic DNA (described in chapter 2, section 2.16). Reverse 
transcription using an oligo dT(ig) primer yielded first strand cDNA which was 
then used as template in PCR reactions with the oligonucleotide pairs shown in 
Table 3.3 to determine which SIP and LPA receptor mRNA’s were expressed in 
CHO-Kl cells (Figure 3.13 (A)). The ability of each oligonucleotide pair to 
amplify a product of the expected size was demonstrated using CHO-Kl 
genomic DNA (Figure 3.13 (B)) and the integrity of the first strand cDNA 
preparation was verified using control GAPDH oligonucleotides. The absence of 
DNA contamination in the RNA preparation was confirmed by the inability of 
the primer pairs to amplify products when the reverse transcription step was 
omitted (not shown) and the identity of each amplified SIP and LPA receptor 
fragment was confirmed by size and restriction digest of that product.
Fragments of the expected sizes were amplified using oligonucleotide pairs 
specific for the S I  Pi, S IP 2 ,  S I P 4  and LPAi receptors; the control GAPDH 
primers also amplified a product of the expected size. The intensity of the 
fragments amplified in this qualitative experiment varied; the S I P 2  fragment was 
the most intense, fragments of the S I  Pi and LPAi receptors, as well as GAPDH 
had lower intensity but were still clearly visible, whilst the S I P 4  fragment was 
very faint. Although this experiment was not quantitative, this result may 
suggest that the transcript for S I P 4  was less abundant than those of the SI Pi, 
S I P 2  and LPAi receptor genes.
- 1 2 3 -
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B
Figure 3.12
Expression of SIP and LPA receptor mRNA in CHO-Kl cells by RT-PCR.
RT-PCR was performed using total RNA that had been extracted from CHO-Kl 
cells, with pairs of oligonucleotides designed to amplify specific regions of 
hamster SIP and LPA receptor coding sequences (A). The ability of these 
primer pairs to amplify products of the expected size was confirmed using CHO- 
Kl genomic DNA as template in a parallel set of PCR reactions (B). 5 pL of a 
20 pL reaction was loaded in each lane. This Figure is representative of two 
independent experiments.
Lane 1 
Lane 2 
Lane 3 
Lane 4 
Lane 5 
Lane 6  
Lane 7 
Lane 8  
Lane 9
SlPi
SIP2
S I P 3
S I P 4
S I P 5
L P A i
L P A 2
L P A ]
GAPDH
- 124
C hap ter  3
3.3 Discussion
At the time this work was started, SIP4 had recently been cloned as the orphan 
receptor Edg6  [Graeler et al,  1998]. This novel sequence was discovered in an 
effort to clone new chemokine receptors and was assigned to the then named Edg 
receptor family on the basis of sequence homology with other Edg receptors. 
The study of an orphan receptor presents a number of challenges, one of the most 
obvious being the inability to use a functional method for screening antibiotic- 
resistant clones which result from a stable transfection of the orphan into a 
suitable cell line. Similarly, commercial antibodies to orphan receptors are 
frequently unavailable, so the use of such an antibody in a technique such as 
Western blotting is also prohibited. For these reasons, SIP4 expression plasmids 
were engineered to contain the HA epitope (YPYDVPDYA) immediately after 
the initiator methionine. This allowed detection of cell-surface receptor via 
FACS analysis, and of full length protein via Western blotting, using an anti-HA 
antibody. The addition of such a tag to the amino-terminus of a GPCR has been 
used previously and was shown to have no effect on the ability of ligand to bind 
the receptor [Roller et al,  1997]. In the case of the SIP4 receptor, the ligand was 
expected to be SIP or a related lysophospholipid, and as such would be most 
likely to bind to the transmembrane helices of the receptor so the inclusion of a 
nine amino acid epitope at the amino-terminus was not expected to interfere with 
ligand binding.
The use of fusion proteins constructed between a GPCR and a G protein is a 
popular approach and has a number of advantages over systems where non-fused 
receptors are studied (reviewed by Seifert et a l,  1999; Milligan, 2000; Wurch 
and Pauwels, 2001). The key benefit of constructing such fusions include a
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defined 1:1 stoichiometry between receptor and G protein, and a physical 
proximity between the proteins. Additionally, construction of a GPCR-Ga 
fusion may be achieved using a Got G protein which has been mutated such that 
it is rendered insensitive to ADP-ribosylation by pertussis toxin [Milligan, 1988; 
Bahia et al,  1998], therefore allowing isolation of the response from the fused 
receptor. This was of particular relevance when applied to a receptor such as 
S IP 4 ,  since it is one of a sub-family of receptors that are activated by S I P  and 
are almost ubiquitously expressed in mammalian cells. This has meant that 
functional responses by untransfected cells are commonplace and can interfere 
with interpretation of results generated using transfected cells. The lack of S I P  
receptor-selective agonists combined with widespread expression of the 
receptors in mammalian cells has complicated the characterisation of this GPCR 
family. Generation of the pertussis toxin-insensitive HA-SlP4-G0Cii(C^ ^^ I) fusion 
protein in this chapter enabled the use of pertussis toxin to eliminate interfering 
signals arising from the presence of endogenous S I P  receptors in the host CHO- 
Kl cells when measuring activation of Gai G proteins by S I P .  Indeed, a similar 
approach was adopted in an early study which examined activation of the related 
LPAi (Edg2) receptor in HEK-293 cells [McAllister et al,  2000].
The cloning strategy adopted to produce fusions between S I P 4  and Gocn resulted 
in the introduction of a five amino acid artificial linker sequence between the two 
elements of the fusion. The presence of this short linker is unlikely to impact on 
the ability of the receptor to signal via the tethered G protein and a published 
study showed that the presence of the large green fluorescent protein (GFP) in a
-126-
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fusion protein between the A1 adenosine receptor, GFP and Gan had little effect 
on ligand binding or effector regulation by this GPCR [Bevan et a l,  1999].
The final section of work undertaken in this chapter was to profile the expression 
of endogenous SIP and LPA receptors in CHO-Kl cells. Whilst it was known 
that most cell types respond to SIP and LPA, and presumably express at least 
one receptor from each of these families, there had been no concerted study to 
determine the repertoire of expression of these receptors in CHO-Kl cells. Some 
interesting observations had been made using Northern blotting techniques, 
however the probes used in these studies were not hamster-gene specific, and 
therefore interpretation of the results needs caution [Okamoto et a l,  1998; Sato 
et al,  1999].
The approach taken in this thesis was to perform RT-PCR using Chinese hamster 
mRNA with oligonucleotides specific to each of the eight Chinese hamster SIP 
and LPA gene coding sequences. Searches of the NCBI Entrez database 
revealed that no SIP or LPA gene sequences from Chinese hamster had been 
deposited. Therefore, semi-redundant oligonucleotides were designed using 
nucleotide and amino acid sequence alignments for each of the eight genes from 
human, mouse and rat. These were used to amplify a portion of each of the eight 
SIP and LPA genes from Chinese hamster genomic DNA. Sequencing of the 
resultant PCR products generated novel sequence data for these Chinese hamster 
genes and comparison of partial sequences with human, mouse and rat 
orthologues demonstrated high levels of identity at both nucleotide and protein 
levels. The amino acid residue present in TM III, which has been proposed to 
control SIP and LPA receptor ligand selectivity [Wang et al,  2001], was found
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to be present in all sequences analysed (Chinese hamster gene fragments for the 
S I P 4  and S IP 5  receptors did not cover this region, however it is probable that 
this residue is also conserved within these sequences). It is therefore unlikely 
that there would be significant species differences with regard to ligand 
selectivity among the orthologues for the S I P  and LPA receptors. Such 
differences are sometimes observed and can complicate drug discovery programs 
due to species-selectivity of ligands and small molecule therapeutics (e.g. 
chemokine receptors).
Each of the partial hamster receptor sequences analysed shared greatest identity 
with rodent orthologues and slightly lower identity with the equivalent human 
sequence. The relative order of identity of Chinese hamster sequences compared 
to mouse, rat and human orthologues was not consistent with respect to the order 
of identity with mouse or rat sequences for the eight SIP and LPA receptors, but 
the rank order for a given receptor was the same at nucleotide and protein levels.
Species-specific oligonucleotides were designed using sequences of the Chinese 
hamster gene fragments for use in the RT-PCR analysis of Chinese hamster total 
RNA to indicate which SIP and LPA receptor genes were endogenously 
expressed in this cell line. This study showed the presence of mRNA for SI Pi, 
SIP2, SIP4 and LPAi receptors in CHO-Kl cells, although the result suggested 
that the SIP4 transcript was not very abundant since it only yielded a faint 
product in the RT-PCR experiment. It would have been interesting to continue 
this study to profile which of these genes were expressed at the protein level, but 
it was not clear whether the available antibodies to human SIP and LPA 
receptors would cross-react with hamster protein and generation of hamster-
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specific antibodies for these four GPCRs was beyond the scope of this 
investigation.
The information from this RT-PCR study may be compared with published 
reports describing expression profiles of the eight SIP and LPA genes in ovarian 
type tissues. This information is summarised in Table 3.4.
Gene Previous reports of expression in ovary or related cell lines (method used)
Result from 
CHO-Kl 
RT-PCR
SlPi
SIP2
SIP3
SIP4
SIP5
LPAi
LPA2
LPA]
Not detected in CHO-Kl cells using rat SI Pi TM 
domains as probe (Northern blot) ^
Expressed in rat ovary (EST expression profiling)  ^
Detected in CHO-Kl cells using rat SIP2 5’ 
fragment as probe (Northern blot) ^
Not detected in CHO-Kl cells using human SIP] 
coding sequence as probe (Northern blot) ^
Not detected in human ovary (Northern blot)
Not detected in CHO-Kl cells using human S1P4 
3’-coding sequence fragment as probe (Northern 
blot) ^
No data published
Expressed in human ovary (Northern blot) ^
Not detected in CHO-Kl cells using human LPAi 
3’-UTR as probe (Northern blot) ^
Not detected in human ovary (Northern blot) ^
Not detected in CHO-Kl cells using human LPA2 
3’-UTR as probe (Northern blot) ^
Expressed in human ovary -  faint (Northern blot)
-1-
Table 3 .4
Summary of SIP and LPA expression data in ovarian tissues and CHO-Kl 
cells.
Data were taken from published reports and RT-PCR analysis of expression in 
CHO-Kl cells described in this chapter.
++ strongly positive in RT-PCR; + faintly positive in RT-PCR; - negative in RT- 
PCR.
References  ^ Okamoto e/a/., 1998
Sato et al,  1999 
Glickman et al., 1999 
Graeler fl/., 1998 
Yamazaki et ah, 2000 
An et ah, 1998 
Bandoh et al., 1999
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The detection of mRNA for SIP and LPA receptors in CHO-Kl cells did not 
always correlate with detection of these transcripts in ovarian tissues and 
probably reflects the heterogeneity of cell types present within ovarian tissues. 
This investigation confirmed the previous observations, that CHO-Kl cells 
express SIP2 but not SIP3 or LPA2 [Okamoto et al,  1998], although detection of 
transcripts for SI Pi and LPAi contradicted this earlier study. This may suggest 
that the use of species-specific reagents is important in such an investigation, 
however it should also be noted that the current study used RT-PCR as the 
analytical tool, which is a more sensitive technique than Northern blotting.
The following chapter describes expression of the HA-SlPVpIRES and HA- 
SlP4-Gotii/pIRES constructs in CHO-Kl cells and analysis of the functional 
responses of the resultant recombinant proteins.
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Chapter 4 -  Expression and Functional Responses
OfSlP4
4.1 Introduction
The lysophospholipid ligand, SIP, is known to elicit myriad cellular responses, 
including stimulation of calcium flux, alterations in cell morphology and 
enhanced cell survival (reviewed by Pyne and Pyne, 2000a; Pyne and Pyne, 
2000b; Maceyka et al, 2002; Pyne and Pyne, 2002; Spiegel et a l,  2002; Hla, 
2003; Spiegel and Milstien, 2003). The sensitivity of some of these responses to 
pertussis toxin was an indicator of the involvement of GPCRs in these processes 
and the subsequent cloning of high affinity receptors for SIP confirmed a role 
for this bioactive lipid as a GPCR agonist. Of the six Edg receptors which had 
been identified when the work described in this chapter was started, three were 
known to be activated by SIP whilst the two remaining Edg receptors to which 
ligands had been assigned were activated by LPA [Graeler et a l,  1998]. The 
orphan receptor SIP4 (then named Edg6 ) showed greater sequence similarity 
with the SIP-activated Edg receptors than with those activated by LPA and it 
therefore seemed possible that SIP might be an agonist for the SIP4 receptor. 
Early characterisations of the known SIP receptors showed that all three coupled 
to GoCi G-proteins and the SIP2 and SIP3 receptors could activate multiple G- 
proteins [Zhang et al, 1999; Kon et a l,  1999; Windh et al,  1999] in response to 
SIP stimulation. Given the common ability of these known SIP receptors to 
couple to Gtti G-proteins, it was postulated that the SIP4 receptor would also 
activate this class of G-proteins.
Activation of a cell-surface GPCR results in the downstream activation of many 
signalling pathways, which may be conveniently monitored and interpreted with
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respect to receptor activation. These include modulation of adenylyl cyclase 
activity, flux of intracellular calcium and activation of MAPK enzymes. There is 
a potential advantage, however, in measuring the consequence of receptor 
activation at the G protein level. Intracellular signalling cascades often involve 
signal amplification and may be subject to positive and negative influences, 
which may complicate interpretation of data. The immediate function of GPCR 
activation is to promote exchange of the guanine nucleotides, GDP and GTP, on 
the G a G protein and this may be represented as the four stage cycle shown in 
Figure 4.1.
nji n
a n i
Figure 4. 1
Schematic diagram showing guanine nucleotide exchange cycle on GaPy G 
proteins.
Exchange of guanine nucleotides on GaPy G proteins is stimulated by the 
binding of an agonist (A) to a GPCR located on the cell membrane.
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During this cycle, occupation of a GPCR by an agonist causes it to become 
activated. Guanine nucleotide exchange is initiated by the binding of the 
activated GPCR to the membrane-associated heterotrimeric G protein. This 
event stimulates the release of bound GDP from the G a G protein and allows 
binding of endogenous GTP, which in turn promotes dissociation of the GPCR 
from the Ga-GTP and G^y G protein subunits. These Ga-GTP and GPy G 
protein subunits then activate effector molecules, such as adenylyl cyclase, 
phospholipase C and ion channels. The intrinsic GTPase activity of the G a G 
protein inactivates the G a G protein entity via hydrolysis of the bound GTP back 
to GDP, with concomitant release of inorganic phosphate. The Ga-GDP subunit 
is then able to reassociate with the GPy G protein subunit to reform the GDP- 
associated heterotrimer, which is ready for another round of activation, thus 
completing the cycle. The existence of this cycle may be exploited in two ways 
to measure receptor activation: one possibility is to measure the rate of 
hydrolysis of ['/^P]GTP and this is employed in the GTPase assay. Alternatively 
the binding of a radiolabelled non-hydrolysable analogue of GTP, [^^S]GTPyS 
may be determined [Windh and Manning, 2002; Milligan, 2003]. These assays 
are typically performed using crude membranes prepared from cells expressing 
the receptor of interest.
The focus of the work reported in this chapter was to try to detect direct 
activation of a G protein in response to stimulation of SIP4 by SIP using an 
adapted [^^SJGTPyS binding assay where specific antisera were used to 
immunoprecipitate Gai G proteins from detergent extracts prepared from 
membranes after incubation with SIP, guanine nucleotides and [^^SJGTPyS.
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This type of GTPyS/immunoprecipitation (GTPyS/IP) assay has been 
successfully used to examine the differential coupling of SlPi/2/3 receptors to 
different G proteins [Windh et a l,  1999].
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4.2 Results
4.2.1 Transient expression of a 2AAR-Gaii(C^^^I) fusion in HEK-293 
ceils
HEK-293 cells were transiently transfected to express the a 2AAR-Gaii(C^^^I) 
fusion protein (detailed in chapter 2, section 3.2), to provide a positive control 
for use in [^^SJGTPyS binding assays. Approximately 48 hours after 
transfection, cells were harvested non-enzymatically and membranes prepared, 
as described in chapter 2, section 4.1. Analysis of the resultant membranes by 
Western blotting using an anti-GOii antibody (Figure 4.2) showed the presence 
of a polypeptide with apparent mass of approximately 40 kDa in both parental 
and transiently transfected cells and is due to expression of endogenous Gau G 
protein. Membranes from transfected cells also contained a polypeptide with 
apparent Mr of 120 kDa, which reflects expression of the a 2AAR-Gaii(C^^^l) 
fusion protein. This mass was greater than that predicted on the basis of amino 
acid sequence and may reflect post-translational modification of the receptor.
4.2.2 Comparison of immunoprécipitation efficiency of different anti-G 
protein antisera in [^^SJGTPyS binding assay
In order to optimise conditions before work started with S lP 4-transfected 
membranes, a comparison was made between two antibodies (sc-262 and SGI) 
for their ability to immunoprecipitate Ga, subunits fi*om HEK-293 membranes 
transiently expressing a 2AAR-Gaii(C^^^l). A [^^SJGTPyS binding assay was 
performed, as detailed in chapter 2, section 5.2, using these a 2AAR-Gaii(C^^^I)- 
expressing membranes, which were incubated with or without the agonist 
UK14304 (used at a single concentration of 1 |xM).
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Figure 4. 2
Expression of a 2AAR-Gaii(C^^^I) in HEK-293 cells.
Membranes from HEK-293 cells which had been transiently transfected to 
express the a 2AAR-Gaii(C^^*l) fusion protein (lane 1) and untransfected HEK- 
293 cells (lane 2) were analysed by Western blotting using an anti-Ga^ antibody. 
Visualisation of immunoreactive proteins was achieved via chemiluminescence 
after incubation of the blot with an appropriate HRP-conjugated secondary 
antibody. The position of the Œ2AAR-Gotj i(C^  ^^ 1) fusion is indicated by an 
arrow.
Both the sc-262 antibody, which cross-reacts with GOi 1/2/3, and the SGI 
anti serum, which recognises G a, 1/2 were used at their previously determined 
maximally effective dilutions of 1 in 100 and 1 in 200, respectively. Whilst an 
agonist-dependent increase in [^^SJGTPyS binding was observed using each 
antibody, the window of stimulation was significantly greater using the SGI 
antiserum (>8 -fold compared to 2.5-fold stimulation with sc-262) (Figure 4.3) 
and may have reflected the ability of SGI to immunoprecipitate a greater 
proportion of the Ga,i/2 G protein from the detergent extract. On the basis of 
these results, the SGI anti serum was used for the immunoprécipitation step in all 
subsequent [^^SJGTPyS assays.
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Figure 4. 3
Comparison of different anti-G protein antisera in [^^S]GTPyS binding 
assay.
Membranes from HEK-293 cells transiently expressing a 2AAR-Gaii(C^^’l) were 
incubated for 10 minutes at 30 °C with [^^SjGTFyS in the absence (basal) or 
presence (stimulated) of 1 \xM UK14304 (an Œ2aAR agonist). The membranes 
were solubilised and immunoprécipitation performed with the sc-262 antibody or 
SGI antiserum after preclearance with non-immune serum. Data are from a 
single experiment and are presented as means of triplicate determinations ± 
SEM.
4.2.3 Stable expression of HA-SIP4 in CHO-Kl cells
The plasmid HA-Sl?4-pIRES (described in chapter 3, section 2.1 was stably 
transfected into CHO-Kl cells, as described in chapter 2, section 3.3. 
Transfection with the HA-SIP4 construct resulted in the presence of a 
polypeptide with apparent Mr of 65 kDa, which cross-reacted with anti-HA and 
anti-SlP4 antibodies (shown in Figure 4.4 (A)) and was consistent with 
expression of full length HA-tagged SIP4 protein. CHO-Kl membranes (both 
parental and transfected) expressed a protein of approximately 40 kDa, which 
was identified using the anti-Ga,i antibody and reflected expression of 
endogenous Gttii G proteins in these cells (not shown). Cell-surface expression 
of HA-tagged SIP4 was confirmed by FACS analysis using an anti-HA antibody 
(shown in Figure 4.4 (B)).
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Figure 4. 4
Expression of HA-SIP4 in CHO-Kl cells.
A Membranes from CHO-Kl cells stably expressing HA-SIP4 (lane 1) and
untransfected CHO-Kl cells (lane 2) were analysed by Western blotting 
using anti-SlP4 (panel I) or anti-HA (panel II) antibodies. Visualisation 
of immunoreactive proteins was achieved using chemiluminescence after 
incubation of the blot with appropriate HRP-conjugated secondary 
antibodies. The position of HA-SIP4 is indicated by an arrow.
B Cell-surface expressed HA-SIP4 was detected by FACS analysis using a
Fluorescein conjugate of the anti-HA antibody, represented by the blue 
trace. Cells were also stained with an isotype matched control antibody, 
denoted by the red trace. Panel I shows the staining obtained using HA- 
SlP4-transfected CHO-Kl cells whilst panel II illustrates staining of 
untransfected CHO-Kl cells. Data are presented as overlay histograms 
and are representative of at least five independent experiments.
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4.2.4 Optimisation of HA-SIP4 response in [^^S]GTPyS binding assay
The concentration of GDP can markedly alter the capacity to monitor specific 
binding of [^^SjGTPyS. To determine the optimal GDP concentration for use in 
[^^SJGTPyS assays with HA-SIP4, membranes were incubated with or without 
10 pM SIP in the presence or absence of varying concentrations of GDP before 
immunoprécipitation of detergent extracts with the SGI antiserum (Figure 4.5).
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Figure 4. 5
Determination of optimal GDP concentration using HA-SIP4 in [^^SjGTPyS 
binding assay.
Membranes from CHO-Kl cells stably expressing H A - S I P 4  were incubated for 
10 minutes at 30 °C with [^^SJGTPyS in the absence (basal) or presence 
(stimulated) of 10 pM S I P  and varying concentrations of G D P .  The membranes 
were then solubilised and S G I  antiserum used to immunoprecipitate Gtti 
subunits after preclearance with non-immune serum. Data are presented as 
means of triplicate determinations ± SEM.
An agonist-dependent increase in [^^SJGTPyS binding was observed and was 
found to be greatest in the presence of 0.1 pM GDP. The level of SIP-mediated 
stimulation observed at the optimal concentration of GDP was relatively small, 
so attempts were made to optimise the assay conditions. Time course 
experiments were performed to determine how the length of incubation could
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influence the window of stimulation. Figure 4.6 (A) shows the variation of 
response with incubation time; the “standard” incubation length of 1 0  minutes 
appeared to be preferred to longer incubations, although the general trend of 
basal and stimulated counts increasing with time suggested that a shorter 
incubation time could give an improved window of response. The relationship 
between basal or SIP-stimulated [^^SjGTPyS binding with time was not linear 
and appeared to have reached a plateau after incubation for 20 minutes. This 
may suggest that [^^SJGTPyS binding was rapid and the linear portion of binding 
occurred within the first few minutes.
The effect of the permeabilising agent saponin was also examined. Saponin has 
been reported to increase signal-to-noise ratio without altering pharmacological 
characteristics of the receptor preparation [Lazareno, 1997] and its effect on the 
window of stimulation achieved using HA-S1 P4-expressing membranes treated 
with or without 10 pM SIP is shown in Figure 4.6 (B). Addition of saponin to 
assay tubes incubated for 1 0  minutes was found to increase the level of 
stimulation over basal firom approximately 30 % to greater than 90 % and was 
therefore chosen to be included in subsequent assays. After a 10 minute 
incubation, the level of counts in stimulated samples was greater than 1 0  % of 
total radioactivity added and so incubation for 5 minutes was deemed preferable, 
to avoid substrate-depletion effects. This length of incubation gave 
approximately 2-fold stimulation over basal (shown in Figure 4.6 (B)), with an 
incorporation of less than 1 0  % of the radionucleide and was therefore used as 
the incubation time for subsequent assays of HA-SIP4 .
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Figure 4. 6
Optimisation of response of HA-SIP4 in [^^SjCTPyS binding assay.
Membranes from CHO-Kl cells stably expressing H A - S I P 4  were assayed for 
[^^SjGTPyS binding in the absence (basal) or presence (stimulated) of 10 pM 
S I P .  The assay was incubated at 30 °C for the times shown (A) and where 
indicated, saponin was included in the assay mix (B). The membranes were then 
solubilised and S G I  anti serum used to immunoprecipitate Ga, subunits after 
preclearance with non-immune serum. Data are the mean of three 
determinations ± SEM from a single experiment and are representative of two 
independent experiments.
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4.2.5 Constitutive activity of HA-SIP4 in [^^SJGTPyS binding assay
In comparison with membranes expressing a 2AAR-Gaii, the level of basal 
[^^SJGTPyS binding observed using HA-S 1 P4-expressing membranes during the 
initial optimisation experiments was noted as being markedly higher. Although 
this could have been due to the difference in host system (aiAAR-Gaii was 
expressed in HEK-293 cells whilst HA-SIP4 was expressed CHO-Kl cells), this 
observation coupled with the relatively small effects of SIP suggested that HA- 
SIP4 might be constitutively active. This was examined further: [^^SJGTPyS 
binding was measured using HA-S 1 P4-transfected, or untransfected, CHO-Kl 
membranes treated with or without 10 pM SIP, or with a vehicle (0.1 % fatty 
acid free BSA) control. Expression of HA-SIP4 in CHO-Kl membranes resulted 
in a significant increase in the level of basal [^^SJGTPyS binding (Figure 4.7). 
This agonist-independent activity represented constitutive activity of the SIP4 
receptor and was also observed with a second clone expressing the same 
construct (data not shown). Treatment with SIP further increased the extent of 
[^^S]GTPyS binding in HA-S 1 P4-expressing membranes and was shown to be 
SlP4-dependent since no such increase was observed using untransfected 
membranes.
4.2.6 Pertussis toxin-sensitivity of HA-SIP4 dose-response to SIP in 
[35g]GTp/ys binding assay
The previous observations that suggested HA-SIP4 was constitutively active 
were examined in detail during the course of E C 5 0  determinations for the ligand 
SIP. SIP-mediated increases in [^^SJGTPyS binding were concentration-
- 1 4 2 -
C hapter 4
saT3
17500-
-ac
15000-
s
0
. f i
12500-
r/) 10000-
£■
H 7500-
a 5000-
2500-
0-
* *
* * * *
Basal 
Vehicle 
Stimul ated
Parental HA-SlP^-transfected
Figure 4. 7
Constitutive activity of HA-SIP4 after expression in CHO-Kl cells.
Membranes from parental or HA-SlP4-transfected CHO-Kl cells were incubated 
for 5 minutes at 30 °C with [^^SJGTPyS in the absence (basal) or presence 
(stimulated) of 10 pM SIP, or 0.1 % fatty acid free BSA vehicle control 
(vehicle). G protein a  subunits were immunoprecipitated after solubilisation and 
preclearance with non-immune serum. Data are the mean of three 
determinations ± SEM from a single experiment, and are representative of three 
such experiments performed. Statistical significance from the basal response of 
parental cells is denoted by ** (P < 0.01).
dependent (Figure 4.8). The mean EC50 obtained for activation of HA-SIP4 by 
SIP was 565 ± 245 nM (n=4). Both SIP-induced and agonist-independent 
['^^SJGTPyS binding were shown to be sensitive to ADP-ribosylation by pertussis 
toxin. Pre-treatment of cells with 100 ng/mL pertussis toxin for 24 hours prior to 
harvesting resulted in [^^SJGTPyS binding levels that were unaffected by the 
presence of SIP and were similar to those seen using parental CHO-Kl 
membranes (Figure 4.7). A second CHO-Kl clone expressing HA-SIP4 gave 
similar results (data not shown), with an EC50 for activation by SIP of 320 nM 
(n=l), significant constitutive activity and complete sensitivity of basal and 
agonist-induced [^^SJGTPyS binding to ADP-ribosylation by pertussis toxin.
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Figure 4. 8
Concentration dependent stimulation of HA-SlP4-mediated [^^SjGTPyS 
binding by SIP.
Membranes from CHO-Kl cells transfected with HA-SIP4 which had been 
cultured in the absence (- PTx) or presence (+ PTx) of 100 ng/mL pertussis toxin 
for 24 hours prior to harvest were stimulated with varying concentrations of SIP 
for 5 minutes at 30 °C in the [^^SjGTPyS/IP binding assay. Ga. G proteins were 
immunoprecipitated after solubilisation and preclearance with non-immune 
serum. Data are the mean of three determinations ± SEM from a single 
experiment, and are representative of four such experiments performed.
4.2.7 Stable expression of HA-S1 P4-G(Xn I) fusion in CHO-Kl cells
CHO-Kl cells were stably transfected with the plasmid HA-SlP4-Gaii(C^^'l) 
(described in chapter 3, section 2.2). Membranes from cells expressing HA- 
SlP4-Gaii(C'^^'l) contained a polypeptide with an apparent Mr of 110 kDa which 
reacted with the anti-HA, anti-SlP4 and anti-Gttii antibodies, (Figure 4.9 (A)). 
This was indicative of expression of the HA-tagged SlP4-Gaii(C^^^I) fusion 
protein. As had been observed with the unfused HA-S 1 P4-transfected
membranes, the apparent mass of the HA-S 1 P4-G(Xi i (C^  ^^ I) was greater than that 
predicted on the basis of amino acid sequence and suggested the presence of 
post-translational modifications. FACS analysis using the anti-HA antibody was 
used to confirm the presence of cell-surface fusion protein (Figure 4.9 (B)).
1 4 4 -
C hapter 4
A
I II III
kDa 1  2 kDa 1  2 kDa 1  2
250----- 250----- 250-----
98---- w m
64---- 64---- 64----
50---- 50---- 50----
B
I
?
g
g
1
?
FLl-H
II
g
g
FL1-H
Figure 4. 9
Expression of HA-SlP4-GOii(C^^^I) in CHO-Kl cells.
A
B
Membranes from CHO-Kl eells stably expressing HA-SIP4- 
Gaii(C^^'l) (lane 1) and untransfected CHO-Kl cells (lane 2) were 
analysed by Western blotting using anti-Sl? 4  (panel I), anti-HA (panel 
II) or anti-Gail (panel III) antibodies. Visualisation of immunoreactive 
proteins was achieved using chemiluminescence after incubation of the 
blot with appropriate HRP-eonjugated secondary antibodies. The 
position of HA-SlP4-Gaji(C^^’l) is indicated by an arrow.
Cell-surface expressed HA-SlP4-Gaji(C^^'l) was detected by FACS 
analysis using a Fluorescein conjugate of the anti-HA antibody, 
represented by the blue trace. Cells were also stained with an isotype 
matched control antibody, denoted by the red trace. Panel I shows the 
staining obtained using HA-SlP4-Gaii(C^^'l)-transfected CHO-Kl 
cells whilst panel II illustrates staining of untransfected CHO-Kl cells. 
Data are presented as overlay histograms and are representative of at 
least five independent experiments.
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4.2.8 Optimisation of HA-SlP4-Ga;i(C^  ^ I) response in [^^S]GTPtS 
binding assay
A similar approach to that used with the HA-SlP4-expressing membranes 
(detailed in this chapter, section 2.4) was applied to optimise the response of 
HA-SlP4-Gaii(C^^^I) in the [^^SJOTPyS binding assay. Figure 4.10 shows the 
effect of GDP concentration on the ability to detect agonist-mediated increases in 
[^^SJGTPyS binding. Similar to the result obtained with the unfused HA-SIP4 
construct, the optimal concentration of GDP was approximately 0.1 pM. Time 
course experiments were performed to determine the optimal incubation time for 
this reeeptor eonstruct. Saponin was included in these ineubations as it had 
successfully increased the window of stimulation observed with the unfused HA- 
SIP4 receptor (described in this ehapter, section 2.4).
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Figure 4. 10
Determination of optimal GDP concentration using HA-SlP4-Gan(G I) in 
[SSsjGxpyS binding assay.
Membranes from CHO-Kl cells stably expressing HA-S 1 P4-G(Xi 1 (C^^ I^) were 
ineubated for 10 minutes at 30 °C with [^^SJGTPyS in the absence (basal) or 
presence (stimulated) of 10 pM SIP and varying eoncentrations of GDP. The 
membranes were then solubilised and SGI antiserum used to immunoprecipitate 
Gtti subunits after preclearance with non-immune serum. Data are presented as 
means of triplicate determinations ± SEM.
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Figure 4.11 shows the effect of incubation time on the stimulation window. In 
contrast to the unfused H A - S I P 4  construct, which gave an optimal level of 
stimulation above basal after 5-10 minutes, the optimal incubation time for the 
H A - S  1 P4-G(Xi 1 I^) fusion was 30 minutes and was used in subsequent
experiments. Similar to observations with the unfused H A - S I P 4  receptor, basal 
and agonist-stimulated [^^SJGTPyS binding did not show a linear relationship 
with time which suggested that the linear portion of [^^SJGTPyS binding 
occurred in the first few minutes.
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Figure 4. 11
Optimisation of response of HA-Sl?4-Gaii(C^^^I) in [^^S]GTPtS binding 
assay.
Membranes from CHO-Kl cells stably expressing HA-S 1 P4GŒi 1 (C^^ I^) were 
assayed for ['^^SjCTPyS binding in the absence (basal) or presence (stimulated) 
of 10 pM SIP and incubated at 30 °C for varying lengths of time. Post assay, 
membranes were solubilised and G a, subunits immunoprecipitated using SGI 
antiserum after preclearance with non-immune serum. Data shown are the mean 
of three determinations ± SEM from a single experiment and are representative 
of two independent experiments.
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4.2.9 Constitutive activity of HA-SlP4-Gaii(C I) in [^^SjGTPyS 
binding assay
Measurement of [^^SJOTPyS binding using HA-SlP4-Gaii(C^^'l)-transfected or 
untransfected CHO-Kl membranes was made after treatment with or without 
10 pM SIP, or with a vehicle (0.1 % fatty acid free BSA) control. Expression of 
HA-S 1 P4-GŒi 1 (C^^ I^) in CHO-Kl cells resulted in higher levels of basal 
[^^SjGTPyS binding than that observed in untransfected CHO-Kl cells and 
treatment with SIP further increased [^^SJGTPyS binding in HA-SIP4- 
GoCi 1 (C^  ^^ I)-expressing membranes in a receptor-dependent manner (Figure 
4.12). This was similar to observations made with the unfused HA-SIP4 receptor 
(this chapter, section 2.5).
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Figure 4. 12
Constitutive activity of HA-SlP4-Ga;i(C^^^I) expressed in CHO-Kl cells.
Membranes from parental or HA-S 1 P4-Goti 1 (C^^^I)-transfected CHO-Kl cells 
were incubated with [^^SJGTPyS in the absenee (basal) or presence (stimulated) 
of 10 pM SIP, or 0.1 % fatty acid free BSA vehicle eontrol (vehiele) for 30 
minutes at 30 °C. G protein a  subunits were immunoprecipitated after 
solubilisation and preclearance with non-immune serum. Data are the mean of 
three determinations ± SEM from a single experiment, and are representative of 
three such experiments performed. Statistical significance from the basal 
response of parental cells is denoted by ** (P < 0.01).
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4.2.10 Pertussis toxin-sensitivity of HA-SlP4-Gaii(C^^^I) dose-response 
to SIP in [^^S]GTPyS binding assay
The potency of the ligand SIP as an agonist of the HA-S 1 P4-Gan(C^^^I) fusion 
construct was determined in the [^^SJGTPyS binding assay (Figure 4.13). The 
ECso for SIP activation was 355 nM ±155 nM (n=3). In contrast to the pertussis 
toxin-sensitivity seen with HA-SIP4 membranes, HA-SlP4-Gaii(C^^^I) 
membranes treated with pertussis toxin for 24 hours prior to harvest were able to 
exhibit increased [^^SJGTPyS binding after SIP stimulation, with an E C 5 0  of 805 
nM ± 1 9 0  nM (n=3) which reflected activation of the fused, pertussis toxin- 
insensitive GoCii G protein. This construct also appeared to be constitutively 
active because basal counts obtained, even after pertussis toxin treatment, were 
appreciably higher than those obtained with untransfected CHO-Kl membranes 
incubated for the same length of time under the same assay conditions (shown in 
Figure 4.12). There was a marked reduction in basal [^^S]GTPyS binding, 
however, following pertussis toxin treatment. This may reflect the ability of HA- 
SlP4-Gotii(C^^^l) to interact constitutively with endogenously expressed Gi G 
proteins. Pretreatment with pertussis toxin also produced a small decrease in the 
extent of the signal produced by SIP. This also suggested a degree of coupling 
of the HA-SlP4-GOii(C^^^l) fusion to endogenous pertussis toxin-sensitive G 
proteins. However, the majority of the signal from the fusion protein was clearly 
mediated via the fused, pertussis toxin-insensitive G protein. A second clone 
expressing the HA-SlP4-GoCii(C^^ I^) protein was also tested (data not shown). 
This clone expressed very low levels of HA-SlP4-GoCii(C^^ I^) and whilst E C 5 0  
values for activation by SIP were somewhat higher than for the original clone 
tested, the overall profile of response was similar: constitutive activity was
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evident even after pertussis toxin treatment and SIP was able to stimulate 
activation of the reeeptor both before and after pretreatment of cells with 
pertussis toxin.
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Figure 4. 13
Concentration dependent stimulation of HA-SlP4-Gan(C^^ I)-mediated 
1” S|GTPtS binding by SIP.
Membranes from CHO-Kl cells transfected with HA-SlP4-GtXii(C^^'l) which 
had been cultured in the absence (- PTx) or presence (+ PTx) of 100 ng/mL 
pertussis toxin for 24 hours prior to harvest were stimulated with varying 
concentrations of SIP for 30 minutes at 30 °C in the [^^S]GTPyS/IP binding 
assay. GoCj G proteins were immunoprecipitated after solubilisation and 
preclearanee with non-immune serum. Data are the mean of three 
determinations ± SEM from a single experiment, and are representative of three 
such experiments performed.
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4.3 Discussion
S I P 4  was cloned as the orphan GCPR named Edg6  [Graeler et al,  1998]. 
Sequence similarity with other Edg receptors suggested the lysophospholipid 
S I P  might be an agonist of this receptor, and that it may couple to Gai G 
proteins. This hypothesis was tested in this chapter.
Initially, HA-SIP4 was expressed in RH7777 cells, which have been reported to 
be unresponsive to SIP and LPA [Zhang et a l,  1999]. Preliminary attempts had 
been made to measure SIP-induced activation of the SIP4 receptor expressed in 
this cell line using conventional [^^S]GTPyS binding, inhibition of cAMP 
accumulation and calcium flux assays. Unfortunately, it was not possible to 
detect activation of this receptor in these assays. The receptor was then 
expressed in CHO-Kl cells and the modified [^^S]GTPyS/lP binding assay used 
to try to measure activation of SIP4 at the level of receptor-G protein interaction.
The concentration of GDP used in this assay was optimised since GDP affects 
the magnitude of agonist stimulated [^^S]GTPyS binding [Windh and Manning, 
2002]. High GDP concentrations suppress basal activity whilst at low GDP 
concentrations, basal activity is unrestricted so the ability of an agonist to further 
stimulate [^^S]GTPyS binding is limited. The optimal concentration of GDP for 
the detection of SIP-stimulated [^^S]GTPyS binding for the S I P 4  receptor was 
0.1 |xM. The time of incubation was optimised such that the window of 
stimulation was maximised. The non-linear profile of the timecourses suggested 
that [^^S]GTPyS binding plateaued rapidly and was not unexpected, since a 
similar profile was reported for the 5-HTia receptor [Windh and Manning,
2002]. Further optimisation of the signal was obtained via the addition of the
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permeabilising agent saponin. In this study, saponin was used at a 1:1 ratio 
relative to the amount of membranes, however it may have been beneficial to test 
other ratios. A study of the SLC-1 receptor (somatostatin-like receptor 1) by 
Audinot and et ah, [2001] investigated the effect of different saponin ratios on 
ligand-induced [^^S]GTPyS binding for this receptor. Saponin was shown to 
produce a bell-shaped curve and the peak stimulation corresponded to a ratio of 
approximately 1:2.5 (saponin:SLC-1 membranes).
Whilst this work was in progress, two independent groups reported the ability of 
SIP to bind to SIP4 and stimulate ERK phosphorylation [Van Brooklyn et a l,  
2000] and calcium flux [Yamazaki et al,  2000]. However, this receptor was 
reported to be non-functional in a study using a conventional GTPyS assay to 
compare the activation of SlPi/2/3 with SIP5, expressed in HEK-293 cells, by 
various analogues of SIP [Im et al,  2001a]. Therefore the results described in 
this chapter were the first demonstration of SIP4 activation measured at the G 
protein level. Subsequently, two groups have shown activation of SIP4 using a 
conventional [^^S]GTPyS assay [Brinkmann et a l,  2002; Mandala et a l,  2002] 
and the data presented in this chapter concurs with these reports.
In this chapter, it has been shown that 1) SIP4 couples to Goq G proteins; 2) SIP4 
is strongly constitutively active when expressed in CHO-Kl cells and 3) SIP4 
can be further activated by treatment with SIP. These results support published 
observations that SIP4 is activated by SIP [Van Brocklyn et a l,  2000; Yamazaki 
et a l,  2 0 0 0 ] but in addition are the first to show the extent of constitutive activity 
displayed by SIP4 . It may be that previous difficulties in observing SIP 
activation of SIP4 reflect this high level of constitutive activity. The increase in
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[^^SJGTPyS binding in SlP4-transfected CHO-Kl membranes when compared to 
untransfected membranes is strongly indicative of a high level of constitutive 
activity of the receptor and warrants further investigation. Additionally, the SIP4 
receptor was seen to exhibit significant levels of basal activity in a high affinity 
GTPase assay (data not shown). The ability of SIP4 to couple to Goti G proteins 
is a feature shared by all of the SIP-activated Edg receptors. In common with 
SIP2/3/5, SIP4 couples to multiple G proteins and has been reported to activate 
Goti and G ai2/i3 [Van Brocklyn et ah, 2000; Yamazaki et a l,  2000; Graeler et 
al., 2003].
The use of fusion proteins constructed between a GPCR and the a  subunit of a G 
protein has become widespread and offers several advantages over systems 
where non-fused receptors are studied (reviewed by Seifert et a l,  1999; Milligan, 
2000; Wurch and Pauwels, 2001). Construction of a GPCR-Ga fusion using a 
mutated G a G protein that is insensitive to ADP-ribosylation by pertussis toxin 
allowed isolation of the response from the fused receptor [Milligan, 2000]. In 
this study, a pertussis toxin-insensitive HA-SlP4-Gaii(C^^^l) fusion protein was 
used, enabling the elimination of signalling from endogenously expressed SIP 
receptors by treatment with pertussis toxin. The ability of the tethered G protein 
to transduce the activation of SIP4 was demonstrated using membranes prepared 
from pertussis toxin-treated cells, where SIP was shown to promote a dose- 
dependent increase in [^^S]GTPyS binding. The HA-SlP4-GOii(C^^^I) fusion 
protein also exhibited constitutive activity.
The lysophospholipid, SIP has been identified as the high affinity ligand for 
several members of the Edg receptor family and these SIP receptors bind SIP
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with dissociation constants in the range 2 nM for SIP5 to approximately 25 nM 
for SIP2/3 [Lee et al, 1998; Kon et a l,  1999; Im et al, 2000a]. In a recent 
parallel study [Im et al,  2001a] a conventional GTPyS binding assay was used to 
compare the efficacy of various agonists, including SIP, to activate SlPi/2/3 and 
SIP5, using membranes prepared from HEK-293 transfected cells. Values for 
the EC50 of SIP-induced GTPyS binding were in the range 0.9 -  2.9 nM for 
SlPi/2/3 and 44 nM for SIP5; these data may be compared with EC50 values 
obtained for activation of the SIP4 constructs described here: 565 nM for HA- 
SIP4 and 355 - 805 nM for the HA-SlP4-GoCii(C^^ l^) fusion protein. Statistical 
analysis indicated that these EC50 values were not significantly different. This 
probably reflects the standard errors associated with these values and is a result 
of each SIP dose-response experiment having been set up using membranes 
prepared from separate cell passages (which expressed different levels of cell- 
surface SIP4). SIP has previously been shown to bind to the SIP4 receptor, 
albeit with a lower affinity than that with which it binds other SIP receptors. 
Dissociation constants for SIP binding to SIP4 expressed in mammalian cells 
fall in the range 20 nM -  95 nM [Van Brocklyn et a l,  2000; Yamazaki et a l,  
2000; Mandala et a l,  2002]. Therefore, whilst SIP does bind to, and activate 
SIP4 , it does so with lower affinity and potency than it does at the other SIP 
receptors, which may suggest that it is not the endogenous ligand for the SIP4 
receptor. Phylogenetic analysis of the Edg receptors (shown in chapter 1, Figure
1.6) shows that whilst the other SIP receptors form a discrete cluster, SIP4 is on 
the edge of this cluster and could represent the first member of a new subset of 
Edg receptors, which are activated by a lipid that is structurally distinct from SIP 
and LPA. A recent survey of GPCRs in the human genome [Vassilatis et a l.
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2003] predicted that the Edg receptor family will not extend past the eight 
members already cloned. It should be noted however, that a related family of 
orphan GPCRs (GPR3, 6  and 12) were recently identified as SIP receptors, 
indicating that there are certainly other GPCRs which respond to SIP and related 
lipids [Uhlenbrock et a l,  2002].
In the following chapter, further investigations into the constitutive activity 
displayed by S I P 4  are described.
- 155-
Chapter 5 -  Use of an Inducible Expression System to 
Examine the Constitutive Activity of SIP4
5.1 Introduction
In chapter 4  it was shown that the S I P 4  receptor is constitutively active and 
whilst this may have been a consequence of the high levels of recombinant 
receptor present in membranes used for these investigations, it could also reflect 
an inherent property of S IP 4 .  This chapter describes work carried out to further 
characterise the ability of S I P 4  to signal in the absence of ligand stimulation.
Constitutive activity is defined as ligand-independent activity and results in G 
protein activation and second messenger production in the absence of stimulation 
by an agonist. The phenomenon of GPCR constitutive activity has been widely 
reviewed [Lefkowitz et a l,  1993; Leurs et a l,  1998; de Ligt et a l,  2000] 
although it is not yet clear whether this property is physiologically relevant. 
Ligand-independent activation may be observed for almost any GPCR, although 
the introduction of a constitutively activating mutation (CAM) is often required 
to induce significant levels of agonist-independent activity (reviewed by Pamot 
e ta l ,  [2 0 0 2 ]).
The finding that certain receptors exhibit constitutive activity has led to a 
modification of traditional receptor theory [Samama et a l,  1993]. It is now 
believed that receptors can exist in at least two conformations, an inactive (R) 
and an active (R*) state and the equilibrium between these two conformations 
strongly favours the inactive receptor state. In some native receptors, and in 
those which have been modified by the introduction of a constitutively activating 
mutation, this equilibrium appears to be shifted so that there is a sufficient
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number of receptors in the active state to initiate signalling, in the absence of 
agonist stimulation.
Constitutive activity is sensitive to the actions of inverse agonists. These ligands 
were previously defined as antagonists, since they were known to bind to, but not 
activate GPCRs. The discovery that many of these as “antagonists” were able to 
decrease agonist-independent activity of constitutively active receptors, and 
therefore possessed negative efficacy, led to their reclassification as inverse 
agonists. Inverse agonists have now been characterised for many receptor 
families and are valuable pharmacological tools that allow definitive 
demonstration of GPCR constitutive activity. At the time of these investigations 
however, no such compounds had been identified for the SIP receptor family.
Studies into the effect of expression level on receptor functionality may be 
undertaken as a way of characterising constitutive activity in the absence of such 
pharmacological tools. One of the more simple methods is to isolate a number of 
clonal cell lines which express a range of receptor densities and use these cell 
line in subsequent functional assays. This method utilises the positive 
correlation which exists between receptor density and agonist-independent 
activity. A potential drawback with such an approach is that it may not be 
possible to isolate clones which express significantly different levels of receptor, 
and by definition, comparisons would be made between different cell lines.
An attractive alternative is to employ an expression system that permits control 
over the level of protein expression via incubation of the cells with an agent 
which drives transcription of the gene of interest (reviewed by Clackson [1997]). 
This technique has the advantage of permitting examination into the effect of 
receptor expression level using the same clonal population of cells. The key
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prerequisites for such a system are low levels of uninduced (background) 
expression and a specific induction agent which induces a large range of 
expression levels, in a dose-dependent manner. This is generally achieved using 
a heterologous transcription factor which binds a DNA sequence that is not 
recognised by endogenous transcription factors, and a small molecule which can 
modulate the activity of the transcription factor. There are two such 
commercially available systems: the tetracycline- and ecdysone-inducible 
mammalian expression systems; the latter of these was chosen for use in studies 
with the S I P 4  receptor.
The edysone-inducible expression system was first used to regulate expression of 
genes in HEK-293 cells [Christopherson et a l,  1992] and is classified as an 
“allosteric on-switch” system [Clackson, 1997] i.e. transcription is stimulated by 
exposure to the induction agent. It is based on the Drosophila moulting 
induction system, which has been modified for use in mammalian systems and 
uses analogues of the ecdysone steroid hormone to potently activate expression 
of the gene of interest via a heterodimeric nuclear receptor composed of a 
modified form of the ecdysone receptor and the retinoid X receptor. Figure 5.1 
shows a schematic diagram of this system. The ecdysone-inducible system has 
been used for the inducible expression of numerous recombinant proteins, 
including the somatostatin SST2 and dopamine D2iong GPCRs [Choi et a l,  2000; 
Cole et al,  2001].
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Figure 5.1
Schematic diagram describing the ecdysone-inducible mammalian 
expression system.
The retinoid X receptor (RXR) and a modified form of the ecdysone receptor 
(VgEcR), which contains the VP16 transactivation domain, are expressed in 
mammalian cells under the control of the rous sarcoma virus (RSV) and 
cytomegalovirus immediate early (CMV) promoters, respectively. In the 
presence of a synthetic analogue of ecdysone, such as ponasterone A (PonA) or 
muristerone A (MuA), the receptors form a heterodimer, the DNA binding 
domains (DBD) of which bind the hybrid ecdysone response elements (E/GRE). 
Transcription of the gene of interest (HA-SIP4 in this instance) is activated from 
the minimal heat shock promoter ( P ahsp) via the VP 16 transactivation domain 
present in the receptor heterodimer.
Synthetic ecdysone receptor hormone analogues commonly used to induce 
protein expression with this system are muristerone A and ponasterone A, the 
structures of which are shown in Figure 5.2. These compounds are steroids and 
possess the characteristic four-ring backbone of this class of molecule. The 
structure of muristerone A is identical to that of ponasterone A other than the 
substituents present at the 5- and 11-positions of the ring system: hydroxyl 
groups in muristerone A and hydrogen atoms in ponasterone A.
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Figure 5. 2
Structures of the ecdysone receptor hormone analogues, ponasterone A and 
muristerone A.
In this chapter, the ecdysone-inducible expression system was used to investigate 
the relationship between S I P 4  expression and agonist-independent activity. 
These results would indicate whether the S I P 4  constitutive activity observed in 
chapter 4 represented an inherent property of this receptor, or was a result of the 
high levels of S I P 4  expression in the cell line used for those studies.
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5.2 Results
5.2.1 Generation of HA-SIP4 inducible expression stable cell line
The plasmid HA-SIP4/PIND, which was produced in chapter 3, section 2.3 was 
stably transfected into CHO-EcR cells as described in chapter 2, section 3.3. 
This commercially available cell line had been transfected to stably express 
functional ecdysone receptor under selection with Zeocin. Stable transfection of 
these cells with the pIND plasmid containing the gene of interest followed by 
dual selection with Zeocin and Geneticin allowed isolation of a stable cell line in 
which expression of the heterodimeric ecdysone receptor was constitutive and 
expression of the gene of interest was under the control of the ecdysone receptor 
hormone analogues, ponasterone A or muristerone A.
5.2.2 Characterisation of the effect of the ecdysone receptor hormone
analogues, ponasterone A and muristerone A, on cell-surface
expression of HA-SIP4
HA-SIP4 receptor expression was measured in the stably transfected CHO-EcR 
cell line, which had been treated with varying concentrations of ponasterone A 
and muristerone A or DMSO vehicle control, for 24 hours at 37 °C. Cell-surface 
expression was determined via FACS analysis using an anti-HA antibody and the 
resultant data were expressed as fluorescence dot plots, such that staining of cell- 
surface HA-SIP4 with the Fluorescein conjugated anti-HA antibody was 
observed as a shift to the right of the dot plot. Parental CHO-EcR cells cultured 
in the absence or presence of each ecdysone receptor hormone analogue, or 
DMSO vehicle control were analysed in this way and shown not to shift to the 
right under any condition (shown in Figure 5.3).
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Figure 5. 3
Dot plot analysis of parental CHO-EcR cells.
Parental CHO-EcR cells were treated with the conditions used to induce 
expression in HA-SlP4-transfected cells i.e. with DMSO vehicle, 10'"^  ^ M 
ponasterone A (PonA) or Muristerone (MuA), or were left untreated (uninduced) 
and subject to FACS analysis using a Fluorescein conjugate of the anti-HA 
antibody. The location of the quadrant was defined using these cells and was 
such that the population was present in the lower left quadrant. Data presented 
are from duplicate determinations of a single experiment and are representative 
of three independent experiments.
Quadrant analysis of the dot plots was used to quantify the percentage of cells 
expressing HA-SIP4. The location of the quadrant was set using parental CHO- 
EcR cells, which had been stained with the anti-HA antibody (Figure 5.3) and 
the same quadrant location used for the analysis of HA-SIP4 expression in the 
transfected CHO-EcR cell line. Comparison of dot plots from parental and HA- 
S1 P4-transfected cells in this manner was performed for cells treated in the same 
way and harvested in parallel.
Ponasterone A was titrated over the range 10"^  ^to 10"^  M and expression of cell- 
surface H A - S I P 4  determined. The dot plots (Figure 5.4 (A)) showed a small 
population of cells in the lower right quadrant in the uninduced and vehicle 
controls, which indicated that there was some constitutive expression of the 
receptor. The proportion of cells in this location increased with the concentration 
of ponasterone A and the level of expression of H A - S 1 P4 was dependent on the 
concentration of ponasterone A used.
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Figure 5. 4
Concentration dependent induction of cell-surface receptor expression by 
ponasterone A treatment of ecdysone-inducible HA-S 1 P4-transfected CHO- 
EcR cells.
Cells were incubated for 24 hours in serum-free medium supplemented with 
varying concentrations of ponasterone A (PonA). Levels of cell-surface receptor 
expression were quantified by FACS analysis using a Fluorescein conjugate of 
the anti-HA antibody. Quadrant analysis of dot plots was used to determine the 
percentage of cells expressing HA-SIP4 (A); the location of the quadrant was 
defined using CHO-EcR cells and those cells present in the lower right quadrant 
were classified as expressing HA-SIP4 . The resultant data are presented 
graphically (B). Data presented are the mean of duplicate determinations ± SEM 
from a single experiment, and are representative of three such experiments 
performed.
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When plotted as a dose-response curve (Figure 5.4 (B)), an EC50 value was 
obtained, although interpretation of this value needed caution, since a plateau of 
maximal receptor expression was not reached. It was not possible to use 
ponasterone A at concentrations in excess of 10"^  ^  M since vehicle effects were 
observed with a vehicle control of the equivalent concentration of DMSO (not 
shown). At the maximal concentration of ponasterone A used (10"  ^  ^M), 80 % ± 
6  % (n=3) cells were determined to be expressing H A - S I P 4 .
A similar experiment was set up using muristerone A and the profile of HA-SIP4 
expression induced by this agent was found to be very similar to that observed 
with ponasterone A. Analysis of the dot plots (Figure 5.5 (A)) showed that a 
proportion of cells expressed HA-SIP4 prior to stimulation with muristerone A, 
and that the number of cells present in the lower right quadrant increased with 
muristerone A concentration, in a dose-dependent manner (Figure 5.5 (B)). As 
was seen when using ponasterone A, it was not possible to use sufficiently high 
concentrations of muristerone A to observe a maximal plateau with this dose- 
response curve. At the maximal concentration of muristerone A used (10"  ^^  M), 
76 % ± 7 % (n=3) cells expressed HA-SIP4, as determined by quadrant analysis 
of the FACS dot plots.
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Figure 5. 5
Concentration dependent induction of cell-surface receptor expression by 
muristerone A treatment of ecdysone-inducible HA-SIP^-transfected CHO- 
EcR cells.
Cells were ineubated for 24 hours in serum-free medium supplemented with 
varying concentrations of muristerone A (MuA). Levels of eell-surface reeeptor 
expression were quantified by FACS analysis using a Fluorescein conjugate of 
the anti-HA antibody. Quadrant analysis of dot plots was used to determine the 
percentage of cells expressing HA-SIP4 (A); the loeation of the quadrant was 
defined using CHO-EeR eells and those cells present in the lower right quadrant 
were classified as expressing HA-SIP4 . The resultant data are presented 
graphically (B). Data presented are the mean of duplicate determinations ± SEM 
from a single experiment, and are representative of three such experiments 
performed.
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The data obtained with each induction agent are summarised in Table 5.1.
Mean EC50 Maximal % cells
Agent ± SEM (pM) expressing
Ponasterone A 5.44 ±0.71 6 8  ± 4
Muristerone A 5.35 ± 1.29 64 ± 4
Table 5.1
Summary of ecdysone analogue potency for induction of HA-SIP4 
expression in HA-SlP 4-transfected ecdysone-inducible CHO-EcR cells.
EC50 values were calculated from dose-response experiments using the ecdysone 
analogues ponasterone A and muristerone A to induce cell-surface expression of 
the HA-SIP4 receptor. The proportion of cells expressing the receptor was 
assessed using FACS analysis with a Fluorescein conjugated anti-HA antibody. 
The values shown above are the means of three independent determinations.
Fluorescence microscopy was used as an alternative method of showing 
induction of HA-SIP4 expression as a dose-dependent response to the induction 
agent. Cells were cultured on microscope slides, in the presence of varying 
concentrations of ponasterone A, or vehicle control. Staining was performed 
with the nuclear stain DAPl, and a Fluorescein conjugate of the anti-HA 
antibody. Images of green fluorescence (due to anti-HA-Fluorescein) and blue 
fluorescence (due to DAPl) were viewed using a fluorescence microscope and 
the two images obtained for each sample were merged. These results (Figure
5.6) correlated well with the previously generated FACS data, although the 
fluorescence microscope was not as sensitive as the FACS method and this 
technique was less suitable for quantitation of the proportion of cells expressing 
HA-SIP4 at a given concentration of ponasterone A. No staining with anti-HA- 
Fluorescein was observed when cells were cultured in vehicle control (Figure 5.6 
(A)), however at the lowest concentration of ponasterone A used (10'^  ^ M, 
Figure 5.6 (B)), a very small proportion of the cells had been stained with the 
antibody. As the concentration of ponasterone A was increased (Figure 5.6 (C)
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Figure 5. 6
Induction of cell-surface receptor expression by ponasterone A treatment of 
ecdysone-inducible HA-S lP 4-tr ansfected CHO-EcR cells detected by 
fluorescence microscopy.
Cells were cultured in the presence of ponasterone A or DMSO vehicle control 
and analysed by fluorescence microscopy (x l6  magnification) using a 
Fluorescein conjugate of the anti-HA antibody; cell nuclei were counterstained 
with DAPL Data are representative of two such experiments performed.
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and (D)), the percentage of cells fluorescing green increased and some cells were 
seen to fluoresce more brightly than other cells. As was observed using FACS 
analysis, less than 100 % of cells were positive for HA-SIP4 expression at the 
maximal concentration of ponasterone A used. This was in contrast to the 
constitutively expressing HA-S 1 P4-transfected cell line described in chapter 4, 
where 100 % of cells stained with anti-HA-Fluorescein (data not shown). No 
staining was seen when untransfected cells were used (Figure 5.6 (E)), or when a 
Fluorescein conjugate of an isotype control antibody was used (data not shown). 
Staining of cell nuclei with DAPl allowed visualisation of cells when there was 
no green fluorescence due to binding of the anti-HA-Fluorescein antibody. Since 
the cells were unfixed and unpermeabilised, staining with the anti-HA antibody 
reflected expression of cell-surface HA-S 1P4 .
The time dependency of receptor expression in the HA-S 1 P4-transfected cell line 
was examined using a single concentration of ponasterone A or muristerone A. 
Quantitation of the proportion of cells expressing HA-SIP4 was performed in the 
same way as described for the dose-response experiments. Exposure of cells to 
10'  ^  ^ M each agent over a range of incubation times from 3 hours to 48 hours 
resulted in a time-dependent increase of HA-SIP4 expression (Figure 5.7). The 
profiles of time-dependent induction obtained with ponasterone A and 
muristerone A were broadly similar. Exposure to the agent for less than 3 hours 
did not increase cell-surface expression of HA-SIP4, as compared to the 
uninduced control whilst maximal expression levels were achieved after 34-48
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Figure 5. 7
Time-dependent induction of cell-surface receptor expression by 
ponasterone A and muristerone A treatment of ecdysone-inducible HA- 
S1 P4-transfected CHO cells.
Cells were ineubated for varying times in serum-free medium supplemented with 
10'^^ M ponasterone A (A), 10'^^ M muristerone A (B) or DMSO vehicle control 
(veh). Cell-surfaee receptor expression was quantified by FACS analysis using a 
Fluorescein conjugated anti-HA antibody. Quadrant analysis of dot plots was 
used to determine the percentage of cells expressing HA-SIP4 . The resultant 
data presented graphically, are the mean of duplieate determinations ± SEM from 
a single experiment and are representative of two independent experiments.
hours. As was observed when the concentration of induction agent was titrated, 
small populations of HA-SlP4-expressing cells were detected in the uninduced
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and vehicle controls. After 24 hours, approximately 25 % of cells expressed 
HA-SIP4 when induced with either ponasterone A or muristerone A. This was 
slightly lower than the proportion of cells assessed to be expressing HA-SIP4 at 
10"^   ^M of either agent in the dose-response experiments and may have been due 
to differences in cell density at the time of induction.
Since there was no significant difference with respect to the concentration- and 
time-dependency of H A - S I P 4  expression induced by each induction agent, 
subsequent experiments were performed using ponasterone A.
Immunoblots of membranes from cells stably transfected to inducibly express 
HA-SIP4 contained a polypeptide with an apparent Mr of 65 kDa, which reacted 
with anti-HA and anti-SlP4 antibodies (Figure 5.8). It was possible to detect 
HA-SIP4 protein in membranes prepared from cells treated with 10"^ '^  M or 10'^’^  
M ponasterone A, but not when lower concentrations of this induction agent 
were used. This presumably reflected the lower sensitivity of this technique, 
compared to analysis of expression by whole cells using FACS. The apparent 
mass of HA-SIP4 expressed using the ecdysone-inducible system was slightly 
lower than that observed using the constitutively expressing HA-SIP4 
membranes (chapter 4, section 2.3). However, the apparent mass of HA-SIP4 
expressed using the ecdysone-inducible system was still greater than that 
predicted on the basis of amino acid sequence (43 kDa), suggesting that the small 
mass differences observed between expression systems were more likely due to 
post-translational variations, rather than proteolysis. Cross-reactivity with the 
anti-HA antibody confirmed the amino-terminus of the protein was intact. The
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apparent molecular mass of HA-SIP4 expressed using this system was found to 
be consistent over a number of clones tested (data not shown).
I II
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Figure 5. 8
Analysis of receptor expression in ecdysone-inducible HA-SlP4-transfected 
CHO-EcR cells using Western blotting.
Membranes from untransfected CHO-EeR eells (Lane 1) and CHO-EcR cells 
transfected to inducibly express HA-SIP4, and cultured in the presence of 10'^^ 
M (Lane 2), 10'^^ M (Lane 3), or 10'"^  ^M ponasterone A (Lane 4) were analysed 
by Western blotting using anti-HA (panel I) or anti-SlP4 (panel II) antibodies. 
Visualisation of immunoreactive proteins was achieved using 
chemiluminescence after incubation of the blot with appropriate HRP-conjugated 
secondary antibodies. The position of HA-SIP4 is indicated by arrow.
This characterisation work enabled conditions under which to culture cells for 
subsequent preparation of membranes and evaluation of receptor functionality in
the [^^SJGTPyS binding assay to be chosen.
5.2.3 The effect of cell-surface receptor expression level on HA-SIP4 
basal activity in [^^SjCTPyS binding assay
In an initial experiment, transfected and parental cells were seeded in complete 
medium and cultured for 24 hours to allow eells to attach to the tissue culture 
plastic. The medium was removed, eells were washed and then cultured for 24 
hours in serum-free medium supplemented with a range of concentrations of 
ponasterone A to induce expression of H A - S I P 4 .  For each concentration of
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ponasterone A, two flasks of cells were prepared and cultured with or without 
100 ng/mL pertussis toxin. Expression of cell-surface HA-SIP4 was confirmed 
using FACS analysis before membranes were prepared. Basal and SIP- 
stimulated signalling was measured using the [^^SJGTPyS binding assay. The 
results from this single experiment (not shown) indicated that at no concentration 
of ponasterone A was constitutive activity of HA-SIP4 observed, however the 
addition of 10 |iM SIP could stimulate [^^SjGTPyS binding at the highest 
concentration of ponasterone A used (10"  ^^  M). The ability of SIP to activate 
the receptor clearly confirmed its functionality but the lack of constitutive 
activity was unexpected. The induction of HA-SIP4 expression in serum-ffee 
conditions was a consequence of the experimental design and resulted in very 
artificial circumstances under which the receptor was expressed. A further 
preliminary experiment was set up where cells were seeded in complete medium 
supplemented with 10"^  ^  |iM ponasterone A and cultured for 24 hours before 
being transferred to serum-ffee medium containing the same concentration of 
ponasterone A with and without pertussis toxin. Cells were cultured for 24 hours 
under these conditions before being harvested. This resulted in expression of 
HA-SIP4 for 48 hours, the first 24 of which were in serum-containing conditions. 
Comparison of the basal and SIP stimulated activities of the 48 hour-induced 
cells with the original membranes from cells induced with 10"^  ^  M ponasterone 
A for 24 hours in serum-ffee conditions in the [^^SjGTPyS binding assay showed 
that induction of protein expression in serum-containing medium conferred 
constitutive aetivity and increased S IP-induced stimulation of the receptor. The 
following eonditions were therefore chosen for the induction of cells for assay of 
constitutive activity:
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1 Concentrations of ponasterone A used: 10'  ^  ^M, 10'  ^^  M, M
2 Cells seeded in complete medium containing appropriate concentration of 
ponasterone A and cultured for 24 hours
3 Medium removed, cells washed and cultured in serum-ffee medium 
eontaining appropriate concentration of ponasterone A, in the presence or 
absence of 100 ng/mL pertussis toxin for 24 hours. Cells harvested and 
membranes prepared for use in [^^SJGTPyS binding assay.
HA-S 1 P4-transfected and parental CHO-EcR cells were cultured under these 
conditions and the resultant membranes used to investigate HA-SIP4 constitutive 
activity. Increased receptor expression caused by incubation with increased 
concentrations of ponasterone A resulted in increased basal activity of the 
membranes (Figure 5.9). Pertussis toxin was used to illustrate the extent of this 
constitutive activity since the level of [^^SJGTPyS binding observed with 
membranes prepared ffom pertussis toxin-treated cells was the same regardless 
of the level of receptor expression.
The level of constitutive activity observed at the highest level of HA-SIP4 
expression was less than that typically observed with the constitutively 
expressing cell lines characterised in chapter 4. This was not entirely 
unexpected, since the level of receptor expression achieved with the highest 
concentration of ponasterone A was still lower than that of the constitutively 
expressing cell line.
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Figure 5. 9
Constitutive activity of HA-SIP4 expressed in ecdysone-inducible CHO-EcR 
cells.
Membranes were prepared from parental or HA-Sl?4-transfeeted eedysone- 
inducible CHO-EcR cells, which had been eultured in the presence of varying 
eoneentrations of ponasterone A (PonA) or vehicle (veh), and in the absence 
(- PTx) or presence (+ PTx) of 100 ng/mL pertussis toxin for 24 hours prior to 
harvest. The membranes were incubated for 5 minutes at 30 °C with ['^^SJGTPyS 
and G protein a  subunits immunopreeipitated after solubilisation and 
preclearance with non-immune serum. Data presented are the mean of three 
determinations ± SEM from a single experiment and are representative of two 
such experiments performed. Statistical significance from the response of non 
pertussis toxin-treated vehicle eontrol HA-SIP4 cells is denoted by ** (P < 0.01).
It was neeessary to show that the basal activity of H A - S I P 4  was a consequence 
of the level of expression of this reeeptor and not due to the effects of residual 
ponasterone A present in the membrane preparations, although this seemed 
unlikely since cells were washed thoroughly before being harvested. Membranes 
from CHO-Kl eells stably expressing H A - S I P 4  (described in chapter 4) were 
tested in the ['^^SJGTPyS binding assay to determine whether the maximal 
concentration of this agent (lO'"^  ^ M) used for induction of H A - S I P 4  expression 
in the eedysone-inducible cell line stimulated the reeeptor. Ponasterone A did
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not stimulate [^^S]GTPyS binding in HA-SlP4-expressing membranes (Figure 
5.10). Henee the effect of cell-surface HA-SIP4 expression level on basal 
[^^SJGTPyS binding appeared to refleet genuine constitutive activity of the 
receptor and was not due to stimulation by residual ponasterone A.
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Figure 5. 10
Constitutive activity of HA-SIP4 is not influenced by the presence of 
ponasterone A.
Membranes from HA-S 1 P4-transfeeted CHO-Kl cells were ineubated for 5 
minutes at 30 °C with [^^SJGTPyS with 0.1 % fatty acid free BSA (basal), DMSO 
control (vehicle), 10'"^  ^ M ponasterone A (PonA) or 10'  ^ M SIP. G protein a  
subunits were immunopreeipitated after solubilisation and preclearanee with 
non-immune serum. Data presented are the mean of three determinations ± 
SEM. Statistical significance from the basal response is denoted by ** (P < 
0.01).
5.2.4 The effect of cell-surface receptor expression level on SIP- 
stimulated HA-SIP4 activity in [^^SJGTPyS binding assay
Membranes, which had been used in section 5.2.3 to characterise the effect of 
receptor expression on constitutive aetivity, were then used to investigate the 
relationship between the expression level of H A - S I P 4  and SIP-mediated 
increases in [^^S]GTPyS binding (Figure 5.11).
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Figure 5. 11
SlP-stimulated activity of HA-SIP4 expressed in ecdysone-inducible CHO- 
EcR cells.
Membranes from parental or HA-S 1 ? 4-transfeeted ecdysone-indueible CHO-EeR 
eells, which had been cultured in the presence of varying eoneentrations of 
ponasterone A (PonA) or vehicle (veh) were ineubated with [^^SJGTPyS for 5 
minutes at 30 °C in the absence (basal) or presence (stimulated) of 10 pM SIP. 
G protein a  subunits were immunopreeipitated after solubilisation and 
preclearance with non-immune serum. Data presented are the mean of three 
determinations ± SEM from a single experiment and are representative of two 
such experiments performed. Statistical significance from the SlP-stimulated 
response of vehicle control HA-SIP4 cells is denoted by * (P < 0.05) or ** (P < 
0 .01 ).
Treatment of membranes with 10 pM SIP was found to promote increased 
[^^SJGTPyS binding when compared to both the level of basal aetivity of those 
membranes, and to membranes prepared from vehicle-treated HA-SIP4- 
transfected eells. The extent of [^^S]GTPyS binding induced by SIP increased 
with receptor expression, with maximal activation being obtained at the highest 
concentration of ponasterone A that was used. SIP was also found to cause a 
small stimulation of [^^S]GTPyS binding in untransfected CHO-EcR membranes, 
although this increase was not statistically significant in every experiment. Such 
a stimulation was not observed when parental CHO-Kl membranes were
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exposed to 10 pM SIP in experiments described in chapter 4 and may suggest 
that the pattern, or levels, of expression of endogenous SIP receptors in CHO- 
EcR cells differed slightly from that of CHO-Kl cells.
5.2.5 Correlation analysis of HA-SIP4 constitutive and SlP-stimulated 
[^^SJGTPyS binding activity with the level of HA-SIP4 cell-surface 
expression
The relationship between the number of cells expressing HA-SIP4, determined 
using the criteria described in this chapter, section 2 .2 , and the activity of the 
reeeptor in the [^^SJOTPyS binding assay, measured in this chapter sections 2.3 
and 2.4, was examined. Data were corrected by subtraction of basal dpm 
obtained using membranes prepared ffom eells which had been treated with 
pertussis toxin such that the resultant value solely represented the activity of HA- 
SIP4. Figure 5.12 shows these data and the linear regression analysis performed 
on these data sets.
Both constitutive and SlP-stimulated [^^SJGTPyS binding attributed to the 
presence of HA-SIP4 were found to correlate strongly (Pearson’s r  ^> 0.96) with 
the proportion of cells expressing the receptor; each relationship showed a good 
approximation to linearity (r  ^ > 0.93) and the correlation result was statistically 
significant (P < 0.001). A summary of this analysis is shown in Table 5.2.
Constitutive activity SlP-stimulated activity
Linearity (r )^ 0.9346 0.9537
Correlation (Pearson’s r )^ 0.9667 0.9766
Significance P <  0.0001 P < 0.0001
Table 5. 2
Summary of statistical analyses performed on data describing the 
relationship between the percentage of cells expressing HA-SIP4 and 
[^^S]GTPyS binding attributable to the presence of this receptor.
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Figure 5. 12
Correlation of HA-SIP4 constitutive- and SlP-stimulated activity from 
membranes prepared from ecdysone-inducible CHO-EcR cells with 
percentage of cells deemed to express HA-SIP4.
Data previously obtained for basal and SlP-stimulated signalling of membranes 
prepared from the HA-SIP4 ecdysone-indueible cell line, which had been 
cultured in the presence of varying concentrations of ponasterone A or DMSO 
vehicle, and the % cells expressing HA-SIP4 determined using FACS analysis 
with a Fluorescein conjugated anti-HA antibody, were corrected with respect to 
[^^SJGTPyS bound for samples treated with PTx and plotted. Data plotted are 
from two independent experiments and are the mean of triplicate determinations 
±SEM.
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5.3 Discussion
The ecdysone-inducible expression system was used to further investigate the 
nature of basal and S IP-mediated activity of the HA-SIP4 receptor. This system 
exploits the role of steroid receptors as transcription factors, the aetivity of which 
is tightly regulated by the binding of the associated steroid ligand, and uses the 
non-mammalian Drosophila ecdysone receptor as a way to achieve a tightly 
regulated expression system that will not suffer interference ffom endogenous 
mammalian steroids.
Since a ligand binding assay was not available for SIP4 , FACS analysis was 
chosen as the method of quantifying the extent of receptor expression. Flow 
cytometry is a sensitive technique (reviewed by Nolan et a l, [1999]) and the 
inclusion of the HA tag at the amino-terminus of the SIP4 sequence facilitated 
detection of cell-surface expressed SIP4 (shown previously in chapter 4). 
Quadrant analysis of FACS dot plots allowed receptor expression level to be 
determined and is a technique which has been used previously [Cole et a l, 
2001]. However, this method was limited to a qualitative assessment of the 
percentage of cells expressing the protein of interest. Although no further 
information regarding the level of expression could be extracted ffom these data, 
it was straightforward to compare receptor expression caused by different 
concentrations of induction agent. An alternative approach might have been to 
measure relative receptor levels using an ELISA-based assay on fixed cells 
[Schoneberg et a l, 1995]; however this method was not tested.
Expression of cell-surface HA-SIP4 was dependent on the concentration and the 
time of exposure to induction agent (ponasterone A or muristerone A). In the
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absence of inducing agent, low levels of cell-surface receptor were observed. 
The ecdysone-inducible system has been used to express other GPCRs. In one 
such study low levels of the dopamine D2 iong receptor were detected using 
radioligand binding assay in unindueed cells [Choi et ah, 2000], whilst Cole et 
ah, [2001] found that expression of mRNA and protein for the somatostatin SST2 
reeeptor in this system was undetectable in the absence of inducing agent.
Ponasterone A and muristerone A were found to have very similar half-maximal 
concentrations for dose-dependent induction of cell-surface HA-SIP4 expression 
and the maximal levels of expression achieved using these agents were 
comparable. It was not possible to induce HA-SIP4 expression in 100 % of 
cells; this is in agreement with a previous report where less than 50 % of 
transfected CHO-Kl cells were found to express the SST2 receptor using a 
maximally effective concentration of muristerone A [Cole et ah, 2001]. In this 
study, a proportion of the SST2-positive eells were collected using FACS and 
cultured before re-induction of expression. The fraction of cells expressing this 
receptor decreased ffom 100 % to approximately 65 % over a four week period. 
The reason for this instability is not known, but was suggested by the authors to 
be unrelated to cell cycle events.
Expression of H A - S I P 4  was found to reach a maximum after 48 hours exposure 
to ponasterone A, or after 34 hours using muristerone A. A published study with 
the S S T 2  receptor showed maximal expression after 24 hours incubation with 
muristerone A [Cole et a l, 2001] which declined after 40 hours. Invitrogen 
report that the half-life of ponasterone A in culture is not known, however they 
observe a 30 % decrease in expression 48 hours after induction, and a 70 %
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decrease after 72 hours. Muristerone A is reported to have a half-life of 24 
hours. The results obtained in this chapter differ from Invitrogen’s observations 
since HA-SIP4 expression in response to ponasterone A was maximal after 48 
hours and may suggest that temporal dependency of protein expression is related 
to the half-life of that protein, as well as the half-life of the induction agent in 
culture.
Treatment of H A - S I P 4  transfected cells with ponasterone A or muristerone A 
induced expression of cell-surface H A - S I P 4  in a population of those cells. At a 
given concentration of induction agent, FACS analysis detected a range of H A -  
S I P 4  expression levels. These ranged from low levels, which corresponded to a 
small shift into the lower right quadrant of the dot plot, to higher levels, which 
corresponded to a larger shift in the dot plot. Similar heterogeneity has been 
reported previously for this expression system [Cole et a l, 2001].
Fluorescence microscopy was also used to detect cell-surface expression of HA- 
SIP4 and the results compared well with those generated using FACS analysis. 
The Fluorescein conjugated anti-HA antibody was found to give the best results 
with this technique. The anti-SlP4 antibody recognises an intracellular epitope 
and preliminary experiments using permeabilised cells found this antibody 
stained less specifically than the anti-HA antibody, and also showed low levels 
of staining in the nuclear region of untransfected cells (data not shown).
Membranes were prepared from cells treated with different concentrations of 
ponasterone A, with or without pertussis toxin, then constitutive and SIP- 
induced activity was measured using the [^^SJGTPyS binding assay. In an initial 
experiment, protein expression was induced for 24 hours in serum-free
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conditions. At none of the concentrations of ponasterone A that were used was it 
possible to detect S I P 4  constitutive activity and stimulation of the receptor by 
S I P  was only observed using membranes expressing the highest level of S IP 4 .  It 
was postulated that this may have been a consequence of the use of serum-ffee 
conditions to express the receptor, so S I P 4  expression was induced using a 
variety of ponasterone A concentrations, in serum-containing medium for 24 
hours. These cells were then cultured in serum-free medium, containing the 
appropriate concentration of ponasterone A in the presence and absence of 
pertussis toxin. Membranes prepared from these cells were shown to be 
constitutively active at all concentrations of ponasterone A that were used, and 
this activity could be further stimulated by addition of 10 p.M SIP. It is unlikely 
that the apparent constitutive activity of the receptor resulted from stimulation of 
S I P 4  by residual S I P  since cells were washed thoroughly after removal of 
serum-containing medium prior to addition of serum-free medium for the final 
24 hour culture period and were also washed thoroughly prior to harvest. It is 
unclear why expression using these modified conditions was necessary for the 
receptor to exhibit constitutive activity (and to respond to S I P  when sub- 
maximal concentrations of ponasterone A were used) and the levels of cell- 
surface receptor detected using these different culture conditions were essentially 
identical. A key difference was the time for which protein expression was 
induced: 48 hours when expression was started in serum-containing medium 
compared with 24 hours when serum-free conditions were used. Immunoblot 
analysis detected no differences in apparent mass when H A - S I P 4  was expressed 
in serum-free conditions, compared to when expression was induced in serum- 
containing medium and then completed in serum-free conditions (data not
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shown). A further possibility to consider is that culture of these cells in the 
presence of serum sustains the expression of an additional factor that is required 
for the detection of constitutively active SIP4 receptor. Further investigations 
are necessary to determine the reason for the disparity of receptor activity 
between expression conditions, however it should be noted that it is more 
physiologically relevant to express a receptor in serum-containing conditions 
since SIP4 expressed in vivo, for instance on a circulating T cell, would be 
exposed to serum continuously.
In the [^^SJGTPyS binding assay, basal activity increased from approximately 
4000 dpm, obtained with untransfected and vehicle treated HA-S1 P4-transfected 
cells, to greater than 8000 dpm for cells treated with the highest concentration of 
induction agent. Increasing receptor expression was also shown to correlate with 
SIP-mediated activity. No HA-SIP4 activity (constitutive- or agonist- 
stimulated) was observed when membranes prepared from vehicle treated cells 
were used, even though these cells expressed low levels of SIP4. This may be a 
reflection of the sensitivity of the GTPyS binding assay or be due to a threshold 
effect whereby SIP4 is not constitutively active until sufficient receptor is 
expressed to allow dimérisation or clustering; however further investigations 
would be needed to confirm if this were the case.
The results obtained in this chapter may be compared with those generated using 
the constitutively expressing HA-S 1 P4-transfected cell line presented in chapter 
4. Treatment of the ecdysone-inducible HA-S 1 P4-transfected cell line with 
10"^  ^  M ponasterone A resulted in high levels of cell-surface expression of HA- 
SIP4 , although less than 1 0 0  % of cells expressed the receptor as determined
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using FACS analysis. Basal, or constitutive, activity observed when 10"^  ^  M 
ponasterone A was used to treat cells was approximately 7300 dpm, and that 
obtained after stimulation with 10 |xM SIP was approximately 15500 dpm. 
Values obtained using the constitutively expressing HA-SIP4 cell line were 
approximately 10000 dpm for basal activity and approximately 19500 dpm for 
activity stimulated by 10 |iM SIP. Therefore, the extent of activation exhibited 
by the ecdysone-inducible HA-S 1 P4-transfected cell line treated with the highest 
concentration of ponasterone A compares favourably to that obtained with the 
constitutively expressing cell line, despite the fact that less than 1 0 0  % of cells 
expressed the receptor in the inducible cell line.
Both basal and SIP-stimulated SIP4 activity were found to show a linear 
relationship with the percentage of cells expressing the receptor. The activity 
attributable to constitutive or agonist-mediated activation of SIP4 was calculated 
by subtracting the mean [^^S]GTPyS binding measured using membranes 
prepared from cells treated with pertussis toxin from the total [^^SJGTPyS 
binding obtained using membranes prepared from cells which had not been 
pertussis toxin treated. The accumulation of [^^SJGTPyS in membranes prepared 
from pertussis toxin treated cells is not unexpected. Although ADP-ribosylation 
of GoCi G proteins with pertussis toxin prevents interaction of GPCR and G 
protein, it does not alter the intrinsic G protein functions such as guanine 
nucleotide exchange and GTPase activity [Gierschik, 1992]. Given that cells 
were categorised as expressing HA-SIP4 if they were detected in the lower right 
quadrant of the FACS dot plot, and that there was no measurement of the level of 
receptor expression, the linearity of this relationship is intriguing. It tends to
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suggest that the shape of the distribution of the extent to which cells express HA- 
S I P 4  is maintained and that application of ponasterone A acts to alter this 
population such that there is a progressive shift in the peak of this distribution, 
and in the size of the population in relation to the concentration of the inducer 
(shown as a model in Figure 5.13).
Level of expression 
[Ponasterone A]
Figure 5.13
Model to represent the effect of ponasterone A concentration on cell-surface 
expression of HA-SIP4 in ecdysone-inducible CHO-EcR cells.
The population of ecdysone-inducible cells defined as expressing H A - S  1 P4 using 
F A C S  analysis may be represented by a bell shaped curve and the area under the 
curve corresponds to the number of cells within this population. As the 
concentration of the induction agent ponasterone A is increased, expression of 
cell-surface H A - S I P 4  is increased and so the location of the population is shifted 
to the right. Concurrently, the area under the curve increases, reflecting 
increased number of cells within this population.
This investigation has shown that S I P 4  is constitutively active when expressed in 
CHO cells. The observed relationship between receptor expression level and 
constitutive activity strongly suggests that the ability of S IP 4  to signal in the 
absence of agonist stimulation is an inherent property of the receptor rather than 
merely arising due to receptor clustering or oligomerisation, which may have 
been a consequence of high levels of expression in a heterologous system. 
Constitutive activity of the S IP 4  receptor was shown to be related to expression
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level and was not a consequence of stimulation of the receptor by residual 
ponasterone A. Treatment of membranes prepared from CHO-Kl cell 
transfected to constitutively express H A - S I P 4  with ponasterone A did not 
increase [^^SJGTPyS binding.
Increased levels of receptor expression are expected to lead to increased 
constitutive activity and indeed this has been shown for the S I P 4  receptor. The 
seminal study of GPCR constitutive activity [Samama et a l, 1993] showed the 
existence of a linear relationship between expression level and basal activity for 
both the wild type and constitutively active mutant of P2-AR, the difference 
being that this function was much steeper for the mutant receptor compared with 
the wild type. Other studies which examined the effect of expression level on 
basal activity of wild type receptors also showed that increased expression 
resulted in enhanced constitutive activity [Cohen et a l, 1997; Casarosa et a l,
2001]. It may have been feasible to further investigate the relationship between 
expression level and basal activity for S I P 4  had it been possible to use a 
radioligand binding assay to determine absolute levels of S I P 4  expression in 
membranes used for the functional assay. However, since it is not known at 
what levels S I P 4  is expressed in a physiological setting (e.g. T cells), it is 
difficult to suggest whether the constitutive activity observed using this artificial 
system is relevant in vivo.
Stimulation of SIP4 was shown using a single concentration of SIP (10 p,M) and 
the extent of activation in response to this maximal concentration of agonist was 
related to expression level. It was not practical to determine whether agonist 
E C 5 0  values altered with increased receptor expression, however classical
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receptor theory predicts that increasing receptor number would initially increase 
the maximal response to an agonist, without a change in potency; once that 
maximal response has been reached, further increases in receptor density are 
predicted to increase agonist potency, without affecting maximal potency. These 
predictions showed good agreement with experimental studies of the m G lula 
receptor (using an IPTG inducible expression system [Hermans et a l, 1999]) and 
of the 5 -HT2B receptor (using sodium butyrate treatment [Jerman et a l, 2001]).
Other SIP receptors have been found to be constitutively active. In a landmark 
study using the baculovirus expression system, constitutive activation of GoCi G 
protein by SIP 1/3 and Gan/is G proteins by SIP2 was observed [Windh et a l,
1999]. A recent publication describing agonist regulated and constitutive 
activation of specific signalling pathways by SIP5 [Niedemberg et a l, 2003a] 
found this receptor constitutively inhibited adenylyl cyclase and activation of 
ERK, but that application of exogenous SIP did not further stimulate these 
responses. In contrast, SIP5 mediated cell rounding via the G a^/n  pathway was 
found to be an intrinsic ability of the receptor, which was further modulated by 
SIP. These data were proposed to suggest that when a receptor is constitutively 
active, and is known to couple to multiple G proteins, that different effector 
systems may be activated to different extents.
The cannabinoid (CB) receptors are closely related to the SIP receptors and have 
also been reported to exhibit constitutive activity when expressed in CHO cells 
[Bouaboula et a l, 1997; Bouaboula et a l, 1999]. Similarly, the LPAi receptor 
was shown to activate Gai G proteins in the absence of ligand stimulation using 
a baculovirus expression system [Yoshida and Ueda, 1999]. Ishii et a l, [2000],
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also reported constitutive activity of LPAi and LPA2 receptors. The recently 
identified second family of SIP receptors, GPR3, 6  and 12 are closely related to 
the Edg and CB receptor families, are constitutively active, and lack the 
generally conserved cysteine residue in the first extracellular loop [Uhlenbrock et 
al., 2002]. The melanocortin (MC) receptor family comprises five members and, 
like the SIP and CB receptors, also lack the cysteine residue in the first 
extracellular loop which is generally present in family A GPCRs. This receptor 
family has also been shown to be constitutively active and interestingly the 
ligands agouti and agouti-related protein have been identified as endogenous 
inverse agonists at the MC receptors [Nijenhuis et a l, 2001].
Although the precise structural and molecular changes which correspond to 
receptor constitutive activity are not known, it has been suggested that 
conformational flexibility may contribute to this phenomenon. A study of the 
P2AR showed that a constitutively active mutant of this receptor possessed 
greater structural instability than the wild type receptor [Gether et a l, 1997]. 
There appears to be evolutionary pressure for most GPCRs to reside in the 
inactive conformation. Two striking examples are the a^A R  and rhodopsin. In 
a landmark study of the a^A R , mutation of A^ ^^  to any other amino acid 
conferred a constitutively active phenotype to this receptor [Kjelsberg et a l, 
1992]. The photoreceptor rhodopsin is maintained in an inactive conformation 
via covalent binding of the ligand retinal within the binding pocket and as a 
consequence the visual system is not subject to photobleaching that would result 
from constitutive activity of this receptor.
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The basis for the constitutive activity observed using the SIP4 receptor is likely 
to be common to the SIP, CB and MC receptor families. The unique property of 
these family A receptors is the lack of the generally conserved cysteine residue 
present in the first extracellular loop. This residue forms a disulphide bond with 
a second cysteine residue present in the second extracellular loop, which 
probably serves to constrain the transmembrane helix bundle. Since movement 
of transmembrane helices, particularly TM III and TM VI has been implicated in 
GPCR activation [Meng and Bourne, 2001], greater mobility of the helices could 
conceivably result in receptor constitutive activity. This notion is reinforced by 
observations that culture of constitutively active GPCRs with agonists and 
inverse agonists increases cell-surface expression of the receptor. This “ligand 
rescue” of constitutively active mutant receptors presumably reflects stabilisation 
of the receptor conformation by the binding of the ligand [Milligan et a l, 2002]. 
Conceptually, it would be interesting to examine the effect of the removal of the 
cysteine residue in the first extracellular loop of a typical family A receptor. In 
practice however, interpretation of such an experiment may be challenging since 
removal of this residue by mutagenesis has been reported to prevent transport of 
the modified receptor to the cell-surface [Ai and Liao, 2002]. An alternative 
approach might be to investigate whether the inclusion of a cysteine residue 
within the first extracellular loop attenuated SIP4 constitutive activity. This 
could be achieved using a sequence alignment of family A receptors to identify 
the position of this cysteine residue and mutation of the appropriate residue in 
the SIP4 receptor.
Expression of constitutively active mutants of GPCRs has often been reported to 
be lower than that of their wild type counterparts. In contrast, expression of high
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levels of cell-surface SIP4 was easy to achieve which may represent a 
fundamental difference between receptors that possess significant constitutive 
activity in their wild type state as compared to receptors which are constitutively 
active as a consequence of mutation.
It appears that receptor constitutive activity may be a relevant pharmacological 
property of certain GPCRs. The viral receptors ORF74 and US28 are 
constitutively active [Casarosa et a l, 2001] and the histamine H3 receptor has 
been shown to be constitutively active in situ in rodent brain [Morisset et a l,
2000] and is thought to control histaminergic neuron activity in vivo. The 
previously discussed observation that the three receptor families which lack the 
cysteine residue in the first extracellular loop (SIP, CB and MC) are 
constitutively active lends weight to this concept. The discovery of 
constitutively active wild type GPCRs begs the question of whether 
physiological systems expressing such receptors also produce endogenous 
inverse agonists, which would inactivate their signalling. This has already been 
shown for the MC receptor family. If this was found to be the case for all 
constitutively active wild type GPCRs it would be an elegant symmetry of the 
classical system, in which endogenous agonists activate wild type receptors.
SIP4 constitutive activity has been shown to be related to expression level and 
was not merely a consequence of the very high levels of expression which are 
commonly achieved using recombinant systems. It is unclear whether this 
receptor is constitutively active in its native environment, and if so, whether this 
property is central to the function of the SIP4 receptor and is controlled by the 
actions of an as yet undiscovered inverse agonist.
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6.1 Introduction
It was shown in chapter 4 that SIP4 coupled to Goti G proteins and could be 
activated by the lysophospholipid SIP. Although SIP does function an agonist 
of this receptor, published reports have shown that SIP binds and activates SIP4 
poorly compared to its actions at other SIP receptors [Brinkmann et a l, 2002; 
Mandata et a l, 2002]. It has also been suggested that SIP may not be the true 
endogenous agonist of SIP4 [Lynch and Im, 1999].
Significant progress has been made in the field since the start of work detailed in 
this thesis. Recent publications have described the actions of phosphoryl 
metabolites of the novel immunomodulatory compound FTY720, and its 
analogue AAL, as potent agonists some of the SIP receptors, including SIP4 
[Brinkmann et a l, 2002; Mandala et a l, 2002]. Additionally, the compound 
phytosphingosine-1 -phosphate (phSlP) has been identified as a high affinity 
agonist for the SIP4 receptor. A published study [Rios Candelore et a l, 2002] 
found that this compound, which is structurally similar to SIP, binds SIP4 with 
approximately 50-fold higher affinity than SIP and suggested that phSlP may 
represent the true endogenous agonist for the SIP4 receptor.
The first aim of this chapter was to determine the potency of these recently 
identified putative endogenous and synthetic SIP4 receptor agonists using the 
[35s]GTPyS binding assay.
Recently, efforts have been made to understand how the SIP and LPA receptor 
families discriminate between their structurally similar ligands. Due to their
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highly hydrophobic nature, direct structural studies of GPCRs are challenging, so 
the technique of mutagenesis is often employed in the characterisation of GPCR 
structure-ftmction relationships. Alignment of the sequences of GPCRs from 
related families allows identification of residues which are highly conserved 
within receptor subfamilies, but which differ between different receptor 
subfamilies. This approach was adopted with the Edg family of GPCRs, where 
sequences of the LPA and SIP subfamilies were compared [Parrill et a l, 2000a; 
Parrill et ah, 2000b; Wang et ah, 2001; Bautista et ah, 2002]. A single residue in 
transmembrane domain III was identified as potentially influencing the ligand 
selectivity exhibited by each receptor subfamily. Computational modelling of 
SI Pi and LPAi receptors, performed by Parrill and co-workers showed a 
probable interaction between this residue and structurally distinct groups present 
on the two lysophospholipid ligands, SIP and LPA. In the SIP receptor 
subfamily, this residue, glutamic acid (E^^ )^ was proposed to form an ion-pairing 
interaction with the positively charged ammonium group of SIP; in the LPA 
receptor subfamily, the glutamine residue which is present at this position 
was believed to hydrogen bond with a hydroxyl group on LPA [Wang et a l,
2001].
The second aim of the work described in this chapter was to extend this 
hypothesis to investigate the role of this position in the SIP4 receptor by 
mutation of the naturally occurring glutamic acid to glutamine and subsequent 
assessment of the ability of the ligands SIP and LPA to activate this E^^^Q SIP4 
mutant. Although the published study used RH7777 cells as a host, it was 
decided that the E^^^Q SIP4 mutant should be expressed in CHO-Kl cells. This 
host had been successfully used in earlier studies (described in chapter 4) and
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preliminary work undertaken at the start of this thesis had been unsuccessful in 
detecting SlP4-mediated increases in [^^SJOTPyS binding using SlP 4-transfected 
RH7777 cells.
It was shown in chapter 3 that CHO-Kl cells endogenously express the LPAi 
receptor, and preliminary experiments (not shown) showed that LPA stimulated 
[^^SJGTPyS binding in parental CHO-Kl cells. A fusion protein between HA- 
S1 P4(E^^^Q) and the pertussis toxin-insensitive GoCii(C^ ^^ I) G protein was 
therefore used for these studies. Expression of this protein in CHO-Kl cells 
followed by treatment with pertussis toxin prior to harvest allowed elimination of 
any signal due to stimulation of endogenous LPA receptors. McAllister et ah, 
[2000], adopted a similar approach for studies of the LPAi receptor. The ability 
of wild type SIP4 to couple to a tethered, pertussis toxin-insensitive Goti G 
protein was previously shown in chapter 4.
Unlike SIP, which exists as a single species in vivo, the term LPA actually refers 
to a family of molecules that take the general form l-o-acyl-2 -hydroxy-.sw- 
glyceryl-3 -phosphate. Naturally occurring forms of LPA contain acyl chains of 
differing lengths, with differing degrees of saturation (see Figure 6.1 for 
examples). Structure-activity relationship studies have examined the potency of 
some of the various naturally occurring forms of LPA and synthetic LPA 
analogues as LPA receptor agonists [Bandoh et a l, 1999; Bandoh et a l, 2000; 
Im et a l, 2000b; Heise et a l, 2001; Tigyi, 2001]. The length and saturation of 
the LPA acyl group has been shown to influence potency at isolated LPA 
receptors [Bandoh et a l, 1999; Im et a l, 2000b] with the general trend of 
decreasing potency with decreasing acyl chain length (18:1 > 16:0 > 14:0).
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Figure 6 .1
Structures of three naturally occurring forms of LPA.
A 18:1 LPA (l-oleoyl-2 -hydroxy-5w-glycero-3 -phosphate)
B 16:0 LPA (l-palmitoyl-2 -hydroxy-5«-glycero-3 -phosphate)
C 14:0 LPA (l-myristoyl-2-hydroxy-.ç«-glycero-3-phosphate)
Comparison of space-filling models of the structures of SIP and these analogues 
of LPA (shown in Figure 6.2) revealed that the acyl chains of 18:1 and 16:0 LPA 
were longer than that of SIP. 14:0 LPA most closely resembled SIP in terms of 
apparent length, which suggested that 14:0 LPA might be a more effective 
agonist of the mutant SIP4 receptor than 18:1 or 16:0 LPA.
The final aim of this chapter was to assess how the length of the hydrocarbon tail 
present on the LPA molecule affected its ability to stimulate the HA-S1P4(E^^^Q) 
receptor.
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Figure 6 . 2
Models of LPA analogues and SIP.
Space-filling models which represent the minimised extended conformation of 
each structure were constructed using SYBYL 6.9 software (Tripos Inc., St. 
Louis, MO., U.S.A.). The distance between phosphorus and terminal carbon 
atoms was predicted for each structure.
Predicted distance between 
P and terminal C atom
A 18:1 LPA 27.0 A
B 16:0 LPA 26.7 A
C 14:0 LPA 24.2 A
D SIP 24.0 A
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6.2 Results
6.2.1 Activation of HA-SIP4 by phSlP in [^^SJGTPyS binding assay
Recently, the lysophospholipid phytosphingosine-1-phosphate (phSlP) was 
described as a high affinity agonist for the SIP4 receptor [Rios Candelore et a l,
2002]. Its potency in the [^^SJGTPyS binding assay was determined using 
membranes prepared from HA-SlP4-transfected cells (Figure 6.3). Treatment 
with this agonist promoted a dose-dependent increase in [^^SjGTPyS binding 
with an EC50 of 40 nM ± 8.2 nM (n=3).
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Figure 6 . 3
Concentration dependent stimulation of HA-S1 P4-mediated [^^SjGTPyS 
binding by phSlP.
Membranes from CHO-Kl cells transfected with HA-SIP4 were incubated with 
varying concentrations of phSlP for 5 minutes at 30 °C in the [^^SJGTPyS 
binding assay. Gai G proteins were immunoprecipitated after solubilisation and 
preclearance with non-immune serum. Data presented are the mean of three 
determinations ± SEM from a single experiment and are representative of three 
such experiments performed.
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6.2.2 Inactivity of FTY720 and AAL compounds as HA-SIP4 receptor 
agonists in [^^SjGTPyS binding assay
The immunomodulatory compounds FTY720 and AAL have been shown to 
promote lymphopenia in vivo. This is believed to be due to the action of their 
phosphoryl metabolites, which have been identified as potent agonists at four of 
the five SIP receptors [Brinkmann et a l, 2002; Mandala et a l, 2002]. In 
contrast, the parent FTY720 and AAL compounds reportedly do not possess 
significant activity as SIP receptor agonists. These parent compounds were 
tested in the [^^S]GTPyS binding assay to determine whether they exhibited 
agonist activity at the SIP4 receptor (Figure 6.4). Over the range of compound 
concentrations tested, neither compound stimulated a statistically significant 
increase in [^^SJGTPyS binding when compared to the basal response. Hence 
these compounds were considered to be inactive at the SIP4 receptor.
6.2.3 In vitro phosphorylation of FTY720 and AAL compounds via 
incubation with rabbit blood
Phosphoryl metabolites of the compounds FTY720 and AAL (FTY720-P and 
AAL-P) have been reported to act as potent agonists of certain SIP receptors, 
including SIP4 [Brinkmann et a l, 2002; Mandala et a l, 2002]. In vitro 
phosphorylation of these compounds may be achieved by incubation with 
purified sphingosine kinase 1 enzyme or with whole blood from species 
including rabbit, mouse and human. Parent compounds were synthesised by the 
Medicinal Chemistry department of Celltech R&D Ltd., and attempts made to 
convert each compound to the phosphate metabolite via incubation with whole 
rabbit blood, using a method based on that reported previously [Mandala et a l,
2002].
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Figure 6 . 4
FTY720 and AAL compounds are unable to stimulate HA-SlP4-mediated 
[^*S]GTPtS binding.
Membranes from CHO-Kl cells transfected with H A - S I P 4  were stimulated with 
varying concentrations of FTY720 or AAL compounds for 5 minutes at 30 °C in 
the [^^SJGTPyS binding assay. Ga, G proteins were immunoprecipitated after 
solubilisation and preclearance with non-immune serum. Data are the mean of 
three determinations ± SEM from a single experiment and are representative of 
two such experiments performed.
Incubations of varying concentrations of each compound were performed at 
37 °C using undiluted whole rabbit blood, or whole rabbit blood that had been 
diluted 1 in 4 with supplemented RPMI medium. Samples were removed after 
various timepoints and the percentage conversion to phosphate derivatives 
determined using liquid chromatography-mass spectrometry (LC-MS). The 
profile obtained for FTY720 (Figure 6.5 (A)) showed time-dependent 
phosphorylation of this compound, with a maximal conversion of approximately 
70 % achieved after overnight incubation with an initial concentration of 
10 |ig/ml FTY720 in undiluted blood. In contrast, the same concentration of 
compound incubated with diluted blood had only undergone approximately 2 0  % 
conversion after this time. The related AAL compound showed a rather different
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profile of conversion to AAL-P (Figure 6.5 (B)). The maximal level of 
conversion was achieved using an initial concentration of 1 |ig/ml AAL and was 
approximately 30 % after incubation for 4 hours.
oPlh
O
>
GOu
70-
60-
50-
40
30-
20 -
10 -
0
0 10
Time (hours)
r
15
T
20
— 1 0  p.g/ml undiluted 
1 |lg/ml 
3 |lg/ml 
1 0  p-g/ml
B
o
0 30-
'W
1  20-<u
Go
0 5 10 15 20
1 |lg/ml 
3 jlg/ml
1 0  |Ig/ml undiluted 
^ 1 0  |Ig/ml
Time (hours)
Figure 6 . 5
Conversion of FTY720 and AAL compounds to phosphate metabolites via in 
vitro incubation with whole rabbit blood.
Compounds were prepared in ethanol and the concentrations shown incubated at 
37 °C with whole rabbit blood that had been diluted 1 in 4 with supplemented 
RPMI medium, or with undiluted blood. Conversion of parent compound to the 
phosphoryl metabolite was monitored using liquid chromatography-mass 
spectrometry (LC-MS).
A FTY720
B AAL
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These results allowed identification of optimal conditions to try to produce 
sufficient FTY720-P and AAL-P to allow isolation and purification of these 
phosphate metabolites. These compounds would then be tested in the 
[^^SJGTPyS binding assay to determine their potency against the H A - S I P 4  
receptor. Conditions were chosen using the absolute amount of phosphate 
produced, rather than merely the most efficient conversion in terms of 
percentage, so as to minimise the amount of rabbit blood required. Therefore, 
for FTY720, although incubation of 1 |ig/ml compound overnight with diluted 
blood gave the highest percentage of conversion, optimal conditions for the 
preparative experiment were 1 0  pg/ml in diluted blood, incubated overnight. 
The same conditions were chosen for the preparative phosphorylation of the 
AAL compound.
Due to the scale of the planned preparative phosphorylation experiments, an 
efficient method for extraction of phosphate from the diluted blood was required. 
It was necessary to process the sample mix to remove proteins and to reduce the 
volume so that it could be injected onto a high performance liquid 
chromatography (HPLC) column so that the phosphate metabolite of each 
compound could be isolated. Attempts were made to optimise extraction of the 
metabolites into the organic phase of a dichloromethane (DCM) extract of the 
sample mix. These included testing whether an initial extraction into acetonitrile 
was beneficial, comparison of different ratios of DCM to sample and the effect 
of high and low pH on DCM extraction efficiency. Unfortunately conditions 
which allowed recovery of a high proportion of the phosphate metabolites from 
the sample mix could not be identified. This meant that only a fraction of the 
each phosphate metabolite could have been recovered and hence the size of
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incubation required to produce these phosphate derivatives beeame prohibitive. 
It was therefore not possible to produee FTY720-P and AAL-P and consequently 
the potency of these compounds as agonists of the SIP4 receptor could not be 
determined.
6.2.4 Stable expression of HA-SlP4(E^^^Q)-Gau(C I) fusion protein in 
CHO-Kl cells
.351i
HA-SIP4 was mutated at position sueh that the naturally occurring glutamic 
acid was replaced with glutamine to generate the construct HA-S1 P4(E'^^Q)- 
Gaii(C^^'l)-pIRES (described in chapter 3, section 2.4). The loeation of this 
mutation is shown in Figure 6 .6 .
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Figure 6 . 6  
Snake plot of S I P 4 .
The sequence of the S I P 4  reeeptor is represented as a snake plot (generated using 
the Viseur program and reproduced with the permission of Dr. Fabien Campagne 
from http://www.gpcr.org/7tm/seq/vis/095977/095977.html). The location of 
the E^^^Q mutation is shown.
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The HA-SlP4(E^^^Q)-Gaii(C^^^I)-pIRES construct was stably transfected into 
CHO-Kl cells (as outlined in chapter 2, section 3.3). Western blotting was used 
to detect expression of this fusion protein. Membranes of HA-S1 P4(E^^^Q)- 
GoCii(C^^^I)-transfected cells contained a polypeptide with an apparent molecular 
mass of approximately 110 kDa, which reacted with anti-HA, anti-SlP4 and SGI 
antibodies (Figure 6.7 (A)). The mass of this construct corresponded to that of 
the wild type HA-SlP4-G0Cii(C^ ^^ I) fusion protein detected previously (chapter 4, 
section 2.7). Confirmation of cell-surface expression of this protein was 
obtained via FACS analysis using the anti-HA antibody (Figure 6.7 (B)).
6.2.5 Investigation of HA-Sl?4(E^ ^^ Q)-GtXii(C^ ^^ I) ligand preference in 
[35g]GTPYS binding assay
HA-SlP4(E^^^Q)-GcXii(C^^^I)-expressing membranes were prepared from cells 
which had been treated with 100 ng/mL pertussis toxin for 24 hours prior to 
harvest. The response of the HA-SlP4(E^^^Q)-Gaii(C^^^I) receptor to the ligands 
SIP and 18:1 LPA was assessed using the [^^SJGTPyS assay. These assays were 
performed under the same conditions used to profile the response of the wild 
type HA-SlP4-GOii(C^^^I) fusion, described in chapter 4, section 2.8. 
Stimulation of pertussis toxin treated HA-SlP4(E^^^Q)-Gotii(C^^^I)-expressing 
membranes by SIP and 18:1 LPA was small: approximately 14 % above basal 
with 10 jiM 18:1 LPA and approximately 23 % above basal with 10 |xM SIP 
(Figure 6 . 8  (A)). Although statistically significant increases in [^^SjGTPyS 
binding were observed at the highest concentration of each agonist used ( 1 0  
pM), it was not possible to calculate an EC50 value for either compound. The
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Figure 6 . 7
Expression of HA-SlP4(E^^^Q)-Gaii(C^^^I) in CHO-Kl ceils.
A
B
Membranes from CHO-Kl cells stably expressing HA-S1 ? 4(E^^^Q)- 
Gaii(C^^'l) (lane 1) and untransfected CHO-Kl cells (lane 2) were 
analysed by Western blotting using anti-Sl? 4  (panel I), anti-HA (panel 
II) or anti-Gail (Panel III) antibodies. Visualisation of immunoreactive 
proteins was achieved using chemiluminescence after incubation of the 
blot with appropriate HRP-conjugated secondary antibodies. The
position of HA-SlP4(E‘^ ^Q)-Ga,i(C.351.
Cell-surface expressed HA-SlP4(E^^^Q)-Gaii(C^^^I)
I) is indicated by an arrow.
was detected by
FACS analysis using a Fluorescein conjugate of the anti-HA antibody, 
represented by the blue trace. Cells were also stained with an isotype 
matched control antibody, denoted by the red trace. Panel I shows the 
staining of HA-SlP4(E‘^ ^Q)-Ga.,(C” 'l)-transfected CHO-Kl cells 
whilst panel II illustrates staining obtained using untransfected CHO- 
Kl cells. Data are presented as overlay histograms and are 
representative of at least five independent experiments.
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Figure 6. 8
Ligand preference of HA-S1P4(E'“ Q)-GOii(C^ '^I) in [^^SlGTPyS binding 
assay.
Membranes from CHO-Kl cells transfected to express HA-S1P4(E'^^Q)- 
Gaii(C^^'l) and incubated with 100 ng/mL pertussis toxin for 24 hours prior to 
harvest, were stimulated with various concentrations of SIP or 18:1 LPA for 30 
minutes at 30 °C in the ['^^SJGTPyS/IP binding assay (A). Membranes from 
parental CHO-Kl cells, or CHO-Kl cells which had been transfected to express 
HA-S 1 P4-G(Xi 1 (C^  ^^ I) and cultured in the presence of 100 ng/mL pertussis toxin 
for 24 hours prior to harvest, were used as controls in this experiment and 
stimulated with 10 pM SIP or LPA for 30 minutes at 30 °C (B). Gaj G proteins 
were immunoprecipitated after solubilisation and preclearance with non-immune 
serum. Data are the mean of three determinations ± SEM from a single 
experiment and are representative of three such experiments performed. 
Statistical significance from the basal responses of each set of membranes tested 
is denoted by * (P < 0.05) or ** (P < 0.01).
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controls for this experiment, shown in Figure 6 . 8  (B) demonstrated that the 
pertussis toxin treated wild-type HA-SlP4-GOii(C^^^I) receptor was unable to 
respond to LPA, however the signalling integrity of these membranes was 
confirmed by stimulation with SIP. Treatment of untransfected CHO-Kl cells 
(which had not been pertussis toxin treated) with 10 pM 18:1 LPA increased 
[^^S]GTPyS binding and demonstrated that LPA was delivered to the assay 
system in a form able to activate Edg family receptors. It therefore appeared 
from these results that mutation of residue to glutamine severely affected the 
ability of SIP4 to respond to SIP, however this mutation did not appear to be 
sufficient to confer LPA-responsiveness to this receptor.
6.2.6 The effect of LPA hydrocarbon chain length on activation of HA- 
SlP 4(E'“ Q)-G(Xii(C^**I) in Cs]GTPtS binding assay
Previous studies have examined the effect of the length of the LPA acyl chain on 
agonist potency at receptors of the LPA family [Bandoh et a l, 1999; Im et a l, 
2000b]. The ability of three variants of LPA (18:1, 16:0 and 14:0 LPA) to 
activate HA-SlP4(E^^^Q)-GoCii(C^^ l^) was tested in the [^^SjGTPyS binding assay 
using membranes prepared from pertussis toxin-treated cells.
The preliminary experiment, shown in Figure 6.9 compared activation of HA- 
SlP 4(E^^^Q)-GoCii(C^^^l)-transfected membranes prepared from PTx-treated 
cells, by a 10 jiM concentration of different forms of LPA. Both 18:1 and 16:0 
LPA caused a small stimulation of [^^SJGTPyS binding (approximately 14 % 
above basal for 18:1 LPA and approximately 23 % above basal for 16:0 LPA). 
The level of stimulation induced by 14:0 LPA was larger (approximately 40 % 
above basal).
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Figure 6 . 9
The effect of LPA acyl chain length on stimulation of HA-S1 P4(E Q)- 
Gaii(C^^ I^).
Membranes from CHO-Kl cells transfected to express HA-S1 ? 4(E^^^Q)- 
Gaii(C^^'l), which had been cultured in the presence of 100 ng/mL pertussis 
toxin for 24 hours prior to harvest, were stimulated for 30 minutes at 30 °C with 
10 |liM of various LPA forms which contained acyl chains of different lengths in 
the [^^S]GTPyS/IP binding assay (A). Membranes from parental CHO-Kl cells, 
or CHO-Kl cells which had been transfected to express HA-SlP4-Gaii(C^^'l) 
and cultured with 100 ng/mL pertussis toxin for 24 hours prior to harvest, were 
used as controls (B). Gai G proteins were immunopreeipitated after 
solubilisation and preclearanee with non-immune serum. Data are the mean of 
three determinations ± SEM from a single experiment and are representative of 
two such experiments performed. Statistical significance from the basal 
responses of each set of membranes tested is denoted by * (P < 0.05) or** (P < 
0.01); ## denotes statistical significance from the response to 18:1 LPA (P < 
0 .01).
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These increases were statistically significant when compared to the basal 
response of untreated membranes and the stimulation promoted by 14:0 LPA 
was statistically different to that produced by 18:1 LPA.
No form of LPA stimulated a statistically significant response in wild type PTx- 
treated HA-SlP4-G0Cii(C^^^I)-transfected membranes when compared to the basal 
response of these membranes, which indicated that the activity observed with the 
g i22Q mutant was a result of the introduction of this mutation. However, 
the responses induced by 16:0 and 14:0 LPA using wild type PTx-treated HA- 
SlP4-Gaii(C^^^I)-transfected membranes were statistically different compared to 
the vehicle response of these membranes (P < 0.05). This is not thought to 
reflect activation of the wild type receptor by these species of LPA since the 
responses were not significantly different from the basal response of these 
membranes, but further replicates of this experiment would be needed to confirm 
this. Interestingly, the profile of activation of endogenous LPA receptors present 
on parental CHO membranes was different to that seen with HA-S1 P4(E^^^Q)- 
GoCii(C^ ^ I^). Untransfected CHO-Kl cells, which have been shown to express 
mRNA for LPAi (described in chapter 3) were activated by each form of LPA 
tested, with the rank order of maximal stimulation of 18:1 ~ 16:0 > 14:0, which 
was in agreement with published data [Im et a l, 2 0 0 0 b].
These results suggested that introduction of the E^^^Q mutation in the SIP4 
receptor could confer LPA-responsiveness, and that a short form of LPA was a 
more effective agonist than the intermediate and longer forms, when tested at this 
single concentration.
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6.2.7 Dose-dependent stimulation of HA-SlP4(E^^^Q)-Gan(C^^ I^) by 
14:0 LPA in [^^SJGTPyS binding assay
The 14:0 form of LPA was tested to determine an EC50 for activation of HA- 
SlP 4(E‘^ ^Q)-GOii(C^’‘l) (Figure 6.10). Stimulation of CS]GTP-yS binding was 
observed at higher concentrations of ligand and was statistically significant when 
compared to the basal response of the membranes. The EC50 value for activation 
of HA-SlP4(E^^^Q)-GOii(C^^^l) was calculated to be 3.8 ± 1 .4  |xM. However, 
since a plateau of maximal stimulation was not achieved in any experiment, 
interpretation of this EC50 value needed caution. This result clearly showed that 
14:0 LPA was a weak agonist of HA-SlP4(E^^^Q)-Gotii(C^^*l) and hence 
confirmed the involvement of residue in SIP4 ligand preference. Similar 
results were obtained using a second CHO-Kl clone expressing this fusion 
protein (not shown).
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Figure 6 . 10
Concentration dependent stimulation of
r35
HA-SlP4(E'^^Q)-GOii(C^®'l)-
mediated [ SjGTPyS binding by 14:0 LPA.
Membranes from CHO-Kl cells transfected with HA-S1 ? 4(E^^^Q)-Gai,(C^  ^^ I) 
which had been cultured in the presence of 100 ng/mL pertussis toxin for 
24 hours prior to harvest were stimulated with varying concentrations of 14:0 
LPA for 30 minutes at 30 °C in the [^^SjOTPyS binding assay. Gai G proteins 
were immunopreeipitated after solubilisation and preclearance with non-immune 
serum. Data presented are the mean of three determinations ± SEM from a 
single experiment and are representative of three such experiments performed. 
Statistical significance from the basal response of parental cells is denoted by * 
(P<0.05) or** (P<0.01).
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6.3 Discussion
This chapter describes investigations that were undertaken to characterise the 
ligand preference of the SIP4 receptor.
A recent publication described the ability of phSlP to act as a high affinity SIP4 
receptor agonist and suggested that this lysophospholipid may represent the true 
endogenous agonist of SIP4 [Rios Candelore et a l, 2002]. This group reported 
that phSlP bound to SIP4 with an apparent dissociation constant of 
approximately 1.6 nM, compared with the 120 nM Kd of SIP in this system. In 
contrast, phSlP was reported to be less potent than SIP (30.8 nM and 12.4 nM, 
respectively) in promoting cell medium acidification and was a partial agonist in 
this assay. In this chapter, the [^^SJGTPyS binding assay was used to show that 
phSlP was approximately 17-fold more potent than SIP as an agonist of SIP4, 
which differs with the published study. The reason for this discrepancy is likely 
to be due to the different assay systems used in these determinations. The 
observed differences in the potency of phSlP to activate SIP4 in these two assay 
systems may suggest that phSlP activates opposing pathways (whilst, 
presumably SIP does not), which are detected using the microphysiometer assay. 
The reported observation that phSlP was a partial agonist of SIP4 was in 
agreement with results obtained using the [^^SJGTPyS binding assay where 
phSlP was found to have an efficacy of approximately 60 %, relative to SIP.
The potency of SIP as an agonist of SIP4 in the cell medium acidification assay 
was in marked contrast to its relatively poor potency in the [^^SJGTPyS assay. In 
experiments described in chapter 4, which agreed with published studies 
[Brinkmann et a l, 2002; Mandala et a l, 2002], the EC50 for SIP activation of
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SIP4 was approximately 355 nM whereas in the cytosensor assay its EC50 was 
approximately 12 nM [Rios Candelore et a l, 2002]. There was little difference, 
however, in the EC50 value determined for phSlP activation of SIP4 in the 
published cytosensor assay (approximately 31 nM) and its potency in the 
[^^S]GTPyS assay described in this chapter (approximately 40 nM). This might 
suggest that the range of signalling pathways activated by SIP differs from those 
activated by phSlP. Results obtained using the [^^S]GTPyS assay indicate that 
each agonist is clearly able to stimulate SlP4-mediated activation of Goti G  
proteins. Acidification of cell medium is a very general response; in contrast, the 
highly defined [^^S]GTPyS assay system offers a convenient way to directly 
compare the potency of different agonists, such as SIP and phSlP.
The novel immunomodulatory compounds, FTY720 and AAL were tested for 
their ability to activate S I P 4  and were found to be unable to stimulate 
[^^S]GTPyS binding at the highest concentration used (10 |liM). This is in 
agreement with the reports of Brinkmann et a l, [2002] and Mandala et a l, 
[2002], in which the unphosphorylated FTY720 and AAL compounds exhibited 
no agonist activity at the S I P  receptors.
The activity of phosphoryl metabolites of FTY720 and AAL compounds as 
potent agonists of four of the five SIP receptors is believed to reflect the in vivo 
mechanism of action of these compounds. When administered in vivo, FTY720 
is rapidly metabolised to the phosphate, which is the predominant form of the 
compound in plasma [Mandala et a l, 2002]. In vitro incubation with whole 
blood results in phosphorylation of these compounds. This reaction is likely to 
be mediated by an isoform of the sphingosine kinase enzyme. The localisation
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of this reaction has not been reported. Since it has been reported that endothelial 
cells constitutively export sphingosine kinase 1 [Ancellin et a l, 2002], it is 
possible that phosphorylation of FTY720 occurs extracellularly. Alternatively, 
the reaction could occur within the cytosol and the resultant phosphoryl 
metabolites transported out of the cell by the P-glycoprotein lipid transporter 
Abcbl [Honig et a l, 2003]. Further work is needed to understand the precise 
location and kinetics of this conversion.
In this chapter, incubation of FTY720 and AAL with whole rabbit blood was 
used as a method for producing phosphate metabolites of these compounds. 
Initially, small scale incubations were performed to allow identification of 
optimal conditions for a larger scale incubation, which would yield sufficient 
phosphate derivative of each compound to allow isolation and purification. The 
profile of phosphorylation obtained after incubation with whole rabbit blood 
differed between FTY720 and AAL. FTY720 was phosphorylated relatively 
slowly and the maximal conversion achieved was approximately 70 %. In 
contrast, AAL was converted more quickly, but reached a plateau after 
approximately 30 % conversion. The basis for the difference in the extent to 
which these reactions progressed probably reflects stereoselectivity of the AAL 
phosphorylation reaction. The AAL compound possesses a chiral centre at the 
C2 atom (which is achiral in FTY720) and was produced as a racemate. It has 
been reported that the (R) isomer is a substrate for sphingosine kinase and shows 
immunomodulatory activity in vivo, whilst the (S) isomer is inactive in vivo and 
cannot be phosphorylated by sphingosine kinase [Brinkmann et a l, 2002]. The 
extent to which phosphorylation of the AAL compound via incubation with 
rabbit blood could progress was therefore limited to 50 %.
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The efficiency of conversion of each compound using this in vitro method was 
low, particularly when higher concentrations of compound were used. Although 
purified sphingosine kinase 1 has been shown to phosphorylate FTY720 in vitro 
[Brinkmann et a l, 2002], the kinetics with which it does so are poor in 
comparison to the ability of this enzyme to phosphorylate sphingosine. Recent 
data have shown that the sphingosine kinase 2 isoform phosphorylates FTY720 
efficiently. It may therefore have been more appropriate to attempt to generate 
FTY720-P and AAL-P compounds via incubation of the parent compounds with 
conditioned medium from endothelial cell cultures.
Large scale incubations of FTY720 and AAL with diluted rabbit blood were 
required to produce sufficient phosphate derivative of these compounds to allow 
purification and accurate quantitation of the mass and purity of the resultant 
products. Significant efforts were made to optimise procedures for extracting 
FTY720 and AAL phosphate metabolites into an organic phase prior to 
purification using HPLC. Although a range of conditions and solvents were 
tested, it was not possible to identify an efficient method. As a consequence of 
the low recovery of even the most efficient extraction method, the scale of 
incubation required to produce sufficient FTY720 and AAL phosphoryl 
metabolites was prohibitive. It was therefore not possible determine the potency 
of these compounds as agonists of the SIP4 receptor using the [^^S]GTP'yS 
binding assay. It has been reported that the phosphate derivatives of FTY720 
and AAL were highly potent SIP4 receptor agonists (EC50 values in [^^S]GTPyS 
binding assay of approximately 63 nM and 4.0 nM, respectively) [Brinkmann et 
a/., 2002].
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The role of residue in SIP4 ligand selectivity was also examined. This amino
acid, which is located at the top of the third transmembrane domain, is a 
conserved glutamic acid in the SIP receptor family, whilst the LPA receptors 
contain a conserved glutamine at this position. Computational modelling of the 
SI Pi receptor suggested this residue in SI Pi) was key in defining Edg 
family ligand selectivity due to its apparent interaction with the positively 
charged ammonium group present on SIP, whilst other important residues such 
as (present in TM III) and R^ ^^  (located in TM VII) are thought to interact 
with structural elements common to both SIP and LPA [Wang et a l, 2001]. 
Experimental analysis of an E^^^Q mutant of SI Pi suggested this model to be 
accurate, since the presence of this mutation conferred the ability for SI Pi to 
bind, and be activated by, LPA [Wang et a l, 2001]. The hypothesis that this 
conserved residue is key in determining ligand selectivity in the SIP receptors 
was further tested using the SIP4 receptor.
The HA-S1P4(E^^^Q) mutant, which had been constructed using PGR, and is 
described in chapter 3, was expressed as a fusion protein, coupled to pertussis 
toxin-insensitive GoCii(C^ ^^ I) G protein. This was necessary since preliminary 
experiments performed using the unfused mutant (not shown) were difficult to 
interpret due to stimulation of endogenous receptors present on CHO-Kl cells by 
LPA. Pertussis toxin treatment of cells expressing this fusion protein prevented 
activation of endogenous Goi G proteins by endogenous receptors thus isolating 
the response from the fused receptor. Expression of the HA-S1P4(E^^^Q)- 
Gotii(C^^^I) fusion in stably transfected CHO-Kl cells was confirmed by Western
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blotting using three antibodies, which recognised different components of this 
protein and FACS analysis showed cell-surface expression of the receptor.
Introduction of this mutation severely affected the response to SIP. In dose- 
response experiments, SIP was only able to cause minimal stimulation of the 
HA-SlP4(E^^^Q)-Gaii(C^^^I) fusion and this occurred only at the highest 
concentration of ligand used. This is in agreement with published observations 
for activation of the equivalent SI Pi mutant [Wang et a l, 2001]. However, in 
contrast to this group’s report, the presence of this mutation in SIP4 did not 
appear to confer sensitivity to activation by 18:1 LPA. Stimulation by this ligand 
was only apparent at the maximal concentration tested and it was not possible to 
calculate an EC50 value from these data. The current study did not measure the 
ability of HA-SlP4(E^^^Q)-Gocn(C^^^I) to bind 18:1 LPA and therefore no 
conclusions could be drawn as to how well the receptor could bind this ligand. It 
is notable, however, that SIP binds and activates the SI Pi receptor with far 
higher affinity and potency than it does the SIP4 receptor. The affinity and 
potency with which 18:1 LPA bound to and activated the SI Pi mutant were 
approximately four-fold lower than those values for SIP at the wild type 
receptor, and suggest that additional interactions affect binding affinity. If the 
same were true for the SIP4 mutant, it might be expected that the potency of 18:1 
LPA acting at this receptor would be very low.
Interestingly, although introduction of the E^^^Q mutation affected responses of 
SIP4 to SIP, the mutant receptor was still constitutively active. This presumably 
reflects perturbation of SIP recognition, whilst not affecting the ability of the 
receptor to spontaneously adopt an active conformation. Similar observations
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have been reported for the P2AR, where a mutation in the sixth transmembrane 
domain abolished agonist activation but not constitutive activity [Hannawacker 
et a l, 2 0 0 2 ].
Investigations into the effect of the length and degree of saturation of the acyl 
chain of LPA have been undertaken for the LPA receptors [Bandoh et a l, 1999; 
Im et a l, 2000b], but no such information is available an S I P  receptor which has 
been mutated to allow recognition of LPA. Therefore, a series of LPA forms 
containing different acyl chains were compared for their ability to activate the 
S1 P4(E^^^Q) mutant. Based on the distance between the phosphate and terminal 
carbon atoms calculated using space-filling models of 18:1, 16:0, 14:0 LPA and 
S I P  molecules, it was predicted that 14:0 LPA might be the most potent agonist 
of S1P4(E^^^Q) since it most closely resembled S I P .  18:1 and 16:0 LPA were 
only able to induce a small stimulation of this receptor, whereas activation in 
response to 14:0 LPA was larger. It had not been possible to calculate an EC50  
value for 18:1 LPA, and 16:0 LPA only induced a small stimulation when tested 
at 10 |iM  so the potency of this ligand was not determined. 14:0 LPA was able 
to induce dose-dependent stimulation of HA-SlP4(E^^^Q)-GOii(C^^^I) with an 
EC50 of approximately 3.8 |LiM. Whilst the LPA models used are approximate, 
and in reality the structures will be highly mobile and flexible, it seems possible 
that the longer forms of LPA tested may simply be too large to fit into the ligand 
binding pocket. Ligand binding data would be needed to confirm this 
suggestion. The results of LPA preference obtained with the S I P 4  mutant are in 
contrast to that shown by LPA receptors, which exhibit the general trend of 18:1 
> 16:0 > 14:0 for potency and maximal stimulation [Im et a l, 2000b]. It would
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be interesting to examine the affinity and potency of this series of LPA 
molecules with the SlPi(E^^^Q) mutant to see if the same trend is exhibited. The 
relatively higher potency of 18:1 LPA at this receptor might make interpretation 
of data easier than it was for the SIP4 mutant.
Stimulation of endogenous receptors on untransfected CHO-Kl cells by these 
LPA molecules followed a different trend of maximal stimulation: 18:1 = 16:0 > 
14:0, which is in agreement to the trend observed for the LPAi receptor [Im et 
a l, 2000b] and is consistent with the detection of LPAi mRNA shown in chapter 
3.
Mutation of residue in the SIP4 receptor from the naturally occurring 
glutamic acid to glutamine conferred responsiveness to 14:0 LPA whilst severely 
affecting responses to SIP. This observation tends to support the hypothesis that 
this conserved residue in the third transmembrane domain of the SIP receptors is 
involved in ligand recognition. This is in contrast to a recent paper describing 
models of several GPCRs, including SIP4, which had been generated using novel 
first principle methods [Vaidehi et a l, 2002]. In this model of SIP4, interactions 
between SIP and residues T^ ^^  (present in TM III) and and E^ "^^  (present in 
TM VII) were observed. Interaction of E^ "^^  with the ammonium group of SIP 
appeared to control ligand selectivity since the other residues appeared to interact 
with the phosphate group, which is present on both LPA and SIP. It is therefore 
surprising that none of these residues are conserved throughout the SIP or LPA 
receptor families. The data presented in this chapter support the assertion that 
the glutamic acid residue present in the third transmembrane domain of the SIP 
receptors controls ligand selectivity and tend to suggest that the SIP4 model
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described by Vaidehi et ah, [2002] is inaccurate. However, it is also possible 
that residue is not directly involved in interaction with ligand and that the 
introduction of the mutation has perturbed the structure of this helix such that 
interaction of SIP with present in TM VII is hindered. This is one of the 
limitations associated with GPCR mutagenesis (discussed by Colquhoun [1998]). 
Further analysis, including the measurement of ligand binding affinities, of the 
(gi22Q )sip 4 receptor is needed to further understand the role of this residue in 
ligand recognition. It would also be fruitful to use the mutagenesis approach to 
discover whether residue is involved in SIP recognition, as proposed by the 
recent model of Vaidehi et ah, [ 2002]. An alternative approach that might be to 
generate a chimæric SIP4 receptor that contained the third TM domain fi*om 
LPAi to determine whether introduction of the entire a-helix from an LPA 
receptor could confer LPA responsiveness to an SIP receptor.
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Chapter 7 -  Final Discussion
7.1 Introduction
When work in this thesis was started, S I P 4  had recently been described as the 
orphan receptor Edg6  [Graeler et a l, 1998]. Phylogenetic analysis suggested 
that this GPCR would be activated by the lysophospholipid S I P  and would 
couple to G proteins of the GoCi class. The first aim of this thesis was to test this 
prediction and attempt to measure receptor activation at the G protein level using 
a modified [^^S]GTPyS binding assay.
S I P 4  cDNA was isolated from a PBMC library using PGR and plasmid 
constructs were produced to allow recombinant expression of the receptor in 
mammalian cell lines. One of the complications associated with the analysis of 
S I P  receptor signalling is the presence of endogenous S I P  and LPA family 
receptors in most cell lines. For this reason, S I P 4  was expressed both as the 
native receptor and as a G protein fusion. The fusion was constructed with a 
mutant of Gau wherein the native residue (which is the site of action of 
pertussis toxin) had been mutated to isoleucine, and hence was insensitive to 
pertussis toxin. This permitted the use of pertussis toxin to inactivate 
endogenous Gai proteins and therefore eliminate any interfering responses 
emanating from activation of endogenous S I P  receptors.
Most cell lines used for recombinant protein expression respond to SIP and 
LPA, which presumably reflects activation of endogenous Edg family receptors. 
Therefore, RT-PCR was used to determine the profile of SIP and LPA family 
receptors expressed in the CHO-Kl cell line that was used in these studies. 
Semi-redundant oligonucleotides were used to clone fragments of each of the
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eight Edg family receptors from Chinese hamster genomic DNA. Sequencing of 
these gene fragments permitted the design of RT-PCR oligonucleotides which 
were specific for Chinese hamster Edg family genes. SlPp2,4 and LPAi receptor 
transcripts were detected in CHO-Kl mRNA. This was the first concerted 
investigation into the repertoire of SIP and LPA receptors expressed in this 
commonly used cell line and unlike previous studies [Okamoto et a l, 1998; Sato 
et a l, 1999], the analysis described in chapter 3 used species-specific 
oligonucleotides.
In chapter 4, it was shown that SIP stimulated the SIP4 receptor causing 
activation of Goti G proteins. These observations concurred with the recently 
published reports of [Van Brooklyn et a l, 2000; Yamazaki et a l, 2000] which 
described SIP as an SI P4 receptor agonist that promoted stimulation of pertussis 
toxin-sensitive pathways. In contrast to these published studies, which measured 
events significantly downstream of receptor activation, the results described in 
this chapter showed stimulation at the level of G protein activation. This was at 
a time when other groups reported difficulty in detecting SlP 4-mediated G 
protein stimulation [Im et a l, 2001a] and hence the results in chapter 4 were the 
first demonstration of SIP4 activation at the G protein level.
Within the studies undertaken in chapter 4, it was apparent that SIP4 exhibited a 
significant level of constitutive activity. It was unclear whether this was a 
consequence of the high levels of SIP4 expression present in the recombinant 
cell lines used for these studies; therefore, further investigations into the nature 
of this constitutive activity were undertaken. In chapter 5, the ecdysone- 
inducible expression system was used to determine the relationship between
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S I P 4  basal activity and receptor expression level. This study revealed a linear 
correlation between these variables and confirmed that the observed constitutive 
activity of S I P 4  represented an inherent property of the receptor and was not 
simply due to high levels of expression.
In chapter 6 , the role of residue was examined within the context of SIP4 
ligand preference. Each SIP receptor contains a glutamic acid residue at this 
position whereas a glutamine residue occupies the equivalent position in the 
LPA1.3 receptors. This residue had previously been shown to be critical in the 
control of ligand selectivity for the SI Pi receptor [Wang et a l, 2001] since 
mutation of the naturally occurring residue to glutamine attenuated SIP binding 
whilst conferring LPA-responsiveness to the receptor. For the SIP4 receptor, 
mutation of this residue to glutamine was found to severely affect the ability of 
the receptor to respond to SIP. The wild type SIP4 receptor did not respond to 
LPA; in contrast, dose-dependent stimulation of the (E^^^Q) mutant by LPA was 
observed. A fusion protein between S1 P4(E^^^Q) and the pertussis toxin- 
insensitive Gai(C^^^I) was used in this investigation so that responses due to 
activation of endogenous LPA receptors could be eliminated by treatment with 
pertussis toxin. The results obtained suggested that residue was important in 
controlling ligand selectivity for the SIP4 receptor. Three forms of LPA were 
tested for their ability to stimulate the SIP4 mutant (18:1, 16:0 and 14:0 LPA). 
14:0 LPA was the most effective agonist of the S1 P4(E^^^Q) receptor. The 
effectiveness of different LPA species in this experiment was proposed to have 
reflected the dimensions of the SIP4 binding pocket. Space-filling models had 
been used to calculate the distance between the phosphorus atom of the head 
group and the terminal carbon atom and revealed that 14:0 LPA most closely
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resembled SIP in this parameter. The other forms of LPA tested (16:0 and 18:1) 
were significantly longer than SIP and binding within the transmembrane helical 
pocket may have been compromised. This study did not assess the binding 
affinity of SIP and the various LPA forms to the wild type and mutant 
SIP4 receptors and the inclusion of this technique would have been beneficial to 
this investigation since these results would have illustrated whether the 
effectiveness of the different LPA species as agonists of the mutant SIP4 
receptor correlated with affinity. An obvious extension of this investigation 
would be to apply computational modelling of the SIP4 receptor in tandem with 
the results described here alongside further mutational studies to gain insight into 
the nature of the SIP4 binding pocket.
The use of the [^^SJGTPyS binding assay for the investigations presented in this 
thesis permitted detection of SIP4 stimulation at the level of G protein activation. 
This assay may be considered to be somewhat artificial since it does not measure 
a “real” cellular response such as chemotaxis or activation of transcription 
factors. In addition, the work described here focussed solely on activation of GOi 
G proteins by this receptor and it was recently reported that SIP4 was able to 
activate both Gi and G12/13 G proteins [Graeler et a l, 2003]. Clearly, the analysis 
of [^^S]GTPyS binding on Goti G proteins in response to SIP4 activation is not 
sufficient to predict the cellular consequences of activation of this receptor. 
However, the use of a simple model system such as the [^^S]GTPyS binding 
assay provides insight into the first event occurring downstream of SIP4 
activation. It is appropriate to complement experiments of this type with those 
measuring cellular responses that may be subject to many levels of amplification, 
in order to build a clearer picture of the nature of SIP4 signalling.
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7.2 The i n  v iv o  role of SIP4
Whilst significant progress has been made within the S I P  receptor field, the in 
vivo function of S I P 4  is still unclear. Its restricted pattern of expression is 
suggestive of a role in immune function, however as yet no processes have been 
identified in which the functionality or presence of this receptor is required. The 
well documented effects of S I P  and sphingoid mimetics (such as the phosphoryl 
metabolite of FTY720) on T cells appear to be S I  Pi dependent (discussed in 
chapter 1).
Investigations into the effect of deleting the SIP4 gene in mice are required, 
although alternative approaches should also be considered given the lack of 
obvious phenotype observed in mice in which the related SIP3 receptor had been 
disrupted [Ishii et a l, 2001]. The use of siRNA to silence SIP4 in a 
physiologically relevant setting, for instance in a T cell line, may be useful when 
coupled with relevant cell based assays such as cytokine production, chemotaxis 
or differentiation. Alternatively, the production and analysis of “knock-in” mice 
expressing a non-functional form of the SIP4 receptor might be useful. This 
approach is similar to the use of dominant negative enzymes and would permit 
direct examination of the effect of disrupting SIP4 function (rather than simply 
deleting the gene) and would be more representative of the effects of an SIP4 
receptor antagonist or inverse agonist. Experiments of this nature will address 
the need to identify processes in which SIP4 is key and hence will assist in 
elucidating the function of this receptor.
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7.2.1 SIP4 constitutive activity
The biological significance of S I P 4  constitutive activity is currently unclear, 
however this property is likely to be functionally relevant given the apparent 
evolutionary pressure on GPCRs to remain in the inactive conformation 
(discussed in chapter 1, section 2.4.3). S I P 4  is one of a subfamily of GPCRs, 
which are naturally constitutively active ( S I P ,  LPA, CB, MC and GPR3, 6 , 12 
receptors). The basis for the common ability of these receptors to signal in the 
absence of ligand stimulation may be related to the absence of the generally 
conserved cysteine residue within the first extracellular loop. Although the five 
S I P  receptors are believed to have descended from a common ancestral gene 
[Contos et a l, 2002b], there has been no suggestion that all of these 
constitutively active GPCRs originate from a shared ancestor. This might imply 
that the constitutive activity of these different receptor sub-families evolved 
independently and was achieved via the simplest route possible: reduction in the 
level of constraint of the transmembrane bundle by the loss or mutation of the 
cysteine residue present within the first extracellular loop. In addition, it has 
been reported that receptors which are caused to be constitutively active by the 
artificial mutation of an appropriate residue can be difficult to express [Milligan 
et a l, 2002]. This does not seem to be the case for the S I P  receptors and may 
indicate that the basis for the constitutive activity exhibited by S I P 4  is 
fundamentally different from the artificial constitutive activity caused by 
mutation.
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7.2.2 Regulation of SIP4
The LPAi/2 and SIP2/3 receptors have been reported to mediate opposing effects 
[Zheng et a l, 2001; Takuwa, 2002], and a similar scenario may exist bet'ween 
SIP4 and another SIP receptor. SI Pi is an obvious candidate since it is 
expressed in many of the locations where SIP4 is detected and its presence on T 
cells has been suggested to account for some of the actions of SIP on these cells 
[Graeler and Goetzl, 2002]. It may be that SI Pi and SIP4 have opposing actions 
which could result in the fate of a particular cell being dependent on the relative 
expression levels of these two receptors, as well as the efficiency of coupling to 
their cognate G proteins.
Another possibility to consider is the formation of heterodimers between SIP4 
and another GPCR such as SI Pi or a chemokine receptor. The phenomenon of 
receptor dimérisation has been extensively studied (reviewed by Angers et a l, 
[2002]). The formation of GPCR heterodimers can be constitutive or ligand- 
dependent and can impart a novel pharmacology to that dimer. Heterodimer 
formation between the k and 6 opioid receptor subtypes was reported to produce 
a novel receptor with ligand binding and pharmacological properties distinct 
from those of the constituent receptors [Jordan and Devi, 1999]. In support of 
this proposal, the ability of SIP receptors to form homo- and heterodimers has 
been reported [Van Brooklyn et a l, 2002], although there is no information 
regarding the effect of dimérisation on SIP receptor pharmacology. Since SIP 
may not be the true endogenous agonist for the isolated SIP4 receptor, formation 
of heterodimers with another GPCR may confer an alternative phenotype that 
may be related to the in vivo functions of this receptor. Investigations of this 
nature would be best pursued using a functionally relevant means of detecting
- 2 2 5 -
C hap ter 7
receptor dimérisation, as the traditional technique of co-immunoprecipitation 
may lead to spurious results. Energy transfer techniques such as BRET and 
FRET (reviewed by Angers et ah, 2000; Angers et a l, 2002), are less ambiguous 
since these methods detect the existence of GPCR oligomers on the surface of 
living cells.
In vivo, the resting activity of SIP4 may be controlled by the actions of an 
endogenous inverse agonist countering constitutive activity. Exposure to SIP, 
present in normal serum and plasma may cause further stimulation of the 
receptor. Maximal activation could be achieved after release of SIP and hence 
exposure of the receptor to higher concentrations of this ligand, or by the 
production of the high affinity SIP4 agonist, phSlP. It is possible that different 
SIP4 agonists may promote activation of different G protein families (agonist 
trafficking), although there is currently no evidence to support this contention. 
The potential for activation of this receptor by multiple ligands, which differ in 
their affinity and potency, may offer increased control over receptor activation 
and the resultant consequences.
A further consideration is the potential for SIP4 receptor activity to be subject to 
modification by accessory proteins. In recent years, it has become apparent that 
GPCRs may interact with other (non G protein) proteins and the effect of this 
interaction can alter the localisation or pharmacology of that receptor (reviewed 
by Brady and Limbird [2002]). This concept is exemplified by the proteins of 
the RAMP (receptor activity modifying protein) family, which have been shown 
to control the pharmacology of the calcitonin receptor-like receptor (CRLR) 
(reviewed by Foord and Marshall [1999]). Interaction with non G protein
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proteins may alter SIP4 signalling so that the receptor responds to different 
agonists, has a higher affinity for pre-existing agonists, or demonstrates 
enhanced or diminished constitutive activity. The identification of such proteins 
might aid in the elucidation of the function of this receptor.
Regulation of SIP4 receptor expression by cell stimuli offers another level of 
control of the signalling of this receptor. For instance, it has been shown that 
expression of both SI Pi and SIP4 on T cells is reduced after T cell activation, 
and this may reflect one of the in vivo functions of these receptors.
7.2.3 Sphingosine-l-phosphate signalling
The enigmatic nature of SIP signalling is not yet fully understood. Whilst there 
appears to be a role for SIP as a second messenger, the lack of an identified 
intracellular target means this idea is still controversial. SIP clearly exerts some 
of its effects via stimulation of the SIP receptors and genetic deletion studies 
demonstrate a requirement for these receptors, particularly SlPi. Studies of the 
effects of FTY720 on the immune system have suggested a role for this molecule 
(and by inference SIP) as a regulator of lymphocyte trafficking and the immune 
response.
Like many GPCRs, S I P  receptors have been shown to internalise after ligand 
stimulation [Liu et a l, 1999; Watterson et a l, 2002; Graeler et a l, 2003] and 
recently the related LPAi receptor was found to be located on the nuclear 
membrane, where stimulation with LPA promoted calcium release and induction 
of pro-inflammatory gene expression [Gobeil, et a l, 2003]. It is therefore 
possible that S I P  receptors, including S I P 4  are capable of being activated when
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located intracellularly, either as a consequence of receptor internalisation or due 
to constitutive intracellular expression.
One thing that is clear about SIP is that it is a most unusual GPCR ligand since 
significant concentrations of this molecule are present in normal serum and 
plasma. Receptor agonists are generally tightly regulated in their production and 
clearance from the site of action in order that the response be transient and well 
defined. Both circulating and endothelial cells will be continually exposed to 
SIP and hence the SIP receptors on those cells may be in a state of continual 
stimulation, desensitisation and recycling. How this is reconciled with the 
constitutive activity of these receptors is unclear, however this scenario might 
suggest the existence of an endogenous inverse agonist. It is possible that part of 
the in vivo function of the SIP receptors is to maintain a tone via an equilibrium 
between receptor constitutive activity and/or exposure to SIP, and the opposing 
effects of any endogenous inverse agonists. Where SIP concentrations are 
elevated, for instance at sites of injury and inflammation, this equilibrium could 
be overcome and complete activation of the relevant receptors may be achieved. 
Similar effects might be achieved by spatial and temporal control of inverse 
agonist production.
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7.3 Summary
Many questions have arisen from the work presented in this thesis, not least the 
uncertainty about the in vivo role of the SIP4 receptor, the identity of its 
endogenous ligand(s) and functional relevance of SIP4 constitutive activity.
Over the past 10 years, the field of lysophospholipid related research has grown 
rapidly and there is now abundant information regarding the signalling pathways 
activated by the Edg family receptors. Some of this information has been 
produced using artificial in vitro systems and some has arisen from studies of 
more physiologically relevant studies, including the analysis of SIP and LPA 
receptor-null mice. Several areas await further investigation; of particular 
interest will be the analysis of SIP4 receptor function in complex tissues during 
normal physiological and pathophysiological situations. This is likely to be 
achieved via the use of genetic manipulations, possibly using conditional 
knockout technology. The development of blocking or activating anti-SlP4 
receptor antibodies will also be interesting and should offer an alternative, highly 
selective route for discovering the consequences of activation or antagonism of 
this receptor. The identification of selective agonists and antagonists/inverse 
agonists which discriminate between different SIP receptor subtypes is a limiting 
step in the elucidation of the physiological, and possible pathophysiological roles 
of the SIP receptors in immune system regulation.
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